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PREFACE 
 
I would like to tell you a short story of how the simplest ideas could turn into one‘s life‘s 
passion, without your knowledge. The following thesis summarizes my research work over 
the last 5 years and represents a work, which started way before that time. I was born and 
raised in a small town in Bulgaria called Shumen. I applied for studies in pharmaceutical 
sciences at the University of Frankfurt. At that time not many people could associate 
Frankfurt with science and research, since it is mainly a finance centre. When I enrolled for 
classes, at first I did not know what to expect. I still remember the welcoming speech of Prof. 
Steinhilber. I was sitting in the back of the B1 lecture room while he spoke passionately about 
the world of pharmaceutical science, research and drug discovery. This gave me some first 
insights into the world of research and practical application of science and was also the 
beginning of my path towards scientific research. I never regretted my choice of subject at the 
university, even if it was not always easy. Parallel to studying, I worked various part-time 
jobs and all these jobs helped me gain some valuable experience and offered me a different 
view in comparison to the academic one. During that time I met a lot of different people, 
many of whom I became good friends with. After passing the second state exam, I began the 
next chapter of my life. I finished my practical year in order to take and pass the third state 
exam and become a pharmacist. My PhD studies brought me to Munich.  
The scientific knowledge which I had accumulated until then could be applied to my studies. I 
then stared working on the main project of my thesis, the development of an oil depot 
suspension. I learned to never underestimate a project just because it appears to be simple on 
the surface.  
I believe in thinking differently and in the fact that progress comes from ideas that are put into 
action. Pharmaceutical technology is for me the kind of science that will give you the tools to 
turn an idea into applicable product. 
 
Yordanka Yordanova 
Munich, 
September 16, 2018 
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The following chapter serves as an introduction to the research work of formulating a 
new parenteral depot of GnRH [6-D-Phe] acetate peptide for swine cycle 
synchronization, referred to as estrous cycle. It starts by covering the physiological 
principles underlying the estrous cycle in the swine and then continues with a brief 
overview of the current procedures employed for estrus synchronization. Their major 
drawbacks are outlined, making the research and development of alternative 
procedures for cycle synchronization necessary. On this basis, the requirements from a 
veterinary and swine physiology perspective were translated into formulation and 
studies from a galenic point of view. 
 
1.1 INTRODUCTION  
Research efforts to synchronize the estrous cycle and ovulation in pigs with the ultimate goal 
of fixed time artificial insemination (AI) date back to 1949 and 1962. Tanabe et al
1
 and Dzuik 
and Baker
2
 reported the first seminal studies for the use of chorionic gonadotropin (hCG) to 
stimulate follicle development and ovulation. The results of these early studies facilitated the 
East German Research efforts into using protocols based on gonadotropins to induce puberty, 
synchronize estrous cycle and implement fixed time insemination strategies
3,4
. The ultimate 
goal of the synchronization protocols was to mimic the reproductive physiology of the pig 
with the advantage of a simultaneous and periodic batch wise AI based on the concept of all-
in-all-out. The developed protocols provided animals in the same reproductive stage thus 
reducing the nonproductive days and labor with an improved economic outcome for the farm. 
The strive in the last years in the pig sector to further reduce the costs and labor as well as the 
enormous pressure to decrease the use of antibiotics has resulted in a demand for new 
approaches and formulations for manipulating the reproductive processes in the female pig. 
This reinforces the need of actively managing reproduction using simple and robust protocols. 
The development of such protocols requires the understanding of the reproductive cycle and 
the availability of hormones and hormonally active substances in suitable galenic 
formulations. In the following we will explain in short the reproductive cycle of a swine, 
which will then lead to the formulation requirements. 
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1.2 THE ESTROUS CYCLE IN PIGS  
In general, the estrous cycle in pigs spans a period of 18-24 days (Figure 1.1). The cycle is 
strictly controlled through an integrated system, involving the hypothalamus, pituitary gland, 
ovary and reproductive tract. The hypothalamus exerts its action on the pituitary gland 
through a decapeptide gonadotropin releasing hormone (GnRH). GnRH is released in a 
pulsatile manner, approximately every 90 minutes, and stimulates the secretion of 
gonadotropins from the anterior pituitary gland, follicle stimulating hormone (FSH) and 
luteinizing hormone (LH). FSH and LH regulate the ovary and the production of estrogen and 
progesterone. These hormones feed back negatively to the hypothalamus suppressing the 
release of GnRH and directly influencing the secretion of FSH and LH by desensitizing the 
anterior pituitary gland to GnRH. In short, the systems is self-regulating and adjusting and 
working on the principle of a cruise control in order to maintain hormonal homeostasis. What 
happens within the cycle? 
The cycle itself can be separated in two major phases, regulated by either FSH or LH. As 
shown in Figure 1.1, it consists of a LH- regulated 13 to 15 days corpus luteum formation 
period (luteal phase) and a FSH-regulated 5 to 7 days follicle growth and development period 
(follicular phase). During the luteal phase, ovarian production of progesterone has a negative 
influence on follicular growth by preventing the secretion of both FSH and LH. It basically 
hits the break on FSH and LH when it senses that the progesterone levels are too high. 
Around days 12 to 14 of the cycle, the progesterone concentration declines. Then the uterine 
production of prostaglandin F2α (PGF2α) of non-pregnant animals causes the rapid regression 
of corpora lutea (luteolysis). With the destruction of the corpora lutea the progesterone 
production ceases. When the break is gone appropriate secretory patterns of FSH and LH 
resume, induced by the pulsatile release of GnRH. FSH and LH stimulate ovarian follicle 
development resulting in increased estrogen production, ultimately inducing behavioural 
estrus. The estrogen inhibits selectively only the production of FSH and induces a surge 
release of LH and subsequent ovulation
5
. 
CHAPTER 1 
5 
 
 
Figure 1.1| Estrous cycle in the pig 
The image was modified from http://crinetsupport.blogspot.de/2015/07/dairy-synchronization-learning.html 
 
1.3 CURRENT SYNCHRONIZATION TREATMENTS 
The current estrous synchronization treatments are based on protocols for suppressing the 
follicle development and/or mimicking the luteal phase, the post ovulation phase. The 
treatments used in these synchronization protocols can be classified in 3 major groups 
depending on their pharmacological effect on the cycle.  
1.3.1 Estrus synchronization 
As the physiological luteal phase is characterized by high concentrations of progesterone, the 
phase can be mimicked by treatment with a gestagen derivative. Earlier studies used 
progesterone and its derivatives and did not prove fully effective for synchronizing the 
estrus
6
. At present a synthetic gestagen derivative, allyl trenbolone, also known as altrenogest 
(Regumate
®
 in Europe and Matrix
®
 in North America) is the only licensed substance, which 
can successfully suppress the follicle development in randomly cycling gilts
7
. It is fed in a 
dose of 15 to 20 mg/day/gilt over a period of 14 to 18 days
8–10
. The precision of estrus 
synchronization is greater in gilts after a treatment for 18 days compared to 14 days. After 
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discontinuing the altrenogest treatment, gilts usually show estrus within 5 to 7 days
3,11
. Other 
approaches to extend the lifespan of corpora lutea and suppress ovarian activity included 
GnRH agonists in a slow release device
12–16
. In a recently published study an implant of the 
GnRH analog deslorelin was applied to suppress the ovarian activity in gilts. However, the 
deslorelin implant failed to succeed and produced a permanent anestrus in the treated gilts, 
which was not reversible through the administration of 400 IU equine chorionic gonadotropin 
(eCG) and 200 IU of human chorionic gonadotropin (hCG)
17
. It basically induced an 
undesirable menopause in the treated animals for an unknown duration of time.  
1.3.2 Stimulation of follicular development  
The onset of the follicular phase can be induced by administration of gonadotropins-like pure 
eCG (with predominantly FSH and minor LH activity) or a mixture of eCG and hCG (with 
predominantly LH and minor FSH activity). The latter combination is commercially available 
as PG 600
®
 (400 IU eCG and 200 IU hCG) in the United States and is used in non-cycling 
animals to induce follicular growth and ovulation. PG 600
®
 acts in a similar way as FSH and 
LH during the follicular phase of the estrous cycle. However, such combinations increase the 
risk of inducing ovarian cysts and premature luteinization of the follicles, which comes from 
the extra hCG and the increased LH activity. This is also the reason why pure lyophilized 
eCG (also known as PMSG-pregnant mare serum gonadotropin) (Pregmagon
®
, Intergonan
®
) 
is preferred in synchronization protocols at 800-1000 IU
7
. Synthetic GnRH analoga, 
Perforelin, Maprelin
®
 (Veyx Pharma) exhibited selective FSH releasing activity in barrows
18
.  
1.3.3 Induction of ovulation  
For a fixed-time AI, the ovulation needs to be induced with compounds with predominantly 
LH activity such as hCG or a short-term GnRH analogue. If hCG is to be applied, the interval 
between the eCG and hCG administration is crucial. hCG should be given as close as possible 
to the endogenous LH peak in order to induce ovulation. This poses a risk for variability in 
the treatment. In contrast to hCG, the GnRH treatment resembles a more biologically relevant 
event, since the pulsatile release of the peptide hormone is part of the follicle phase within the 
reproductive cycle. A GnRH agonist analogue GnRH [6-D-Phe], under the tradename 
Gonavet
®
 50 µg/mL Veyx Pharma was more effective in synchronizing the ovulation in swine 
compared to earlier applied GnRH
19
. 50 µg of GnRH [6-D-Phe] proved to be appropriate to 
synchronize the ovulation of swine diagnosed as non-pregnant
20
.Porceptal
®
 4 µg/mL 
MSD/Intervet containing another GnRH agonist analogue buserelin (GnRH-[6-D-Ser(Bu
t
)] 
[10-Pro-NHEt] acetate]) has proved as well successful to induce ovulation in pigs 30 to 33 
hours after application
21
.  
 
1.4 GENERAL FORMULATION REQUIREMENTS FROM A 
VETERINARY PERSPECTIVE 
Currently all swine estrus synchronization protocols require the administration of large 
amounts of altrenogest (17-α-allyl-17-β-hydroxyestra-4, 9, 11-trien-3-one). The 
environmental disrupting potential of this synthetic progestin is of a growing concern
22–24
. 
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Exposure to levonorgestrel, a human contraceptive, at 0.8 ng/mL reduces fecundity in fish
24
. 
Compared to levonorgestrel, altrenogest is utilized at an even larger scale
25–27
. In a typical 
synchronization protocol a swine receives 210-360 mg dose of altrenogest over 12 to 18 days. 
The doses recommended by the manufacturer translate then into several thousands of kg of 
annual altrenogest usage among 66 000 000 pigs. Consistent with the agricultural adaptation 
practices, additional extensive use is to be expected in Asian and Pacific regions
28
. 
Presumably because of its veterinary use, altrenogest has been overlooked in the last couple of 
years in environmental reviews of progestin pharmaceuticals
29
.  
Which are the other procedures currently used parallel to altrenogest? One is the use of 
intravaginal progesterone releasing insert, like CIDRs which are under development for cattle 
and sheeps
30
. However, progesterone is another gestagen product with a detrimental effect on 
the environment. A second option is the serial administration of estradiol between day 11 and 
14 of the estrous cycle to induce pseudo-pregnancy, prolong the luteal phase and then induce 
lyteolysis. The estradiol mimics the early embryonic signaling to the mother. A major 
disadvantage, however, is that this procedure is labor intensive and estradiol is not cleared for 
use in pigs
31
. A third possibility of induction of a prolonged luteal phase is the administration 
of a single dose hCG on the 12 day of the cycle
32
. The hCG induces the follicle development 
and thereby production of estradiol to mimic early embryonic signaling. However, this last 
treatment is still being researched since the duration of the inter-estrus intervals varies
33,34
.  
The focus from a veterinary perspective is therefore the development of an environmentally 
sound product, which can reduce the hormone load coming from the swine sector. This can be 
achieved through a single dose injection, which can reduce the labor involved with feeding 
altrenogest over 14 to 18 days. The single dose injection should contain a luteal phase 
prolonging active substance, which is easily metabolized into inactive compounds with no 
environmental impact. A suitable candidate fulfilling this requirement is the long acting 
GnRH analogue, GnRH [6-D-Phe] acetate
35,36
. The peptide has shown an effect in earlier 
synchronization protocols as a single dose injection of 50 µg/mL Gonavet
®
 for the successful 
induction of ovulation in pigs
20
. GnRH [6-D-Phe] acetate is a synthetic superagonistic 
decapeptide, analogue to the physiological GnRH that possesses greater potency than the 
natural hormone. It contains D-Phe
6
 in place of Gly
6
, which hinders the enzymatic 
degradation and prolongs its plasma half-life. Compared to the natural hormone it possesses 
an increased affinity to the GnRH receptors in the pituitary gland. As mentioned earlier, the 
GnRH release from the hypothalamus occurs in a pulsatile manner. 
What happens when GnRH [6-D-Phe] acetate is administered in pharmacological doses each 
day over a longer period of time? According to the cruise control analogy, FSH and LH levels 
will initially rise, also known as flare-up phenomenon. After a few days, when the system 
senses the change, their concentration will begin to fall because of target tissue 
desensitization/down-regulation of pituitary GnRH receptor. The levels of LH and FSH will 
consequently decrease and the follicle maturity and ovulation is prevented. This principle was 
applied successfully for a long term reversible suppression of estrus in female dogs using 
another superagonist, nafarelin acetate (GnRH-[6-D-Nal(2)] acetate), via a subcutaneously 
implanted osmotic pump over 18 months treatment period
37
. Similar cycle blockage in the 
swine could be achieved with osmotic pumps delivering 1.06 µg/h or 2.12 µg/h GnRH [6-D-
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Phe] acetate
38
. The high production costs and the difficulty to remove and terminate their 
action when necessary, renders the pump systems unsuitable for wider application in the 
veterinary sector. Therefore, the goal is the development of a new multidose depot 
formulation of GnRH [6-D-Phe], with a simple application, which is going to be administered 
once through an injection on the 11
th
 day of the estrous cycle and will induce an estrous cycle 
blocking effect of two weeks or longer. This will inhibit the LH-surge at the beginning of the 
next estrous cycle and prolong the luteal phase until either a physiological or treatment 
induced ovulation occurs.  
 
1.5 RESEARCH FOCUS, FORMULATION DEVELOPMENT 
REQUIREMENTS AND STUDIES 
In order to achieve a two week physiological effect with GnRH [6-D-Phe] acetate, a number 
of factors should be taken into consideration. First, although the plasma half-life of GnRH [6-
D-Phe] acetate, is prolonged in comparison to GnRH, it still reaches only hours
39–41
 and the 
pharmacological effect should be maintained over days. Thus a suitable depot vehicle is 
required, which can deliver GnRH [6-D-Phe] in a controlled and sustained manner. Several 
approaches have been tried in the past for the long term delivery of peptide and protein 
drugs
42,43
. Among the wide variety of systems, a suspension is one of the easiest and cheapest 
pharmaceutical dosage form, which can offer a sustained release of a peptide from a 
subcutaneous or intramuscular depot at the injection site
44
. This was accomplished in 1948 by 
Buckwalter and Dickison with an oil depot suspension of procaine penicillin G suspended in 
peanut oil, gelled with 2 % aluminium monostearate
45
. The formulation was tested in 1000 
human subjects and gave 96 h blood levels in 86 % of the patients. Similar results were 
obtained using a sesame oil vehicle instead of peanut oil and no significant difference 
regarding the absorption of the oil at the injection site was detected
46
. A great number of 
formulations were based on gelled oil vehicles as delivery systems for drugs
47,48,49,50
. In 1975 
injectable oil peptide suspensions and methods for their preparation were patented. Another 
patent described the sustained release of proteins from a polyol/oil suspension, where spray-
dried G-CSF (Granulocyte-Colony Stimulating Factor) was first suspended in glycerol and 
then dispersed in 1 % aluminium monostearate thickened sesame oil. At least a one week 
effect was accomplished
51
. The oily suspension of ACTH (adrenocorticotropic hormone) and 
MSH (melanocyte stimulating factor) gelled with 2 % aluminium monostearate achieved 
prolonged peptide action for several days
52
. Long acting oil depot formulations of 1 mg/mL 
GnRH salts in sesame oil gelled with 2 % aluminium monostearate were tested in rats. The 
acetate salt of GnRH showed a 38 day effect, whereas the zinc tannate salt and pamoate salt 
led to a return to estrous cycle after 120 days
53
. It is however to be noted that the estrous cycle 
within rodents is very short and spans only over 4-5 days, making the task of synchronizing 
the cycle easier in comparison to a swine cycle
54
. The above mentioned principles formed the 
basis for Posilac
®
, Monsanto. The formulation consists of N-methionyl-recombinant bovine 
somatotropin (rBSt) complexed with zinc salt and suspended in sesame oil with 5 % 
aluminium monostearate. It is injected every two weeks subcutaneously in lactating dairy 
cows to boost the milk production
55,56
.  
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1.5.1 Selection and Composition of the Oily Vehicle  
Vegetable oils contain various triglycerides in different proportions. Their composition can 
influence vehicle viscosity, density and stability. Ideally the oils to be used as vehicles should 
be chemically and physically stable, inert to reactions with the peptide, relatively low in 
viscosity, resuspendable, syringeable, injectable, non-irritating and free of antigenic 
properties
57,58
. Oils, which potentially fulfill these characteristics and are suitable for 
injection, include: cottonseed oil, almond oil, olive oil, sesame oil, soybean oil, peanut oil, 
corn oil, castor oil, canola oil, coconut oil, sunflower oil, palm oil, palm kernel oil or linseed 
oil. Alternatively, synthetic fatty acid esters such as isopropyl myristate, ethyl oleate, benzyl 
benzoate and medium chain triglycerides can be incorporated. The fatty acid composition of 
selected oils is summarized in Table 1.1. The higher the amount and the degree of 
unsaturation of the fatty acids, the more susceptible the oils are to oxidation and autoxidation. 
The addition of oxygen to the double bonds produces hydroperoxides, susceptible to further 
reactions. It has been well established that the ease of formation of fatty acid radicals 
increases with increasing degree of unsaturation. Oleic acid for example has been estimated to 
be 10-40 times less susceptible to oxidation than linoleic acid
59
. Therefore, our focus lied on 
oils with a low percentage of oleic, linoleic and linolenic acid e.g. castor oil, peanut oil, 
sesame oil, wheat germ oil, cottonseed oil, corn oil, palm oil, palm kernel oil and coconut oil. 
Castor oil, which is characterized by a high content of ricinoleic acid shows a rather high 
oxidative stability due to an additional hydroxyl moiety preventing the formation of 
hydroperoxides. Furthermore, the hydroxyl group of ricinoleic acid similar to other hydrogen 
donating excipient such as n-octanol, dodecanol or myristic alcohol proved to significantly 
decrease the in vitro drug release from the oil vehicle
60
. As with regards to the in vivo release, 
the lipolysis of the oil vehicle at the injection site plays a major role 
61
. Oils are cleared from 
the intramuscular and subcutaneous injection site within 2 to 30 days
62,63,64,65,66
. 
Oils Fatty acid composition [%] 
Caproic/ 
Caprylic and 
Capric acid 
(C6, C8, C10) 
Palmitoleic acid 
(C16:1) 
Oleic acid 
(C18:1) 
Linoleic acid 
(C18:2) 
Linolenic 
acid 
(C18:3) 
Arachidic acid 
(C20:0) 
Cottonseed oil  0.60.8 15.618.6 50.555.8 0.3 0.1 
Almond oil  < 1 68 25 < 18.0 - 
Olive oil  0.7 78 8.3 0.8 0.5 
Sesame oil  < 0.5 3550 3550 < 1 <1. 
Soybean oil   23 53 7  
Peanut oil   35.069.0 1243  12 
Corn oil  0 24.2 58 0.7 0 
Castor oil   87.7Ricinoleic 
acid 
4.7 0.5 0.3 
Canola oil  0.2 61.6 21.7 9.6 0.6 
Coconut oil 0.5; 7.8; 6.7  6.2 1.6   
Sunflower oil   14.039.4 48.374 <0.3 0.1–0.5 
Palm oil  0.1–0.3 37.3–40.8 9.1–11 0–0.6 0.2–0.7 
Palm kernel oil       
Linseed oil   27 29 60  
 
Table 1.1| Chemical Composition of commonly used Vegetable Oils for Parenteral Drug Delivery67 
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1.5.2 Incorporated GnRH [6-D-Phe] acetate and Micronization Process 
Shape, size and distribution of GnRH [6-D-Phe] acetate particles suspended in the oil phase 
can influence both the stability of the suspension, its injectability, syringeability as well the 
release characteristics. Therefore, spherical and smaller particles with narrow size distribution 
are desired since they offer the least surface area per volume, can be easily resuspended and 
can achieve better dose uniformity
68,69
. In addition, smaller particles offer a larger specific 
surface area for particle-particle interactions. For instance, in highly concentrated suspensions 
this effect promotes high viscosity and thixotropic character, which can reduce the spreading 
of the oil vehicle at the injection site and might counteract an initial burst release
70
. In 
contrast, larger particles in a suspension will increase the settling rate as explained by Stoke‘s 
law and decrease suspension stability. As the oil suspension is intended for a veterinary i.m. 
application, the suitable needle size range lies between 14 G and 18 G. According to a general 
rule it is advisable to avoid any particle greater than one forth to one third of the needle inner 
diameter
71
. This corresponds to an upper particle size limit for 18 G needle size of 
approximately 300 µm. An easy and fast reduction of the particle size can be achieved 
through a grinding process. Either a cryogenic grinding of GnRH [6-D-Phe] acetate avoiding 
thermal stress and increasing brittleness or a suspension-milling process in the dispersing 
medium can be viewed as suitable for GnRH [6-D-Phe] micronization
72
. 
1.5.3 Sustained Release 
Factors which can influence the release of GnRH [6-D-Phe] after intramuscular injection are 
peptide diffusion out of the oil vehicle, particle sedimentation at the oil–tissue fluids interface 
and subsequent dissolution as well as spreading and dispersion of the oil vehicle at the 
injection site
61
. The peptide liberation of the oil vehicle is influenced by the peptide particle 
size and solubility. A complexation of GnRH [6-D-Phe] acetate with metal salts or polymers 
can decrease its solubility and sustain peptide release. This strategy was traditionally used for 
the precipitation of insulin
73
 and corticotropin (ACTH)
74
 and more recently to achieve 
sustained release of recombinant hirudin
75,76
. Similarly, Posilac
® 
(Monsanto) is a Zn-rBSt 
complex applied to increase the milk, fat and protein yield in cows with an effect over 14 
days
77
. A substitution of the zinc gelled sesame oil base by vitamin E and lecithin based 
formulation Boostin-S
®
 (LG Life Sciences) reduced the milk yield in dairy cattle due to a 
high variation and more inconsistent 14 day effect within the group
78
. Besides peptide 
solubility the oil vehicle fatty acid composition and viscosity may have a direct impact on the 
release characteristics of the suspension
62
. A suitable combination of oily components and 
additives may assure the long lasting in vivo effect of GnRH [6-D-Phe] acetate. Such 
compositions were mainly developed as production animal medicines and tend to be very 
profitable. Excede
® 
is used for the treatment of respiratory diseases in herds and follows a 
sustained release pattern in order to deliver at least 7 days of therapeutic plasma levels of 
ceftiofur
79
. Excenel
®
 RTU contains the hydrochloric salt of ceftiofur and is administered 
every 24h for 3-5 days. Adding aluminium monostearate to the sesame oil vehicle of the 
short-acting Excenel
®
 RTU suspension provides therapeutically effective plasma 
concentrations similar to the long-acting Excede
®80
. 
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1.5.4 Selection of a Suitable In Vitro Release Model 
The effect of the oil vehicle and additives on the GnRH [6-D-Phe] acetate release needs to be 
studied in vitro and in vivo in order to develop a formulation with the targeted two week 
pharmacological effect. For this purpose a suitable in vitro release model is mandatory and a 
number of factors needs to be taken into consideration. The release is estimated according to 
mass transport models and is highly dependent on the surface area between the oil vehicle and 
the tissue fluids at the injection site
81,82,83
. After intramuscular injection the oil is squeezed 
between the muscle fibers, increasing the surface area of the oil depot. The resulting surface 
area is much larger than the perfect sphere frequently used in mathematical calculation 
models
83
. The hydrophilic nature of GnRH [6-D-Phe] acetate and its low affinity for the 
vehicle make its release mostly dependent on the amount of tissue fluid available at the 
injection site, the oil/tissue fluid interfacial area and the diffusion distance
61
. 
Currently, no standard methods exist for testing drug release from parenteral depot products
84
. 
According to Larsen et al. a lipophilic solution floating on the top of the release medium
85
, 
dialysis techniques
86,87
 and continuous flow models
61
 are the current methods of choice. As 
the injected oil depot is supposed to have an overall contact with the muscle tissue fluid the 
most suitable model appears to be the dialysis technique. This release model has its biggest 
advantage in the defined interfacial area for mass transfer, which equals the total membrane 
area covered by the oil donor phase
61
. One challenge this release model may pose is the lack 
of agitation within the donor cell, which can cause agglomeration of GnRH [6-D-Phe] acetate 
particles and sedimentation. 
 
1.6 AIMS 
Various hormonal products are currently available that allow for the manipulation of almost 
all key reproductive processes in the swine, making fixed time insemination possible. 
Recently different options for estrous synchronization in the form of osmotic pumps, releasing 
GnRH agonists, have been investigated. In the following chapters a development of a long 
acting oil depot formulation of GnRH [6-D-Phe] acetate has been anticipated, translating the 
veterinary requirements into a formulation which is more environmentally safe and at a 
reasonable cost (Figure 1.2). 
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Figure 1.2| Thesis outline 
 
In the first step, pure oil mixtures with incorporated GnRH [6-D-Phe] acetate were 
investigated. The effect of oil matrix viscosity on syringeability and injectability and the in 
vitro release rate of GnRH [6-D-Phe] acetate were explored. The focus lied on the 
development of a rugged in vitro release test that can be used to demonstrate formulations 
differences with regards to an initial burst effect. The in vivo effect of selected formulations 
was evaluated in the first preclinical study. 
In the second step, the chemical and physical stability of GnRH [6-D-Phe] acetate 
formulations was evaluated. 
Subsequently, the effect of oil thickening agent, as well as resuspendibility enhancers was 
analyzed. Using the advantages of Self-Emulsifying Drug Delivery Systems, a continuous and 
controlled release was envisioned. The in vivo effect of selected formulations was later 
analyzed in the second preclinical study. 
Lastly, we investigated the effect of polymers and metal salt on GnRH [6-D-Phe] release 
prolongation. 
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2 Pure Oil Mixtures as a Delivery Vehicle for GnRH [6-D-Phe] 
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Gonadorelin (GnRH) is a hypothalamic 10 amino acids long peptide hormone with a 
very short plasma half-life. In the search for suitable oil vehicles for its sustained release 
after i.m. injection, combinations of vegetable oils as well as synthetic fatty acid esters 
were prepared and evaluated for miscibility and physical stability. Physically stable and 
homogenous mixtures of castor oil and middle chain triglycerides (MCT) were selected 
for further tests. GnRH [6-D-Phe] acetate was incorporated in low viscosity castor oil: 
MCT 50:50 % (w/w) and high viscosity castor oil: MCT 90:10 % (w/w) mixtures. The 
result from the in vitro release showed an initial burst from both oil matrices. 
Approximately 50 % of the peptide were released within the first 48 hours. A slightly 
lower initial release was achieved with a higher concentration and viscosity. In the first 
in vivo preclinical study the low viscosity GnRH [6-D-Phe] formulation distinguished 
itself from the rest of the tested formulations with a longer and more consistent cycle 
blocking effect. 
2.1 INTRODUCTION 
The nobel–prize winning discovery of GnRH peptide, involved in a number of physiological 
processes, transformed the understanding of the reproduction regulation and led to the 
development of effective treatments for many conditions
1,2
. Its clinical application, though, is 
limited by its short half-life. In order to overcome this drawback, chemical modifications to 
increase its potency and extend its half-life from minutes to hours as well as delivery methods 
have been studied thoroughly
3–6
. A modification or substitution in the amino acids at positions 
6 and 10 of the native peptide gives rise to superagonists, which are more degradation 
resistant to the endopeptidase and the post-proline carboxyamide peptidase enzymes
7
. 
Although this allows for an increased receptor binding affinity and lowers the dose to reach 
half maximal receptor activation, a suitable depot vehicle for the controlled and prolonged 
delivery is still necessary.  
Up until now, the delivery platforms mostly used for incorporating GnRH analogues for either 
human or veterinary purposes are polymeric microparticles and implants
8,9
. The products are 
widely used in oncology to induce reversible chemical castration in patients with advanced 
prostate cancer. Prominent examples are microsphere-based formulations such as Lupron 
Depot
®
, Enantone
®
 and Trenantone
®
 as well as gel-based implants Eligard
®
 with Leuprolide 
acetate (GnRH-[6-D-Leu] [10-Pro-NHEt] acetate), Zoladex
®
 implant with Goserelin acetate 
(GnRH-[6-D-Ser(Bu
t
)] [10-Pro-NH-NHCONH2 acetate], Vantas
®
 implant with Histerelin 
acetate (GnRH-[6-D-His(N
Ƭ
–Bzl)] [10-Pro-NHEt] acetate) and Pamorelin
®
, Trelstar
®
, 
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Decapeptyl SR 
®
 with Triptorelin pamoate (GnRH-[6-D-Trp] pamoate). In the veterinary 
sector a number of products are used to promote ovulation as part of an artificial insemination 
process: Suprelorin
®
 and Ovuplant
®
 with Deslorelin acetate (GnRH-[6-D-Trp] [9-Pro-NHEt]) 
acetate) Dalmarelin
®
 with Lecilerin acetate (GnRH-[6-Tle] acetate), Maprelin
®
 (Perforelin 
acetate), Porceptal
® 
with buserelin (GnRH-[6-D-Ser(Bu
t
)] [10-Pro-NHEt] acetate]) and 
Gonavet Veyx
®
 (GnRH-[6-D-Phe] acetate). In recent years alternative depot delivery systems 
such as insitu forming gels
10
, self-microemulsifying delivery systems
11,12
, lipid microparticles, 
liposomes, microsphere, microcapsules, solid lipid nanoparticles have become the focus of 
research
13
. 
Lipids and oil vehicles have been used as depot vehicles since many years in the treatment of 
schizophrenia and in the hormone replacement therapy
14–18
. In the form of microparticles or 
oil suspensions, they can be an appealing alternative to the already mentioned polymeric 
matrices for incorporating peptides
8
. They are ideal to incorporate compounds with very low 
solubility, poor stability or compounds that may cause irritations if injected in aqueous 
vehicle
19,20,21,22
. In recent years, lipid microparticles were prepared and evaluated for 
sustained release of small molecules such as local anaesthetics and antibiotics as well as 
proteins and peptides
23–25
. They are easily administered, generally biocompatible and can 
provide a sustained release from several days up to months
26
. Simple oily suspensions are 
even easier to manufacture and to apply. Therefore, here we anticipate the idea of selecting a 
suitable oil vehicle for compounding a stable GnRH [6-D-Phe] oil depot suspension. The 
product could be used as a part of an artificial insemination protocol with its major use in 
veterinary medicine. The formulation should be able to offer a sustained release of GnRH [6-
D-Phe] acetate with at least two week physiological effect after application. 
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2.2 RESULTS AND DISCUSSION 
2.2.1 Oil mixtures for extended release of GnRH [6-D-Phe] 
The viscosity of the pure oils was measured and categorized according to the values in four 
groups. Castor oil displayed with 780 mPas the highest viscosity, followed by corn oil, 
sesame oil, peanut oil, wheat germ oil and cottonseed oil with viscosities in the range of 60 to 
70 mPas. The middle chain triglycerides (MCT) viscosity of 30 mPas was second to the last. 
The synthetic fatty acid esters, ethyl oleate and isopropyl myristate were with 3-4 mPas by far 
the least viscous vehicles (Table 2.1). The high viscosity and Newtonian flow of castor oil 
makes its injection a strenuous task, requiring high pressure forces. This was solved by 
preparing blends with low viscosity oil. The resulting viscosity of the mixtures can be 
estimated by equation: 
                      
27 
 
Equation 2.1| Viscosity of an oil mixture  
V1 and V2 and η1 and η2 represent the volume and viscosity of the individual oil vehicles and η is the viscosity of the mixture 
 
The process of oil mixing required temperature of 65° C in order to reduce the castor oil 
viscosity. Castor oil blends with corn oil, sesame oil and peanut oil were oxidized at this 
temperature. Coconut oil, palm oil and palm kernel oil mixtures were excluded from further 
examination, since they showed solid components separation below 10° C. Vehicles 
containing castor oil and MCT, ethyl oleate or isopropyl myristate with a targeted oil viscosity 
between 100 mPas and 600 mPas were clear and homogenous. For the following experiments, 
MCT was selected because of its low oxidation tendency as a triglyceride containing 
primarily saturated fatty acids and its common parenteral use. The mixtures with the highest 
and the lowest viscosity were selected for incorporation of GnRH [6-D-Phe] acetate (Table 
2.2). 
Oily vehicle viscosity at 25° C 
[mPas] ± SD 
viscosity at 39° C 
[mPas] ± SD 
t 1/2 i.m back 
[days] ± SD
28
 
castor oil 780.4 ± 3.3 331.1 ± 2.1 19.0 ± 2.9 
corn oil 58.4 ± 0.7 37.9 ± 2.1  
cottonseed oil 61.4 ± 0.5 38.7 ± 0.2  
wheatgerm oil 2.1 ± 1.1 38.5 ± 0.6  
peanut oil 72.3 ± 0.4 45.2 ± 1.5 25 
sesame oil 63.4 ± 0.6 39.4 ± 0.5 21.4 ± 5.5 
MCT 27.6 ± 0.5 17.3 ± 0.3 11.6 ± 1.8 
ethyl oleate 6.3 ± 0.5 4.7 ± 0.5 10 
isopropyl myristate 4.9 ± 0.8 3.1 ± 1.1 18.3 ± 3.5 
 
 
Table 2.1| Viscosity and t1/2 of oily vehicles for the incorporation of GnRH [6-D-Phe] 
(a) at 25° C (b) at 39° C 
 
oil mixtures Viscosity [mPas] ± SD 
25° C 39° C 
castor oil: MCT 90:10 % (w/w) 436.3 ± 2.9 163.5 ± 1.5 
castor oil: MCT 50:50 % (w/w) 112.6 ± 9.6 53.5 ± 4.5 
 
Table 2.2| Viscosity of castor oil/MCT mixtures for the incorporation of GnRH [6-D-Phe] 
(a) at 25° C (b) at 39° C 
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2.2.2 Oil Spreading at the Injection Site  
The viscosity has a direct impact on the spreading and distribution of the oil vehicle at the 
injection site. A higher viscosity and consequently a reduced oil vehicle spreading could 
counteract a possible burst release upon injection. Absorption of aprotinin from a low 
viscosity emulsion, which spread more extensively within the muscle, was shown to be 
greater than from the high viscosity formulation
29
.  
Ultrasonography of the muscle tissue after injection provided the first insights into the 
spreading behaviour of oils with different viscosity and enabled to judge the ease of manual 
application. The low viscosity 50:50 % (w/w) castor oil/MCT mixture showed a greater 
spreading at the injection site in comparison to the high viscosity 90:10 % (w/w) castor 
oil/MCT vehicle. The low viscosity mixture formed an oblong shape, following the muscles 
fibers (Figure 2.1 a), while the high viscosity formulation counteracted the tissue pressure and 
resulted in a well-defined circular depot (Figure 2.1 b). 
a b 
  
 
Figure 2.1| Ultrasonography images at the injection site  
(a) castor oil/MCT 90:10 % (w/w) (b) castor oil/ MCT 50:50 % (w/w)  
 
2.2.3 GnRH [6-D-Phe] Micronization and Particles Characterization  
In order to select a suitable GnRH [6-D-Phe] particle size range and micronization process, 
the particle size distribution of two commercially available oil suspensions for veterinary 
purposes, Cemay 
®
 and Naxcel
®
, were analyzed and taken as reference. Cemay
®
 is composed 
of 50 mg/mL ceftiofur hydrochloride salt in cottonseed oil, hydrogenated lecithin 
(Phospholipon
®
90H) and sorbitan monooleate with particles Dv50 5.2 ± 0.1 µm; Dv90 = 32.7 ± 
0.9. Naxcel
®
 is composed of 200 mg/mL free crystalline acid of ceftiofur in cottonseed oil 
and MCT with particles Dv50 5.2 ± 0.3 µm; Dv90 = 29.2 ± 0.2 (Table 2.3). 
The GnRH [6-D-Phe] acetate bulk lyophilisate was cryo-and suspension-milled. A frequency 
increase from 15 Hz to 25 Hz in suspension-milling of GnRH [6-D-Phe] in castor oil: MCT 
90:10 % (w/w) resulted in a decrease of the Dv50 particle size from 51.1 ± 1.9 µm to 38.5 ± 
0.9 µm. Prolongation of the grinding time from 11 min to 15 min had less to no effect with 
Dv50 decrease from 43.3 ± 2.9 µm to 38.5 ± 0.9 µm (Figure 2.2 a). In comparison, the Dv50 
particle size after cryogenic grinding of the lyophilisate was 8.7 ± 0.9 µm; Dv90 = 17.6 ± 0.3 
(Figure 2.2 b). The particle size distribution of all measured fractions was non-symmetric. 
One major disadvantage of the cryogenic grinding process is that it requires an additional 
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dispersing step of the micronized peptide. Therefore cryogenic grinding was considered to be 
second choice. The suspension-milling for 11 min at 25 Hz was used for the preclinical 
sample preparation. 
 
a b 
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Figure 2.2| Mean (the mean particle diameter over volume) and median particle size of GnRH [6-D-Phe]  
after (a) suspension-milling (b) suspension- and cryogenic-milling  
 
Grinding Fraction Grinding  
Parameters 
[Time/ Frequency] 
DV50 
[µm] ± SD 
DV90 
[µm] ± SD 
GnRH [6-D-Phe] in castor oil: MCT 90:10 % (w/w) 11 min /25 Hz 43.3 ± 2.9 93.8 ± 5.9 
15 min/ 25 Hz 38.5 ± 0.9 90.1 ± 4.9 
15 min / 15 Hz 51.1 ± 1.9 113.9 ± 5.4 
11 min/ 15 Hz 48.2 ± 1.2 104.9 ± 6.4 
GnRH [6-D-Phe] 8 min/25Hz 8.7 ± 0.9 17.6 ± 0.3 
Cemay® - 5.2 ± 0.1 32.7 ± 0.9 
Naxcel® - 5.2 ± 0.3 29.2 ± 0.2 
 
Table 2.3| Particle size distribution and Dv50 and Dv90 fractions  
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2.2.4 Suspension-and Cryogenic-Milled GnRH [6-D-Phe]  
The particle morphology of suspension and cryogenic milled GnRH [6-D-Phe] was needle-
and platelet-like and confirmed the broader particle size distribution of GnRH [6-D-Phe] in 
castor oil: MCT 90:10 % (w/w) (Dv50 ≤ 50 µm and Dv90 ≤ 100 µm ) in comparison to Cemay
®
 
and Naxcel
®
 (Dv50 ≤ 10 µm Dv90 ≤ 50 µm) (Figure 2.3). 
a  b 
  
c d 
  
 
Figure 2.3| Light microscopy and particles shape characterization 
(a) suspension-milled GnRH [6-D-Phe] (11min/25Hz in castor oil: MCT 90:10 % (w/w) (b) Cemay® (c) Naxcel® (d) 
scanning electron microscopy of cryoground GnRH [6-D-Phe] (8min/25Hz) 
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2.2.5 GnRH [6-D-Phe] Oil Depot Suspension 
In previous experiments ovulation was successfully blocked delivering 1.06 µg/h GnRH [6-D-
Phe] over 14 days using an osmotic pump
30
. By taking this into account and compensating for 
an initial burst release from the suspension, 375 µg/mL and 1875 µg/mL suspensions were 
further evaluated (Figure 2.4). 
 
 
Figure 2.4| 1st generation GnRH [6-D-Phe] oil depot suspension 
 
2.2.6 Rheology  
The four GnRH [6-D-Phe] formulations exhibited Newtonian flow. Because of their high 
particle concentrations, the references Cemay
®
 and Naxcel
®
 showed thixotropic behaviour 
with strong particle-particle interaction, which breaks at high shear rates (Figure 2.5 a). 
Formulations like this can be more easily administered, since the viscosity decreases at high 
shear rates, making the flow through the needle easier. Once it has been injected into the 
muscle, the reduction of shear rate leads to the formation of a more viscous oil depot. The 
measured viscosity at 1 s
-1
 shear rate reflects the viscosity during formulation storage in the 
container and after application at the injection site. The viscosity at 500 s
-1
 shear rate reflects 
the flow through the narrowest needle gauge at the slowest injection rate (Supplementary Data 
Table 2.4). The viscosity at 39° C reduced to half its value at 25° C, mimicking the in vivo 
behaviour after application (Figure 2.5 b).  
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Figure 2.5| Viscosity of (a) castor oil: MCT GnRH [6-D-Phe] oil depot suspension and (b) Cemay® and Naxcel®  
at 25° C and at 39° C 
 
2.2.7 Injection Force Determination  
In general, the expelling of a formulation out of a syringe can be divided in three different 
stages: the first is related to the force required to displace the plunger initially, the plunger-
stopper break loose force (PBF). This force maximum is followed by a force plateau as the 
formulation bulk is continuously expelled through the needle, the dynamic glide force (DGF). 
Finally, the force rapidly increases as the syringe plunger pushes against the end of the 
syringe body
31
. This profile was visible with all formulations when injected through a 16 G 
needle (Figure 2.6 a). The PBF of all tested formulations was similar with the exception of the 
reference Naxcel
®
, which required higher PBF. The injection forces of the GnRH [6-D-Phe] 
formulations through a 16 G were lower in comparison to an 18 G needle (Figure 2.6 b) and 
indicated easy handling. This made 16 G the needle of choice for application. 
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Figure 2.6| Pressure required to expell the formulations (N) as a function of the distance (mm) of the syringe plunger  
(a) 16 G (b) 18 G needle 
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2.2.8 In vitro Release Model Selection and Studies 
In order to establish a robust in vitro release model able to differentiate between formulations, 
a Float-a-Lyzer
®
 (FDS-Floating Dialysis System) and a dialysis bag method were tested. 
Preliminary experiments showed that an FDS with MWCO larger than 5 kD and preferably 
300 kD and higher offered an unhindered diffusion of the GnRH [6-D-Phe], making the oil 
vehicle the rate limiting factor in the release (Supplementary Data Figure 2.9). Furthermore a 
300 kD MWCO was compared with 12-14 kD MWCO dialysis bags. 
Overall, the release from the FDS was incomplete (Figure 2.7 a). The suspended GnRH [6-D-
Phe] particles in the oil phase settled on the FDS plastic bottom and the contact with the 
release medium was prevented. This was not the case with the test vehicle in the dialysis bag, 
where the oil vehicle stayed in contact with the release medium over the release time. For this 
reason, the dialysis system was selected for further in vitro testing.  
The GnRH [6-D-Phe] formulations in the dialysis bag exhibited an initial burst release with 
approximately 50 % of the amount released within the first 48 hours. A slightly lower initial 
release was achieved with a higher concentration and viscosity. Thus increasing the 
concentration of GnRH [6-D-Phe] acetate or the viscosity could not compensate the burst 
effect completely and did not affect the in vitro release profile significantly (Figure 2.7 b). 
a b 
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Figure 2.7| In vitro release profiles of GnRH [6-D-Phe] formulations from castor oil: MCT  
(a) FDS MWCO 300 kD and (b) visking dialysis tubing, MWCO 12 – 14 kD  
 
2.2.9 In vivo 1st Preclinical Study 
The four formulations were tested in vivo:  
castor oil: MCT 50:50 % (w/w) 375 µg/ml GnRH [6-D-Phe] 
castor oil: MCT 50:50 % (w/w) 1875 µg/ml GnRH [6-D-Phe] 
castor oil: MCT 90:10 % (w/w) 375 µg/ml GnRH [6-D-Phe]  
castor oil: MCT 90:10 % (w/w) 1875 µg/ml GnRH [6-D-Phe] 
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The effect was evaluated and considered successful if first, the estrous cycle was blocked and 
there were no follicles larger than 5mm and second, the corpus luteum (CL) showed a reduced 
size in comparison to previous measurements. A CL regression was expected on days 15-17 
of the estrous cycle, corresponding to 4-6 days post application. If a follicle growth, an 
ovulation or cyst development appeared, the cycle blockage was regarded as unsuccessful. 
The control group received the oil matrix without GnRH [6-D-Phe]. Ultrasonography showed 
a follicle growth and no effect of the placebo (0.2 ± 0.4 days) (Figure 2.8). Castor oil: MCT 
50:50 % (w/w) 375 µg/ml GnRH [6-D-Phe] resulted in 2 to 3 days cycle blocking effect. One 
tested animal in the group displayed no cycle blocking effect and developed transient ovarian 
cysts 13 days after application. Thus the average effect was estimated to be 1.8 ± 1.1 days. 
The five animals injected with castor oil: MCT 50:50 % (w/w) 1875 µg/ml GnRH [6-D-Phe] 
showed follicle growth between day 9 and day 12, resulting in an effect of 2 to 5 days. One 
tested animal in the group showed an irreversible cycle blocking effect. After CL regression, 
the animal displayed an irregular follicle growth without ovulation. The average effect was 
3.8 ± 1.3 days. The animals which received castor oil: MCT 90:10 % (w/w) 375 µg/ml 
GnRH [6-D-Phe] had an average cycle blocking effect of 1.2 ± 1.3 days. The animals treated 
with castor oil: MCT 90:10 % (w/w) 1875 µg/ml GnRH [6-D-Phe] showed the most 
irregularities. Cycle blockage for 11 and 12 days was seen in two animals, two others showed 
an irregular cycle and one developed multiple cysts with a permanent anestrus. The average 
effect lasted 6.0 ± 9.6 days (Supplementary Data Table 2.6). 
Statistical analysis showed that the mean cycle blocking effect of castor oil: MCT 50:50 % 
(w/w) 375 µg/ml GnRH [6-D-Phe] and castor oil: MCT 50:50 % (w/w) 1875 µg/ml GnRH [6-
D-Phe] was significantly longer than the one of the control group (p<0.05) (Supplementary 
Data Table 2.7, Table 2.8). There were no significant differences between castor oil: MCT 
90:10 % (w/w) 375 µg/ml GnRH [6-D-Phe], castor oil: MCT 90:10 % (w/w) 1875 µg/ml 
GnRH [6-D-Phe] and placebo (p>0.05) (Supplementary Data Table 2.9, Table 2.10). 
In summary, the in vivo study could confirm that a treatment with GnRH [6-D-Phe] oil depot 
suspension could successfully prolong the luteal phase of the estrous cycle and inhibit a 
follicle development and growth. The most pronounced cycle blocking effects, with regards to 
duration, synchronicity and observed adverse reactions, were detected in the groups castor oil: 
MCT 50:50 % (w/w) 1875 µg/ml GnRH [6-D-Phe] and castor oil: MCT 50:50 % (w/w) 
375 µg/ml GnRH [6-D-Phe]. A longer effect was obtained with a higher peptide concentration 
(3.8 ± 1.3 days vs. 1.8 ± 1.1 days). The results of the in vivo study showed that a low viscosity 
GnRH [6-D-Phe] formulation could achieve a longer and more consistent cycle blocking 
effect compared to a high viscosity formulation.  
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Figure 2.8| In vivo effect of the oil depot GnRH [6-D-Phe] formulations 
 
2.3 CONCLUSION 
The experiments demonstrated that sustained release of GnRH [6-D-Phe] can be achieved 
with castor oil/MCT oily vehicles. Still formulation optimization will be necessary to achieve 
a more consistent release rate and in vivo effect. Furthermore, the relatively high viscosity at 
25° C and Newtonian flow behaviour of the formulations can pose a challenge for a multiple 
dose application. This might be resolved with Non-newtonian oily suspensions, e.g. 
incorporating an oil gelling additives such as aluminium stearate. 
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2.4 MATERIALS AND METHODS 
Gonadorelin [6-D-Phe] acetate peptide (pE1–H2–W3–S4–Y5–(D)F6–L7–R8–P9–G10–NH2) or (pGlu-His-
Trp-Ser-Tyr-D-Phe-Leu-Arg-Pro-Gly-NH2) was provided by BFC Biopept-Feinchemie as lyophilized powder 
and acetate salt (purity 99.76 %, water content 6.73 % and acetate peptide ratio (MW/MW) 1.8). Oil vehicle: 
miglyol
®
812 (MCT), ethyl oleate, isopropylmyristate (Caesar & Loretz, D-Hilden), castor oil, corn oil, sesame 
oil, peanut oil, coconut oil, palm oil, palm kernel oil (Gustav Heess,D-Leonberg). 
Oil mixtures preparation The mixtures of castor oil and a second oily component (corn oil, sesame oil, peanut 
oil, coconut oil, palm oil, palm kernel oil, ethyl oleate, isopropyl myristate, MCT) were homogenized and heated 
at 65° C for 20 minutes without the addition of an antioxidant and under normal atmosphere in a silicone oil bath 
containing a metal holding plate with vials holder. In order to estimate the extent of miscibility of the oils, the 
prepared mixtures were visually evaluated. 
Ultrasonography images at the injection site The formulations high viscosity castor oil/MCT 90:10 % (w/w) 
and low viscosity castor oil/MCT 50:50 % (w/w) were administered by intramuscular injection using a 
18Gx1―1.2 mm x 25 mm needle in the post-auricular region of the neck of two swine carcasses of mature 
German Landrace x Piétrain. The ultrasonography images were taken with Fazone CB (Fujifilm) at 6 MHz 
frequency and 10 cm depth.  
GnRH [6-D-Phe] micronization The suspension milling- and cryogenic micronization of GnRH [6-D-Phe] bulk 
lyophilisate were performed using a Retsch Cryo Mill (Retsch Technology, Haan, Germany). The suspension-
milling was performed in the high viscosity medium castor oil/MCT 90:10 % (w/w) at room temperature and a 
concentration of 7.5 mg/mL. The grinding jar of 25 mL and 15 mm grinding balls was filled with each grinding 
fraction and cooled down in liquid nitrogen for 5 minutes in order to reduce the stress applied to GnRH [6-D-
Phe] during the grinding process. The cryogenic grinding process was performed for the duration of 8 minutes at 
25 Hz. The cryogenic cycle included a precooling phase of 10 min at 5 Hz. 
GnRH [6-D-Phe] particle size distribution and characterization The particle size distribution was analysed 
employing a Laser Diffraction Particle Size Analyzer LA-950 (Retsch Technology, Haan). The samples were 
prepared in triplicate (n=3). 0.2 mL of the oil suspension was measured in a solution of 1 % sorbitan monooleate 
in isooctane (m/v) in a standard measuring cell with 10 mL volume. 
Light microscopy and Scanning Electron Microscopy The SEM images of the cryoground GnRH [6-D-Phe] 
lyophilisate were taken with JSM 6500-F (Jeol, Peabody, MA, USA) and Inca Software (Oxford Instruments, 
Oxfordshire, UK). The SEM images were collected at a magnification 1000x and an accelerating voltage of 
2.0 kV. The light microscopy images of the suspension milled GnRH [6-D-Phe] fractions, Cemay
®
 and Naxcel
®
 
suspensions were taken with VHX – 500 FD (Keyence, Osaka, Japan). 
GnRH [6-D-Phe] oil depot suspension preparation The high and low viscosity mixtures were heated and 
agitated under inert atmosphere (N2) at 60° C and then cooled down to room temperature at 25° C. GnRH [6-D-
Phe] was suspended in the oil vehicles using an Ultra-Turrax T-10 basic (IKA-Labortechnik, Staufen, Germany) 
for 5 min at 2000 rpm and later suspension-milled for 11 min at 25 Hz frequency in a grinding jar of 25 mL and 
15 mm grinding balls with the Cryo Mill (Retsch Technology, Haan, Germany). Four castor oil/MCT 
formulations were composed: Castor oil: MCT 90:10 % (w/w) /1875 µg/mL; Castor oil: MCT 90:10 % (w/w) 
/375 µg/mL; Castor oil: MCT 50:50 % (w/w) /1875 µg/m and Castor oil: MCT 50:50 % (w/w) /375 µg/mL. 
Rheology Viscosity measurement and flow curves evaluation of the pure oils and the mixtures were performed 
with MCR 100 (Anton Paar Germany, Ostfildern-Scharnhausen) cone plate system CP – 1 (50 mm diameter, a 
cone angle of 1 °, and a gap of 0.042 mm). The viscosity η was defined depending on the shear rate ẏ and 
measuring sections a) 0 – 500 s
-1 
(30 points, 6 s per point; 180 s measurement time), b) 500 s
-1 
(1 point, 6 s per 
point, 6 s measurement time), c) 500 – 0 s
-1 
(30 points, 6 s per point, 180 s measurement time).  
Injection force determination The injectability/syringeability experiments were performed with the 
TA.XT.plus Texture Analyser (Stable Micro Systems, Godlming, UK). The formulations were injected into air 
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using a terumo syringe 2.5 mL Luer Lock Tip (Terumo Europe N.V, Leuven, Belgium) with either a FINE-JECT 
18Gx1‘‘, 1.2x38mm needle (Henke-Sass-Wolf GmbH, Tuttlingen, Germany) or a FINE-JECT 16Gx1‘‘, 
1.6x25 mm needle (Henke-Sass-Wolf GmbH, Tuttlingen, Germany). The software Exponent was set to 
compression test mode with the parameters: 5.0 mm/sec pre-test speed, and 2.5 mm/sec test speed, and 20.00 
mm/sec post-test speed, trigger force: 0.001 N. The applied force from the texture analyser was recorded in [N] 
against the distance of the syringe plunger (max. 24.5 mm). 
Preliminary in vitro release study and release model selection The preliminary study was performed with a 
100 µg/mL solution of GnRH [6-D-Phe] in 3.5-5 kD, 8-10 kD, 20 kD, 50 kD, 100 kD, 300 kD and 1000 kD 
Float-a-Lyzer
®
 G2 systems (Spectrum Europe BV, Breda, Netherlands). The preparation and activation of the 
membrane required: 1. Pre-wetting the membrane of the Float-a-Lyzer, filling with a 10 % ethanol solution, 
soaking the filled membrane into 10 % ethanol solution for 10 min. Then the device was thoroughly flushed with 
deionized water, filled and soaked for 20 min in deionized water. The prepared membranes were stored in PBS 
(pH 7.4) (Na2HPO4x2H2O 1.44 mg/mL; KH2PO4 0.2 mg/mL; NaCL 8 mg/mL; KCL 0.2 mg/mL; Natriumazid 
0.05 % (w/v)) at 2-8° C. 1.5 mL aqueous solution of GnRH [6-D-Phe] was filled in the Float-a-Lyzers. The 
release medium was 40 mL PBS buffer (pH 7.4). The experiment was performed in duplicate (n=2), in an 
incubated shaking water bath Julabo SW 21/2 (Julabo GmbH, Seelbach, Germany) at 39° C and agitation rate 
90 min
-1
.  
In vitro release study The in vitro release study was conducted using VISKING
®
 dialysis tubing, MWCO 12 – 
14 kD, RC, 28 mm (SERVA, Germany) and the Float-a-Lyzer
®
 G2 300 kD, 1 mL 1.5 mL formulation was filled 
in the tube and the FDS (Floating Dialysis System) and released in 30 mL PBS (pH 7.4). The in-vitro evaluation 
was performed in duplicate (n=2), in an incubated shaker 3031 (GFL, Germany) at 39° C and 60 rpm. 1 mL 
sample was used for the RP-HPLC analysis at the following intervals 1 h, 3 h, 5 h, 7 h, 22 h, 25 h, 28 h, 46 h, 
52 h, 76 h, 100 h, 172 h, 196 h, 220 h, and 336 h (14 days). The GnRH [6-D-Phe] content in the oil vehicle and 
in the donor cell was extracted using organic solvents, dichloromethane (DCM), where GnRH [6-D-Phe] is not 
soluble in combination with PBS (pH 7.4). 2 mL sample was weighted into a falcon tube, 4 mL DCM and 6 mL 
PBS (pH 7.4) were added. The tube was vortexed at room temperature (25° C) and put into an incubated shaker 
3031 (GFL, Germany) at 39° C and 60 rpm for 24 h. The quantity of the peptide in the upper aqueous phase was 
analysed by RP-HPLC at 220 nm.  
Determination of the GnRH [6-D-Phe] (RP-HPLC) The GnRH [6-D-Phe] content was analysed by RP-HPLC 
using a LUNA C8 (4.6 mm x 250 mm; size = 5 µm; Phenomenex, USA) column, with a C8 pre-column (4 mm x 
3 mm; size = 5 µm) at an HPLC Agilent 1100/1200 series (Agilent Technologies, USA) (mobile phase A (water 
+ 1 mL/L Trifluoroacetic acid (TFA) (v/v)) and mobile phase B (800 g Acetonitrile + 200 g water + 1.2 mL 
TFA), 1.1 mL/min flow, column temperature 40° C, and autosampler temperature 2 – 8° C. The Retention Time 
(RT) of GnRH [6-D-Phe] was 8.5 ± 1.5 minutes with UV detection at 220 nm. The HPLC Gonadorelin 
Quantification Method and Calibration curve, HPLC Gonadorelin Selectivity, HPLC Gonadorelin Linearity, 
HPLC Gonadorelin Accuracy, HPLC Intermediate Precision/Precision as well as HPLC LOD and LOQ were 
performed. 
In vivo 1
st
 preclinical study The first in vivo testing and analysis of results were performed between 09.04.2014 
and 25.06.2014 from the University in Leipzig by Prof. Dr. Johannes Kauffold with the support of Dr. Haukur 
Sigmarrson, Dr. Mathias Hoops, Rosa Stark and Catherine Poser. The number of tested animals was 25 (german 
landrace and pietrain breeds) with an average weight of 148 KG and 241- 243 days old. The gilts were 
administered with Altrenogest, eCG and GnRH in order to synchronize the estrus cycle of the gilts according to 
an established schedule (Supplementary Data Table 2.5). The sonography was performed with a Fazone CB 
(Fujifilm), C9-3 curved array type and 3-9 MHz frequency. The examination was done at 6 MHz frequency, 
10 cm depth and a gain of 84 dB. The sonography examination represented a new method developed by Prof. Dr 
Johannes Kauffold
32,33
. The follicle, corpora hemorrhagica and corpora lutea were analyzed. Follicles with a 
diameter of 10 mm or larger, which did not ovulate were considered to be ovarian cysts. Single cysts were 
differentiated from polycystic ovarian syndrome. The ovulation included the collapse of the preovulatory follicle 
and the appearance of the corpora hemorrhagica. 
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Statistical Analysis The effect of treatment and a comparison between the formulations was performed using a 
t-test: two sample assuming unequal variances with the software QI Macros 2017 (Denver, USA). 
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2.6 SUPPLEMENTARY DATA 
 
Injection rate 
[mL/s] 
Shear rate  
[s
-1 
] 
16G/1.194 mm 17G/1.067mm 18G/0.838mm 
0.05=0.078mm/s 199.4 279.4 576.7 
0.1=0.156mm/s 398.8 558.8 1153.5 
0.2=0.312mm/s 797.5 1117.6 2306.9 
0.4=0.624mm/s 1595.1 2235.1 4613.8 
2=3.12mm/s 7975.4 11175.6 23069.2 
2.5=3.9 mm/s 9969.2 13969.5 28836.5 
 
Table 2.4| Shear rate through different needle sizes in correlation to injection rate 
 
The shear rate has been calculated using the equation: 
 ̅  
      
        
 
 
    
    
 
 
Equation 2.2| Shear rate through injection needle 
       is the injection rate,   is the radius of the needle,   is a constant=1 for Newtonian flow behaviour 
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Figure 2.9| Preliminary in vitro release study and release model selection  
Permeability of Floating Dialyis System (FDS) to GnRH [6-D-Phe] solution in correlation to the MWCO 
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Step I. Preclinical Study 
Oil Depot Suspension of Gonadorelin[6-D-Phe] acetate 
1 1. day Sonographic  examination of the 25 gilts to determine sexual maturity 
2 11.-28. day Daily administration of 5 ml Regumate
®
 4 mg/ml (= 20 mg Altrenogest) per oral over 18 
days to inhibit the follicle development 
3 30. day  
(40 h after last 
Regumate 
administration) 
4,2 ml Intergonan
®
 240 I.E./ml intramuscular(i.m.) (= 1000 IE equine chorionic-
gonadotropin (eCG)) to stimulate the folicle development 
4 33. day 
(78 h after  eCG 
administration) 
1,0 ml Gonavet Veyx
®
 i.m. (= 50 µg Gonadorelin[6-D-Phe]) to induce ovulation 
5 35.-45. day Daily clinical and sonographic examination of the 25 gilts 
6 46. day Clinical and  sonographic examination of the 25 gilts; separating the 25 gilts in 5 groups 
with different substances for application for intramuscular application 
5 Gilts 
Group 1 
375 µg/ml 
Castor oil: MCT 
50:50 % (w/w) 
5 Gilts 
Group 2 
1875 µg/ml 
Castor oil: MCT 
50:50 % (w/w) 
5 Gilts 
Group 3 
375 µg/ml 
Castor oil: MCT 
90:10 % (w/w) 
5 Gilts 
Group 4 
1875 µg/ml 
Castor oil: MCT 
90:10 % (w/w) 
5 Gilts 
Group 5 
Castor oil: MCT 
90:10 % (w/w) 
7 47.-72. day Daily clinical and sonographic examination of the 25 gilts 
 
Table 2.5| In vivo Study Timetable 
 
 
 
Group Results 
Placebo 
Castor oil: MCT 90:10 % (w/w) 
n=5 
normal cycle 7 d p.i. and ovulation 
normal cycle 7 d p.i. and ovulation 
normal cycle 8 d p.i. and ovulation 
normal cycle 7 d p.i. and ovulation 
normal cycle 7 d p.i. and ovulation 
GnRH [6-D-Phe] 375 µg/ml 
Castor oil: MCT 50:50 % (w/w) 
n=5 
no cycle blocking effect 
2 days cycle blocking effect 
2 days cycle blocking effect 
2 days cycle blocking effect 
3 days cycle blocking effect 
GnRH [6-D-Phe] 1875 µg/ml 
Castor oil: MCT 50:50 % (w/w) 
n=5 
2 days cycle blocking effect 
3 days cycle blocking effect 
4 days cycle blocking effect 
5 days cycle blocking effect 
5 days cycle blocking effect 
GnRH [6-D-Phe] 375 µg/ml 
Castor oil: MCT 90:10 % (w/w) 
n=5 
no cycle blocking effect 
no cycle blocking effect 
1 day  cycle blocking effect 
2 days cycle blocking effect 
3 days cycle blocking effect 
GnRH [6-D-Phe] 1875 µg/ml 
Castor oil: MCT 90:10 % (w/w) 
n=5 
no cycle blocking effect 
3 days cycle blocking effect 
4 days cycle blocking effect 
23 days cycle blocking effect 
permanent cycle blocking effect 
 
Table 2.6| In vivo Study Results 
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t-Test: Two-Sample Assuming 
Unequal Variances 
a=0.05    
Equal Sample Sizes      
  Placebo Treatment 1 
GnRH [6-D-Phe] 
375 µg/ml 
Castor oil: MCT 
50:50 % (w/w) 
 
diff 95 % Confidence Interval 
Mean 0.2 1.8 -1.600 -2.960 -0.240 
Variance 0.2 1.2    
Observations 5 5    
Hypothesized Mean Difference 0     
df 5     
t Stat -3.024     
P(T<=t) one-tail - Difference < 
Hypothesized Difference 
0.015 0.985 Difference > Hypothesized Difference 
T Critical one-tail 2.015     
P(T<=t) two-tail 0.029  Reject Null Hypothesis because p < 0.05 (Means 
are Different) 
T Critical Two-tail 2.571         
 
Table 2.7| Statistical analysis t-test placebo-GnRH [6-D-Phe] 375 µg/ml Castor oil: MCT 50:50 % (w/w) 
 
 
t-Test: Two-Sample Assuming Unequal 
Variances 
α =0.05     
Equal Sample Sizes      
  Placebo Treatment 2 
GnRH [6-D-
Phe] 
1875 µg/ml 
Castor oil: 
MCT 50:50 % 
(w/w) 
diff 95% Confidence Interval 
Mean 0.2 3.8 -3.600 -5.312 -1.888 
Variance 0.2 1.7    
Observations 5 5    
Hypothesized Mean Difference 0     
df 4     
t Stat -5.840     
P(T<=t) one-tail - Difference < 
Hypothesized Difference 
0.002 0.998 Difference > Hypothesized Difference 
T Critical one-tail 2.132     
P(T<=t) two-tail 0.004  Reject Null Hypothesis because p < 0.05 
(Means are Different) 
T Critical Two-tail 2.776         
 
Table 2.8| Statistical analysis t-test placebo-GnRH [6-D-Phe] 1875 µg/ml Castor oil: MCT 50:50 % (w/w) 
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t-Test: Two-Sample Assuming Unequal 
Variances 
a=0.05     
Equal Sample Sizes      
  Placebo Treatment 3 
GnRH [6-D-
Phe] 
375 µg/ml 
Castor oil: 
MCT 90:10 % 
(w/w) 
diff 95 % Confidence Interval 
Mean 0.2 1.2 -1.000 -2.712 0.712 
Variance 0.2 1.7    
Observations 5 5    
Hypothesized Mean Difference 0     
df 4     
t Stat -1.622     
P(T<=t) one-tail - Difference < 
Hypothesized Difference 
0.090 0.910 Difference > Hypothesized Difference 
T Critical one-tail 2.132     
P(T<=t) two-tail 0.180  Cannot Reject Null Hypothesis because p > 
0.05 (Means are the same) 
T Critical Two-tail 2.776         
 
Table 2.9| Statistical analysis t-test placebo-GnRH [6-D-Phe] 375 µg/ml Castor oil: MCT 90:10 % (w/w) 
 
 
t-Test: Two-Sample Assuming Unequal 
Variances 
a=0.05     
Equal Sample Sizes      
  Placebo Treatment 4 
GnRH [6-D-
Phe] 
1875 µg/ml 
Castor oil: 
MCT 90:10 % 
(w/w) 
diff 95 % Confidence Interval 
Mean 0.2 6 -5.800 -17.819 6.219 
Variance 0.2 93.5    
Observations 5 5    
Hypothesized Mean Difference 0     
df 4     
t Stat -1.340     
P(T<=t) one-tail - Difference < 
Hypothesized Difference 
0.126 0.874 Difference > Hypothesized Difference 
T Critical one-tail 2.132     
P(T<=t) two-tail 0.251  Cannot Reject Null Hypothesis because p > 
0.05 (Means are the same) 
T Critical Two-tail 2.776         
 
Table 2.10| Statistical analysis t-test placebo-GnRH [6-D-Phe] 1875 µg/ml Castor oil: MCT 90:10 % (w/w) 
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3 GnRH [6-D-Phe] acetate Oil Depot Suspension Stability 
Yordanka Yordanova
1
, Wolfgang Zaremba
2
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2
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1
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Universitaet, Butenandtstrasse 5, 81377 Muenchen, Germany 
2. Veyx Pharma GmbH, Scientific Department, Soehreweg 6, 34639 Schwarzenborn, Germany 
An oily depot suspension of a GnRH superagonist appears to be a promising alternative 
to the available on the market aqueous Gonavet Veyx
®
 formulation for estrous control 
in swine. The stability of GnRH [6-D-Phe] suspended in castor oil: MCT 50:50 % (w/w) 
as a multi-dose vial was evaluated over 12 months at 2-8° C, 25° C and 40° C. The 
formulation was analysed in terms of GnRH [6-D-Phe] stability, content uniformity, 
particle size distribution, viscosity, injectability and oil vehicle oxidation. The study 
demonstrated that the stability and content uniformity were assured at all tested 
temperatures over the period of 12 months. 
 
3.1 INTRODUCTION 
Formulating peptides and proteins in non-aqueous mediums such as oils can minimize the 
hydrolytic degradation pathways. For instance, hydrolytic degradation of leuprolide (LHRH) 
in dimethylsulfoxide (DMSO) was only 93 % compared to 75 % in aqueous solution after 2 
years storage at 37° C
1,2
. One other example showed that the use of oil vehicle or DMSO 
could prevent the commonly observed aggregation and gelation of aqueous solutions of 
bovine growth hormone releasing factor
3
.  
In the case of GnRH [6-D-Phe] acetate, degradation is most pronounced under strong acidic 
(pH<3) and alkaline (pH>9) conditions, at which C-terminal deamidation and D-Ser
4
 
epimerization of the peptide occur
4,5,6,7
. For this reason, the aqueous injection solution of 
GnRH [6-D-Phe], Gonavet Veyx
®
, is formulated in acetate buffer pH 5
8,9
.  
The purpose of this study was to evaluate the stability of one exemplary oily suspension from 
the first preclinical study and compare it to the marketed aqueous Gonavet Veyx
®
 
formulation. The suspension vehicle is composed of castor oil with a high content of 
ricinoleic acid, representing a polar protic solvent and MCT, a polar aprotic medium. This 
matrix should be less prone to oxidative instability compared to other oily vehicles containing 
higher amounts of oleic, linoeic and linolenic acid esters
10
. The chemical stability of the 
peptide was analysed by RP-HPLC. Light microscopy, particle size distribution, rheology and 
oil vehicle oxidation were additionally evaluated. 
  
SUSPENSION STABILITY 
46 
3.2 RESULTS AND DISCUSSION 
3.2.1  Content Uniformity  
The extraction recovery of GnRH [6-D-Phe] was calculated to be 95 % +/- 10 % (95 % CI). 
At 40° C storage temperature, some method-derived variability in the GnRH [6-D-Phe] 
content was visible (Figure 3.1). 
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Figure 3.1| Content uniformity of the castor oil: MCT 50:50 % (w/w) 1875 µg/ml GnRH [6-D-Phe] formulation 
 
Chromatograms analysis of GnRH [6-D-Phe] samples generated by treatment with alkali, 
acid, hydrogen peroxide and light revealed degradation products at relative retention time 
(RRT) 0.914, 0.509 and 0.789 (Table 3.1). These products did not appear in the recorded 
HPLC chromatograms of the suspension.  
 
GnRH [6-D-Phe] degradation GnRH [6-D-Phe] 
Sample RT 
[min] 
Nearest 
Peak RT  
[min] 
Nearest 
Peak RRT 
[min] 
Blanc H20 injected 
normal conditions 
- - - 
Chem. Stress 1N 
HCL 1.5% H202 12h 
6.925 6.331 0.914 
Chem. Stress 1N 
NaOH 1.5% H202 
12h 
8.068 4.111 0.509 
Light Stress 8.235 6.503 0.789 
 
Table 3.1| HPLC analysis of GnRH [6-D-Phe] degradation  
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3.2.2 Particle Size Distribution and Characterization  
Particle size serves as an indicator for the physical stability of the suspension over time. The 
increase of particle size might accelerate settling and lead to the caking of the sediment. 
Larger particles may clog the needle and affect the injection forces. For castor oil: MCT 
50:50 % (w/w) 1875 µg/ml GnRH [6-D-Phe], the median and mean particle size of the 
dispersed samples remained under 50 µm at all storage temperatures. The particle size 
distribution of all measured samples was non-symmetric (Figure 3.2, Table 3.2). The 
microscopy images showed the formation of single large particles after 6 months of storage at 
40° C (Figure 3.3). This might be due to some large but loosely connected particle 
agglomerates. Similarly at 9 and 12 months of storage the mean particle size was slightly 
increased. However, no negative impact on the injection force was observed (Figure 3.5). 
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Figure 3.2 |Mean (the mean particle diameter over volume) and median particle size of castor oil: MCT 50:50 % 
(w/w) 1875 µg/ml GnRH [6-D-Phe] oil depot suspension at 2-8° C, 25° C and 40° C over 12 months 
 
 Temperature: 2-8° C Temperature: 25° C Temperature: 40° C 
Time 
[months] 
Dv50 [µm] ± SD Dv90 [µm] ± SD Dv50 [µm] ± SD Dv90 [µm] ± SD Dv50 [µm] ± SD Dv90 [µm] ± SD 
0 7.7 ± 0.1 108.1 ± 5.5 7.7 ± 0.1 108.1 ± 5.5 7.7 ± 0.1 108.1 ± 5.5 
1 8.6 ± 0.2 93.6 ± 1.9 7.0 ± 0.1 13.2 ± 0.8 6.2 ± 0.1 11.9 ± 0.4 
3 8.8 ± 0.2 56.2 ± 2.3 10.4 ± 0.4 108.7 ± 6.7 8.3 ± 0.1 16.0 ± 6.5 
6 21.6 ± 2.9 74.3 ± 1.5 14.8 ± 3.5 75.1 ± 2.4 32.2 ± 2.5 55.3 ± 1.8 
9 7.2 ± 0.2 102.8 ± 0.6 6.6 ± 0.1 17.8 ± 2.7 6.8 ± 0.1 10.4 ± 0.5 
12 27.8 ± 6.2 119.4 ± 4.5 13.1 ± 3.3 91.3± 6.0 7.4 ± 0.2 98.7 ± 7.1 
 
Table 3.2| Particle size distribution and D v50 and D v90 fractions  
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Figure 3.3| Light microscopy of castor oil: MCT 50:50 % (w/w) 1875 µg/ml GnRH [6-D-Phe] oil depot suspension at 2-
8° C, 25° C and 40° C over 12 months 
 
3.2.3 Rheology  
Additionally, neither the Newtonian flow behaviour nor the viscosity at 25° C as well as at 
39° C changed over 12 months at the storage temperatures (Figure 3.4). The viscosity was 
approx. 120 mPas at 25° C and 60  mPas at 39° C.  
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Figure 3.4| Viscosity of castor oil: MCT 50:50 % (w/w) 1875 µg/ml GnRH [6-D-Phe] oil depot suspension at 2-8° C, 
25° C and 40° C over 12 months at 25° C and 39° C 
 
Furthermore, oscillatory rheometry did not indicate any change upon storage. The loss 
modulus G‖ was greater than the storage modulus G‘, confirming the viscous character of the 
depot suspension (Table 3.3, Table 3.4)
11,12
.  
25° C 
 
 2-8° C  25° C  40° C ' 
Time 
[months] 
G’ 
[mPa] 
G” 
[mPa] 
     G’ 
[mPa] 
G” 
[mPa] 
     G’ 
[mPa] 
G” 
[mPa] 
     
0 (Start) 5.4 303.7 56.2 .4 303.7 56.2 5.4 303.7 56.2 
1 16.6 488.6 29.4 12.6 530.1 42.1 13.7 540.7 39.5 
3 13.9 492.3 35.4 10.3 4821 46.8 8.7 439.6 50.5 
6 10. 498.5 46.1 11.8 443. 37.6 11.3 502.7 44.5 
9 11.4 493.4 43.2 12.1 456.4 37.7 12.1 498.5 41.2 
12 11.3 496.7 43.9 11.9 476.6 40.0 13.1 501.4 38.3 
39° C 
 
 2-8° C  25° C  40° C  
Time 
[months] 
G’ 
[mPa] 
G” 
[mPa] 
     G’ 
[mPa] 
G” 
[mPa] 
     G’ 
[mPa] 
G” 
[mPa] 
     
0 (Start) 4.5 163.3 36.3 4.5 163.3 36.3 4.5 163.3 36.3 
1 12.3 246.0 20.0 13.8 275.0 19.9 10.2 264.0 25.8 
3 8.9 244.1 27.4 8.2 248.7 30.3 5.4 224.0 41.5 
6 10.7 257.3 24.0 8.6 230.3 26.7 11.2 166. 14.8 
9 10.4 244.2 23.5 8.3 248.9 29.9 12.3 224.0 18.2 
12 10.2 257.5 25.2 8.7 230.7 26.5 12.6 246.0 19.5 
 
Table 3.3| Rheometer-Amplitude Sweep of castor oil: MCT 50:50 % (w/w) 1875 µg/ml GnRH [6-D-Phe] oil depot 
suspension at 2-8° C, 25° C and 40° C over 12 months at 25° C and 39° C 
G‘: storage modulus; G‖: loss modulus; tan δ= G‖/ G‘, determined in the viscoelastic region (τ= 0.1-10 Pa) 
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25° C 
 
 2-8° C  25° C  40° C  
Time 
[months] 
G’ 
[mPa] 
G” 
[mPa] 
ŋ*[mPas] G’ 
[mPa] 
G” 
[mPa] 
ŋ*[mPas] G’ 
[mPa] 
G” 
[mPa] 
ŋ*[mPas] 
0 (Start) 3.7E-6 4.0 112 3.7E-6 4.0 112 3.7E-6 4.0 112 
1 2.5 3. 113 5.5 3.2 150 3.3E-6 3.5 98.3 
3 0.4 2.7 160 2.9E-6 3.2 106 2.8 2.8 106 
6 4.2 3.1 114 3.9 2.9 137 1.32 3.3 97.8 
9 2.6 3.3 115 5.8 3.4 112 3.1E-6 3.4 105 
12 2.1E-6 2.2 113 1.5 2.6 115 0.9 2.5 98.9 
39° C 
 
 2-8° C  25° C  40° C  
Time 
[months] 
G’ 
[mPa] 
G” 
[mPa] 
ŋ*[mPas] G’ 
[mPa] 
G” 
[mPa] 
ŋ*[mPas] G’ 
[mPa] 
G” 
[mPa] 
ŋ*[mPas] 
0 (Start) 3.3E-6 3.5 76.6 3.3E-6 3.5 76.6 3.3E-6 3.5 76.6 
1 3.1 1.4 74.7 3.1 1.4 74.7 3.2E-6 3.4 75.3 
3 2.6E-6 2.8 77.7 2.6E-6 2.8 77.7 3.4E-6 3.6 79.6 
6 2.8 3.6 78.7 1.9E-6 2.0 55.9 3.3 1.0 76.3 
9 2.2E-6 2.4 75.6 2.2E-6 2.4 56.7 3.4E-6 3.6 56.8 
12 2.4E-6 3.5 76.7 3.1 3.5 58.7 3.3 3.5 57.9 
 
Table 3.4| Rheometer-Frequency Sweep of castor oil: MCT 50:50 % (w/w) 1875 µg/ml GnRH [6-D-Phe] oil depot 
suspension at 2-8° C, 25° C and 40° C over 12 months at 25° C and 39° C 
G‘: storage modulus; G‖: loss modulus; ŋ*: complex viscosity determined in the viscoelastic region (f=0.1-10 Hz) 
 
3.2.4 Injection Force Determination  
High viscosity and larger particles can lead to unstable injection forces and longer injection 
times, impacting negatively the syringeability and injectability. The Dynamic Glide Force 
(DGF) and the maximal glide force (F max) for castor oil: MCT 50:50 % (w/w) 1875 µg/ml 
GnRH [6-D-Phe] oil depot suspension remained ≤ 3 N and ≤ 5 N through 16 G and 18 G 
needles respectively, indicating an unproblematic manual application (Figure 3.5). 30 N is the 
value considered to be the maximum force for a manual injection
13
. 
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Figure 3.5| Maximal force (F max) and dynamic glide force (DGF) of castor oil: MCT 50:50 % (w/w) 1875 µg/ml 
GnRH [6-D-Phe] oil depot suspension at 2-8° C, 25° C and 40° C over 12 months  
(a) 16 G (b) 18 G needle 
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3.2.5 Oil Vehicle Oxidation  
The peroxide value (PV) is an indicator of the oxidative level and the tendency of oils and fats 
to become rancid
14,15
. A PV between 1 – 5 meq/ kg is classified as low oxidation state, 
between 5 – 10 meq/ kg as moderate oxidation and above 10 meq/ kg as high oxidation state. 
The para-anisidine value (p-AV) expresses the degree of secondary degradation products of 
fats and oils after thermal stress and is a more reliable indicator of oxidation in the long term 
and should lie below 10 g
-116,17
. The total oxidation value (TOTOX) is the sum of PV and AV 
and an overall indicator of the oxidative degradation of lipids and oils
18
. Both PV and AV 
remained under 1 mEq/ kg and 1 g
-1
 respectively, indicating the low oxidation state of the oil 
depot formulation. The TOTOX increased during the first months of the stability study at all 
storage temperatures. The lowest values were observed at 2-8° C storage temperature (Figure 
3.6). 
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Figure 3.6| PV, AV and TOTOX value of the castor oil: MCT 50:50 % (w/w) 1875 µg/ml GnRH [6-D-Phe] oil depot 
suspension at 2-8° C, 25° C and 40° C over 12 months 
 
3.3 CONCLUSION 
No considerable decrease in the content of GnRH [6-D-Phe] in the castor oil/ MCT 50:50 % 
(w/w) matrix over 12 months at 2-8° C, 25° C and 40° C could be detected. The slight 
increase in GnRH [6-D-Phe] particle size after 6 months of storage might be due to some 
large but loosely connected particle agglomerates, which were also observed by microscopy. 
However, these particles did not have any negative impact on the physical stability of the 
suspension with regards to viscosity and injectability. The total oil vehicle oxidation was 
higher at 40° C storage temperature in comparison to 2-8° C and 25° C. Overall, the oxidation 
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was marginal and below the TOTOX limit
19
. Hydrogen peroxide induced degradation 
products of GnRH [6-D-Phe] with RRT (retention time) 0.914, 0.509 and 0.789 were not 
visible in the recorded HPLC chromatograms of the suspension. Thus the chemical and 
physical stability of castor oil: MCT 50:50 % (w/w) 1875 µg/ml GnRH [6-D-Phe] oil depot 
suspension at 2-8° C, 25° C and 40° C storage temperatures over 12 months can be assured. 
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3.4 MATERIALS AND METHODS 
Gonadorelin [6-D-Phe] acetate peptide (pE1–H2–W3–S4–Y5–(D)F6–L7–R8–P9–G10–NH2) or (pGlu-His-
Trp-Ser-Tyr-D-Phe-Leu-Arg-Pro-Gly-NH2) was provided by BFC Biopept-Feinchemie as lyophilized powder 
and acetate salt (purity 99.76 %, water content 6.73 % and acetate peptide ratio (MW/MW) 1.8); Oil vehicle: 
miglyol
®
812 (MCT) (Caesar & Loretz, D-Hilden), castor oil (Gustav Heess, D-Leonberg). 
Stability samples preparation & setup Stability sample preparation was performed under a laminar flow 
cabinet in a two-step process. The GnRH [6-D-Phe] was cryo-ground with a precooling phase (10 min/ 5Hz) and 
a grinding phase (8 min/25 Hz) in 25 mL grinding jar with 15 mm grinding balls. Particle size of D v50 10.7 ± 
0.2 µm was obtained. The mixture of castor oil and MCT in 50:50 % (w/w) was heated up at 60° C under N2 
atmosphere and filtered at room temperature through a 1.2 µm Minisart
®
 Single use filter unit. The cryo-ground 
GnRH [6-D-Phe] was suspended in the oil matrix using an Ultra-Turrax T-10 basic (IKA Labortechnik, 
Germany) for 5 minutes at 2000 rpm. The castor oil: MCT 50:50 % (w/w) 1875 µg/ml GnRH [6-D-Phe] oil 
depot suspension was aliquoted in 20 R glass vials, stoppered and crimped. In total, 20 vials were prepared and 
stored upright at 2-8° C, 25° C and 40° C over 12 months without applying agitation. Each vial contained 22 mL 
with a volume overfill of appr. 10 % (Supplementary Data Table 3.5). At 1, 3, 6, 9 and 12 months GnRH [6-D-
Phe] content uniformity, suspension particle size distribution, morphology, injectability, rheology and oil vehicle 
oxidation were evaluated. 
GnRH [6-D-Phe] extraction from the oil matrix GnRH [6-D-Phe] was extracted from castor oil: MCT 
50:50 % (w/w) 1875 µg/ml GnRH [6-D-Phe] oil depot suspension using dichloromethane (DCM) and toluene, 
where GnRH [6-D-Phe] is not soluble, in combination with PBS (pH 7.4). DCM Extraction: 2 mL weighted oil 
suspension with added 4 mL DCM and 6 mL PBS (pH 7.4) was shaken at room temperature (25° C) and put into 
an incubated shaker 3031 (GFL, Germany) at 39° C and 60 rpm for 24 h. Toluene extraction: 2 mL weighted 
oil suspension with added 4 mL toluene and 6 mL PBS (pH 7.4) was shaken and centrifuged (12.000xg, 10 min) 
at room temperature (25° C). PBS (pH 7.4) extraction: 2 mL weighted oil suspension with added 6 mL PBS 
(pH 7.4) was shaken and centrifuged (12.000xg, 10 min) at room temperature (25° C). The preparation 
techniques using either PBS (pH 7.4) or toluene required centrifugation because of the organic solvent high 
density. Reference sample: weighted pure GnRH [6-D-Phe] was dissolved in 6 mL PBS (pH 7.4) and 4 mL 
DCM was added. The tube was shaken and put into an incubated shaker 3031 (GFL, Germany) at 39° C and 
60 rpm for 24 h. The RP-HPLC analysis at 220 nm detection wavelength showed the highest recovery and was 
the method of choice for the analysis of the stability time points. The value of DCM extracted pure GnRH [6-D-
Phe] was used to correct the obtained recovery values. The highest calculated recovery ratio of GnRH [6-D-Phe] 
was in DCM (Supplementary Data Table 3.6). 
GnRH [6-D-Phe] content uniformity and stability The frequency of a normal human shaking and oscillating 
wrist lies at 6-12 Hz derived as a value from the Duhaime Study and represents the usual shoulder motion
20
. At 
each stability time point the formulation was shaken 2 minutes at 12 Hz with a Mixer Mill MM200 (Retsch 
Technologies, Germany) and 5 aliquots of 2 mL were withdrawn. The GnRH [6-D-Phe] content was analysed 
using RP-HPLC. 
Determination of the GnRH [6-D-Phe] content. The GnRH [6-D-Phe] content was analysed by RP-HPLC 
using a LUNA C8 (4.6 mm x 250 mm; size = 5 µm; Phenomenex, USA) column, with a C8 pre-column (4 mm x 
3 mm; size = 5 µm) at an HPLC Agilent 1100/1200 series (Agilent Technologies, USA) (mobile phase A (water 
+ 1 mL/L Trifluoroacetic acid (TFA) (v/v)) and mobile phase B (800 g Acetonitrile + 200 g water + 1.2 mL 
TFA), 1.1 mL/min flow, column temperature 40° C, and autosampler temperature 2 – 8° C. The Retention Time 
(RT) of GnRH [6-D-Phe] was 8.5 ± 1.5 minutes with UV detection at 220 nm. In order to detect degradation 
products the following separations were performed: 1. A blanc run after injection of water to show that there is 
no signal found in the region of the RT of GnRH [6-D-Phe].2. A separation of 2.5 mL solution of GnRH [6-D-
Phe] (50 µg/mL), 1mL H2O2 (30% v/v) and 2.5 mL HCL (1N) diluted to 25 mL with water, separation 12 hours 
after dilution. 3. A separation of 2.5 mL solution of GnRH [6-D-Phe] (50 µg/mL), 1 mL H2O2 (30% v/v) and 
2.5 mL NaOH (1N) diluted to 25 mL with water, separation 10 minutes after dilution. 4. A separation of 2.5 mL 
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solution of GnRH [6-D-Phe] (50 µg/mL) after treatment with light (1.5mLux/h for 12 h in quartz dish), 
separation without dilution. 
GnRH [6-D-Phe] particle size distribution and characterization The particle size distribution of the stability 
samples at each time point was analysed employing a Laser Diffraction Particle Size Analyzer LA-950 (Retsch 
Technology, Haan). The samples were prepared in triplicate (n=3). 0.2 mL of the oil suspension was withdrawn 
from the vial and measured in a solution of 1 % sorbitan monooleate in isooctane (m/v) in a standard measuring 
cell with 10 mL volume. 
Light microscopy and Scanning Electron Microscopy. The light microscopy of castor oil: MCT 50:50 % 
(w/w) 1875 µg/ml GnRH [6-D-Phe] oil depot suspension was taken with VHX – 500 FD (Keyence, Osaka, 
Japan) at the 2-8° C, 25° C and 40° C storage temperature over 12 months. 
Rheology: Viscosity profile Viscosity measurement and flow curves evaluation of the stability samples were 
performed with MCR 100 (Anton Paar Germany, Ostfildern-Scharnhausen) cone plate system CP – 1 (50 mm 
diameter, a cone angle of 1° and a gap of 0.042  mm). The viscosity η was defined depending on the shear rate ẏ 
and measuring sections a) 0 – 500 s
-1 
(30 points, 6 s per point; 180 s measurement time), b) 500 s
-1 
(1 point, 6 s 
per point, 6 s measurement time), c) 500 – 0 s
-1 
(30 points, 6 s per point, 180 s measurement time). Amplitude 
sweep Amplitude sweep measurements were performed with cone plate system CP – 1 (50 mm diameter, a cone 
angle of 1°, and a gap of 0.2 mm). The storage and loss moduli G‘/G‘‘ were defined depending on strain γ or 
shear stress τ and the measuring sections a)                      ; discarded (12 points, 5 s per point, 
60 s measurement time), b)                    ; (30 points, 15 s per point, 450 s measurement time), 
tan δ was determined in the viscoelastic region (τ= 0.1-10 Pa). Frequency sweep Frequency sweep 
measurements of the stability samples were performed with cone plate system CP – 1 (50 mm diameter, a cone 
angle of 1°, and a gap of 0.2 mm). The storage and loss moduli G‘/G‘‘ were defined depending on strain γ or 
shear stress τ and the measuring sections a)                        ; discarded (12 points, 5 s per point, 
60 s measurement time), b)                      ; (30 points, 15 s per point, 450 s measurement time), 
ŋ* was determined in the viscoelastic region (f=0.1-10 Hz). 
Injection force determination The injectability/syringeability were performed with the TA.XT.plus Texture 
Analyser (Stable Micro Systems, Godlming, UK). The formulations were injected into air using a NORM-JECT 
1 mL Tuberkulin + Luer syringe (Henke-Sass-Wolf GmbH, Germany) with either a FINE-JECT 18 Gx2‘‘, 
1.2x50 mm needle (Henke-Sass-Wolf GmbH, Germany) or a FINE-JECT 16 Gx1½‘‘, 1.6x40 mm needle 
(Henke-Sass-Wolf GmbH, Germany). The software Exponent was set to compression test mode with the 
parameters: 10 mm/sec pre-test speed, and 3.9 mm/sec test speed, and 10.00 mm/sec post-test speed, trigger 
force: 0.001 N. The applied force from the texture analyser was recorded in [N] against the distance of the 
syringe plunger (max. 64 mm). 
Oil vehicle oxidation The PV at each stability time point was determined with the Pierce Quantitative Peroxide 
Assay Kit for lipid-compatible formulations. The assay consists of two reagents: Reagent A 25 mM ammonium 
ferrous (II) sulfate and 2.5 M H2SO4 and Reagent C 4 mM Butylhydroxytoluol (BHT) and 125 µM xylenol 
orange in methanol. The hydroperoxides convert Fe
2+
 to Fe
3+
. Fe
3+
 reacts with xylenol orange dye and results in 
a coloured product, photometrically detectable at 595 nm. The working reagent was prepared from 1 volume 
Reagent A and 100 Volumes Reagent C and was stable for 12 h. The peroxide standards were prepared with 
30 % (8.8 M) hydrogen peroxide in methanol (Supplementary Data Table 3.7). The AV: 0.5 – 4 g (w) of the oil 
suspension at each time point were dissolved in 25 mL isooctane and the absorbance of this fat solution (A1) was 
measured against a blank of isooctane at 350 nm. 5 mL of the solution and 5 mL of the isooctane solution (as 
blank) were transferred in falcon tubes and 1 mL of the anisidine solution was added to each. After 10 min, the 
absorbance (A2) was measured with the NanoDrop 2000 Spectrophotometer (Thermo Scientific, USA) at 
350 nm. The p-AV was calculated according to the equation: 
        
         
 
 
Equation 3.1| AV calculation 
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The TOTOX value is the sum of both PV and AV 
                      
Equation 3.2| TOTOX calculation 
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3.6 SUPPLEMENTARY DATA 
Vial Sample Temperature [° C] Filled Volume [mL] % Overfill 
1 Gona_t0 5, 25, 40 21.9 9.1 
2 Gona_t1_5° C 5 22.1 9.4 
3 Gona_t1_25° C 25 21.9 9.0 
4 Gona_t1_40° C 40 22.2 9.7 
5 Gona_t3_5° C 5 21.9 9.0 
6 Gona_t3_25° C 25 21.9 9.0 
7 Gona_t3_40° C 40 22.0 9.1 
8 Gona_t6_5° C 5 22.1 9.3 
9 Gona_t6_25° C 25 22.0 9.1 
10 Gona_t6_40° C 40 22.0 9.2 
11 Gona_t9_5° C 5 22.2 9.8 
12 Gona_t9_25° C 25 22.1 9.3 
13 Gona_t9_40° C 40 21.9 9.1 
14 Gona_t12_5° C 5 22.0 9.1 
15 Gona_t12_25° C 25 22.1 9.4 
16 Gona_t12_40° C 40 22.1 9.3 
17 Gona_res 5 20.9 4.7 
18 Gona_res 25 20.9 4.5 
19 Gona_res 40 20.9 4.5 
 
Table 3.5| Stability samples preparation 
 
Extraction 
method 
Extraction efficiency 
[%] ± SD 
DCM 81.9 81.9 78.2 78.2 84.8 81.2 81.1 ± 2.5 
Toluene 77.4 77.4 82.4 82.3 75.2 75.1 78.3 ± 3.3 
PBS 73.1 73.1 74.2 74.4 72.8 72.9 73.4 ± 0.7 
GnRH [6-D-
Phe]_DCM 
89.9 89.8 93.2 93.1 92.9 92.9 91.9 ± 1.7 
 
Table 3.6| GnRH [6-D-Phe] extraction method efficiency from the castor oil/ MCT 50:50 % (w/w) matrix 
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Standard µl H2O2 H2O2 MeOH 
1 1000 11 µl 8.8 M 100 ml 
2 500 100 µl std.1 100 µl 
3 250 100 µl std.2 100 µl 
4 125 100 µl std.3 100 µl 
5 62.5 100 µl std.4 100 µl 
6 31.25 100 µl std.5 100 µl 
7 15.63 100 µl std.6 100 µl 
8 7.81 100 µl std.7 100 µl 
9 3.91 100 µl std.8 100 µl 
10 1.95 100 µl std.9 100 µl 
Sample Gona_tX MeOH 
Gona_tx_1 90 µl 10 µl 
Gona_tx_2 90 µl 10 µl 
Gona_tx_3 90 µl 10 µl 
Gona_tx_blank 90 µl 10 µl 
 
Table 3.7| Pierce Quantitative Peroxide Assay, tx, where x stands for 0, 1, 3, 6, 9 and 12 months 
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The release of GnRH [6-D-Phe] from low viscosity pure oil mixtures of castor oil and 
medium chain triglycerides (MCT) is superior to the high viscosity ones because of their 
more consistent in vivo effect. The formulation remains stable over 12 months at 5° C, 
25° C and 40° C with respect to particle size, injection forces, viscosity and oxidation. 
The incorporation of gelling and stabilizing agents in the Newtonian formulation 
obtained a shear thinning behaviour. The in vitro release of GnRH [6-D-Phe] from the 
oil depot with additives, intended for swine reproduction cycle manipulation, was slower 
and consistent over 8 days. The in vivo effect of the formulation was tested in a second 
preclinical study and proved to resemble the observed in vitro effect.  
 
4.1 INTRODUCTION 
Excipients in parenteral oil depot suspensions, e.g. gelling agents, resuspendibility enhancers, 
wetting agents and antioxidants, are used in order to enhance and maintain formulation 
stability, assure applicability and/or prolong the drug release. Gelling agents from the group 
of metallic stearates specifically aluminiummono or -distearate are known to improve the 
suspending properties and to reduce the spreading in the tissue after injection. The second can 
be related to the shear-thinning behaviour and increased formulation viscosity at rest
1
. The 
reduced spreading is further expected to delay the drug release. In 1950 an oil depot 
suspension of the antibiotic, penicillin G procaine in sesame oil and peanut oil gelled with 
2 % aluminium monostearate produced prolonged therapeutic blood levels of penicillin G 
after i.m. injection
2
. Similar gelled oil matrices were applied successfully in the delivery of 
50 % normorphinone and 40 % oxazepine either as free base or pamoate salt
3,4
. Subsequently, 
oil gelled formulations for the sustained release of proteins and peptides were tested, e.g. a 
2 % suspension of relaxin gelled with aluminium monostearate
5
 and a  superagonist analogue 
of the luteinizing hormone-releasing hormone (LHRH) in peanut or sesame oil, gelled with 
aluminium stearate
6,7
. 
A 5 % aluminium monostearate gelled oil matrix forms the basis of Posilac
®
, a single-dose 
syringe of rbST-Zn 
2+
 (recombinant bovine somatotropin) oil depot suspension
8,9
. An 
alternative to using a gelling agent is to increase the drug concentration. Ivomec
®
 Gold is 3.15 
fold higher concentrated compared to a standard Ivomec
®
 suspension. It exhibits unique 
thixotropic characteristics due to stronger particle-particle interactions, indirectly allowing the 
slow release of Ivermectin from the depot upon injection
10
. A structured vehicle approach, 
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using either a gelling agent or an increased compound concentration can keep the dispersed 
particles of the suspension in a deflocculated state, reducing the sedimentation rate. Wetting, 
dispersing and stabilizing agents are added to improve the resuspendibility and dose 
uniformity of the oil suspension and induce the formation of a stable flocculated system
11,12
. 
The main advantage of a stable flocculated system is the formation of loose particles 
aggregates in a network-like structure, which break up easily under the application of force or 
shear stress, allowing for an unproblematic multi-dose application. However, it should be 
noted that the stability of a suspension is influenced by the concentration of added 
flocculating agents. At higher concentration they make the resuspension of agglomerated 
particles difficult
13
. In the following study we tested suitable gelling agents and flocculating 
additives for the development of a stable oil GnRH [6-D-Phe] depot suspension with 
improved injectability and flow characteristic. We evaluated the effect of the additives on the 
in vitro release of GnRH [6-D-Phe]. The in vivo effect of the formulations was analysed in a 
preclinical study. 
 
CHAPTER 4 
65 
4.2 RESULTS AND DISCUSSION 
4.2.1 Preliminary Study of Gelling Agent, Wetting Agent and Resuspendibility 
enhancer  
In the following the effect of added gelling, wetting agents and resuspendibility enhancer on 
the flow characteristics of middle chain triglycerides (MCT) was investigated. The measured 
viscosity of pure MCT is 27.6 ± 0.5 mPas at 25° C and 17.3 ± 0.3 mPas at 39° C (Chapter 2, 
Table 2.1). The addition of aluminium monostearate (Al-MonoSt), regardless of the 
concentration, displayed a nearly unchanged viscosity value and Newtonian flow behaviour 
with no gel and desirable thixotropic characteristics. An oil phase separation upon storage was 
visible. The addition of 3 % could achieve a marginal viscosity increase of the MCT oil from 
28 mPas to 31 mPas (Figure 4.1 a, b). In contrast, samples with 3 % aluminium distearate (Al-
DiSt) possessed a distinct thixotropic character at 25° C, which was preserved at higher 
temperatures, 39° C. The addition of 2 % and 3 % to MCT increased the viscosity to 53 mPas 
and 108 mPas at 500 s 
-1
, respectively (Figure 4.1 c, d). Both formulations were 
unproblematic for a manual injection. Mixtures composed of MCT + 3 % gelling agent Al-
DiSt + 1 % wetting agent (hydrogenated lecithin) + 10 % resuspendibility enhancer (polyoxyl 
(PEG)-35 castor oil) were homogeneous upon visual inspection. The thixotropy of 3 % Al-
DiSt was preserved after the addition of hydrogenated lecithin and PEG- 35 castor oil (Figure 
4.1 e, f). Concentrations of the wetting agent and resuspendibility enhancer higher than 1 % 
and 10 % respectively, induced sedimentation and phase separation.  
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Figure 4.1| Rheology of mixtures of MCT with a gelling agent and/or wetting agent and/or resuspendibility enhancer  
(a), (c), (e) at 25° C (b),(d),(f) at 39° C 
 
4.2.2 GnRH [6-D-Phe]-Additives Oil Depot Suspension 
The first preclinical study could show that a concentration of 1875 µg/mL GnRH [6-D-Phe] in 
castor oil: MCT 50:50 % (w/w) induced a synchronous in vivo effect of 2 days minimum and 
5 days maximum (Chapter 2, Table 2.6). Thus formulations with 1875 µg/mL GnRH [6-D-
Phe] were further evaluated (Figure 4.2). In total 11 formulations were composed (Table 4.1). 
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Figure 4.2| 2nd generation GnRH [6-D-Phe] oil depot suspension 
 
Formulation Al-DiSt % (w/w) gelled MCT 
Hydrogenated Lecithin 
(Phospholipon®90H) % 
(w/w) 
Polyoxyl (PEG)-35 castor oil 
(Kolliphor®ELP) % (w/w) 
F1 1 - - 
F2 2 - - 
F3 3 - - 
F4 3 1 5 
F5 3 2 5 
F6 3 1 0.05 
F7 3 1 10 
Formulation Al-DiSt % ( w/w) gelled MCT 
Sorbitan monooleate 
(Span®80) % (w/w) 
Ethoxylated sorbitan monooleate 
Polysorbate 80 
(Tween ®80) % (w/w) 
F8 3 5 5 
F9 3 0.05 0.05 
F10 3 2 2 
Formulation Castor oil: MCT 50:50 % 
(w/w) 
- - 
F11 - - - 
 
Table 4.1| Composition of F1-F11 1875 µg/ml GnRH [6-D-Phe] oil depot formulation 
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4.2.3 Rheology  
The GnRH [6-D-Phe] formulations gelled with 2 % (F2) and 3 % (F3) Al-DiSt showed a 
temperature independent shear-thinning behaviour compared to the previously tested 
Newtonian castor oil – MCT mix (F11) (Figure 4.3). The addition of hydrogenated lecithin 
and polyoxyl (PEG)-35 castor oil lowered the viscosity of the gelled matrix. The recorded 
high viscosity value of formulations F3 and F9 at 39° C in comparison to 25° C might be 
related to the absence or low concentrations of wetting and resuspendibility enhancer, 
inducing GnRH [6-D-Phe] particles agglomeration and increase in viscosity. 
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Figure 4.3| Rheology of F1-F11 1875 µg/ml GnRH [6-D-Phe] oil depot formulations  
(a), (c), (e) at 25° C (b), (d), (f) at 39° C 
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Furthermore, oscillatory rheometry was applied. When applying stress on the vehicles, there 
are two possible scenarios which can result. The first one indicates a structure of loosely 
connected particles, where the applied mechanical force overrides the particle-particle 
interaction, breaking the structure and inducing the flow of the suspension (G―>G‗). The 
second possibility is strong gel structures, which are hard to separate through the induced 
mechanical stress (G‗>G―). Increasing the amount of the gelling agent from 1 % (F1) to 3 % 
(F3) led to the formation of a strong gel structure. This was further confirmed through a 
decreased tan δ value (Table 4.2). The formulation with 10 % PEG-35 castor oil showed 
increased tendency to break upon application of stress. Similar observations were made for 
the formulation with 5 % sorbitan monooleate and 5 % polysorbate 80 (Table 4.2, Table 4.3).  
Rheometer-Amplitude Sweep Rheometer-Amplitude Sweep 
25° C 39° C 
 
Formulation G’ [mPa] G” [mPa]      
F1 9.93 151 15.21 
F2 48.58 216 4.45 
F3 62 629.6 1.01 
F4 1322 329.8 2.49 
F5 74.54 280 3.76 
F6 9.66 115.6 11.97 
F7 29.86 286.8 9.60 
F8 9.13 193.6 21.19 
F9 119.4 342 2.86 
F10 19.72 185.2 9.39 
F11 10.19 360.2 35.33 
Formulation G’ [mPa] G” [mPa]      
F1 8.07 107 13.26 
F2 65.85 98 3.00 
F3 1217.5 670 0.55 
F4 5.23 180 3.58 
F5 29.35 152 5.18 
F6 14.35 72.72 5.07 
F7 25.13 186 7.40 
F8 7.65 125 16.34 
F9 188.25 352.5 1.87 
F10 6.95 113.75 16.36 
F11 5.54 186.25 33.58 
 
 
Table 4.2| Rheometer-Amplitude Sweep of F1-F11 1875 µg/ml GnRH [6-D-Phe] oil depot formulations at 25° C and 
39° C 
G‘: storage modulus; G‖: loss modulus; tan δ= G‖/ G‘, determined in the viscoelastic region (τ= 0.1-10 Pa) (Supplementary 
Data Figure 4.13) 
 
Frequency-Amplitude Sweep Frequency-Amplitude Sweep 
25° C 39° C 
Formulation G’ [mPa] G” [mPa] ŋ* [mPas] 
F1 7.10 97.81 1.03 
F2 17.51 116.75 37.27 
F3 437.31 378.23 228.82 
F4 91.32 187.6 71.98 
F5 45.42 158.48 50.72 
F6 9.78 99.85 26.25 
F7 25.01 153.15 49.28 
F8 10.98 135.61 40.96 
F9 81.48 218.11 76.95 
F10 18.53 129.95 40.15 
F11 13.30 272.44 79.45 
 
Formulation G’ [mPa] G” [mPa] ŋ* [mPas] 
F1 7.46 75.45 25.06 
F2 38.04 122.75 41.72 
F3 737.15 637.54 448.31 
F4 45.22 116.52 43.87 
F5 8.20 72.52 24.30 
F6 114.28 243.40 76.58 
F7 22.91 108.57 35.48 
F8 11.62 97.84 31.12 
F9 44.82 195.37 69.89 
F10 17.84 92.09 29.92 
F11 5.26 143.29 2.92 
 
 
Table 4.3| Frequency-Amplitude Sweep of F1-F11 1875 µg/ml GnRH [6-D-Phe] oil depot formulations at 25° C and 
39° C 
G‘: storage modulus; G‖: loss modulus; ŋ*: complex viscosity determined in the viscoelastic region (f=0.1-10 Hz); 
(Supplementary Data Figure 4.14) 
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Formulations F7 (MCT + 3 % Al-DiSt + 1 % hydrogenated lecithin + 10 % PEG-35 castor 
oil) and F8 (MCT + 3 % Al-DiSt + 5 % sorbitan monooleate + 5 % polysorbate 80) showed 
phase separation within 24 hours after preparation (Figure 4.4). The high concentrations of 
wetting and resuspendibility enhancer might induce the formation of flocculated system, 
where the sediment is rapidly formed. 
 
F1_0h F1_24h F2_0h F2_24h F3_0h F3_24h 
      
F4_0h F4_24h F5_0h F5_24h F6_0h F6_24h 
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Figure 4.4| Camera images of F1-F11 1875 µg/ml GnRH [6-D-Phe] oil depot formulations over 24 h 
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4.2.4 Injection Force Determination  
Injecting a gelled oil vehicle can be a strenuous task and might require forces that can be hard 
to manage manually. Consequently, the injectability of F1-F11 was tested. Both the Dynamic 
Glide Force (DGF) and the maximal force (Fmax) for the injection of F1-F11 through 16 G 
and 18 G needles were below 3 N, 10 times lower than the estimated maximum force for 
manual injection, 30 N
14
 (Figure 4.5). 
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Figure 4.5| F max and DGF of F1-F11 1875 µg/ml GnRH [6-D-Phe] oil depot formulations  
(a) 16 G (b) 18 G needle 
 
4.2.5 Particle Size Distribution and Characterization 
GnRH [6-D-Phe] particle size can have an impact on the suspension sedimentation rate, 
stability and dose uniformity. The median particle size Dv50 for the dispersed formulations 
remained nearly unchanged. The particle size distribution of all measured samples was non-
symmetric (Figure 4.6). Increasing the hydrogenated lecithin concentration to 2 % and 
reducing the concentration of PEG-35 castor oil to 0.1 % resulted in the formation of larger 
particles, visible through the increase of the Dv90 and mean particle size. There was no 
considerable difference between formulations with 5 % and 10 % PEG-35 castor oil. The 
dispersed formulations without wetting and resuspendibility agent showed an overall larger 
particle size (Table 4.4). 
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Figure 4.6| Mean (the mean particle diameter over volume) and median particle size of F1-F11 1875 µg/ml GnRH [6-
D-Phe] oil depot formulations 
 
Formulation Dv50 [µm] ± SD Dv90 [µm] ± SD 
F1 9.17 ± 0.22 23.24 ± 9.54 
F2 8.94 ± 0.11 71.92 ± 8.97 
F3 8.97 ± 0.18 101.48 ± 9.69 
F4 9.86 ± 0.12 29.99 ± 1.15 
F5 11.53 ± 0.51 100.14 ± 28.38 
F6 10.52 ± 0.22 48.49 ± 5.45 
F7 8.21 ± 0.19 28.08 ± 2.00 
F8 14.06 ± 0.31 64.00 ± 4.33 
F9 5.97 ± 0.01 15.31 ± 0.45 
F10 13.95 ± 0.45 48.39 ± 0.93 
F11 9.30 ± 0.07 57.90 ± 0.04 
 
Table 4.4| Particle size distribution and Dv50 and Dv90 fractions  
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4.2.6  Oil-Water Interface  
In order to visualize the behaviour of the formulations upon contact with aqueous phase, drop 
shape analysis and light microscopy of the formulation/water interface were performed. 
Formulations F1, F2, F3, and F11 without additives showed reduced spreading when injected 
into the PBS (pH 7.4). The surfactants led to a reduction of the surface tension promoting 
spreading of the oil vehicle (Figure 4.7). 
F1 F2 F3  
   
 
F4 F5 F6 F7 
    
F8 F9 F10 F11 
    
 
Figure 4.7| Drop shape analysis in PBS (pH 7.4) of F1-F11 1875 µg/ml GnRH [6-D-Phe] oil depot formulations 
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Formulations F4-F7 and F8-F10 with stabilizing agents got emulsified upon contact with 
aqueous buffer. The formulations with gelled oil or only oil, F1-F3 and F11, showed no 
emulsified oil drops in PBS (Figure 4.8). 
F1 F2 F3 F11 
    
F4 F5 F6 F7 
    
F8 F9 F10  
   
 
 
Figure 4.8| Light microscopy of F1-F11 1875 µg/ml GnRH [6-D-Phe] oil depot formulations emulsified in PBS pH 7.4 
 
4.2.7 Self-Emulsifying Character  
F2, F4, F9 and F11 were injected into PBS to understand the in vivo behaviour upon contact 
with tissue fluid. F4 spontaneously formed an emulsion with droplet in the low micrometer 
range (Figure 4.9 a, b). The other formulations did not show this characteristic. Reduction of 
the hydrogenated lecithin concentration did not affect the formation of the microemulsion 
(Figure 4.9 e, f). The combination of PEG-35 castor oil and lecithin has been well established 
and applied into the formation of self-emulsifying systems. These are vehicles, which build a 
fine dispersed microemulsion using chemical rather than mechanical means
15–17
. A 
combination of a hydrophilic surfactant, PEG-35 castor oil (HLB=14-16), with a lipophilic 
surfactant hydrogenated lecithin (HLB ~ 3) in the oil phase, induces upon contact with the 
aqueous phase the formation of a mixed surfactant based self-emulsifying drug delivery 
system (SEDD) with incorporated GnRH [6-D-Phe]
18,19
 (Figure 4.9). This could assure a 
more consistent and controlled release of GnRH [6-D-Phe] from the oil matrix and improve 
its in vivo effect.  
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Figure 4.9| Light microscopy and Transmission electron microscopy (TEM) of the oil phase and the microemulsified 
oil phase 
(a, b) F4 in PBS (pH 7.4)  
(c, d) F4.0: MCT+ 3% Al-DiSt+ 1% hydrogenated lecithin+ 5% PEG-35 castor oil (e, f) F4.1: MCT+ 3% Al-DiSt+ 0.5% 
hydrogenated lecithin+ 2.5% PEG-35 castor oil injected in 6 mL PBS (pH 7.4) at 39° C in an incubated shaker after 24h 
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4.2.8  In vitro Release Studies 
In order to select formulations for the in vivo study an in vitro release experiment was 
performed.  
This showed a correlation between the Al-DiSt content and the GnRH [6-D-Phe] release: the 
higher the Al-DiSt content, the more delayed the release of GnRH [6-D-Phe] (F1-F3) (Figure 
4.10 a). The total amount of released GnRH [6-D-Phe] could be markedly increased by the 
addition of hydrogenated lecithin or PEG-35 castor oil (F4-F7, Figure 4.10 b). Hydrogenated 
lecithin and PEG-35 castor oil concentrations higher than 2 % and 10 % respectively induced 
a burst release of GnRH [6-D-Phe] from the oil depot. The third group (F8-F10) containing 
sorbitan monooleate/ polysorbate 80 mixtures showed higher burst with increasing 
concentration from 0.05 % in F9 to 5 % in F8, reaching the release values of castor oil: MCT 
50:50 % (w/w) oil depot from the first preclinical study (F11, Figure 4.10 c). 
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For in vivo testing the following three formulations were selected: 
MCT + 2 % (w/w) Al-DiSt (F2), displaying a shear-thinning behaviour with a relatively low 
viscosity. 
MCT + 3 % (w/w) Al-DiSt + 1 % (w/w) hydrogenated lecithin + 5 % (w/w) PEG-35 castor oil 
(F4), showing narrow particle size distribution, no visible phase separation upon storage and 
good emulsification properties. 
MCT + 3 % (w/w) Al-DiSt + 0.05 % (w/w) sorbitan monooleate + 0.05 % (w/w) polysorbate 
80 (F9), exhibiting a low burst release, good rheological properties and good emulsification. 
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Figure 4.10| In vitro release profiles of F1-F11 1875 µg/ml GnRH [6-D-Phe] oil depot formulations in visking dialysis 
tubing, MWCO 12 – 14 kD  
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Increasing the concentration of GnRH [6-D-Phe] acetate to 3750 µg/mL could not 
compensate the burst effect and did not affect the in vitro release profile significantly (Figure 
4.11). The established in vitro model could differentiate between the four formulations; 
however, it does not allow a prediction of their in vivo behaviour. 
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Figure 4.11| In vitro release profiles of GnRH [6-D-Phe] oil depot formulations in visking dialysis tubing, MWCO 12 – 
14 kD 
 
4.2.9 In vivo 2nd Preclinical Study 
The four formulations were tested in vivo: 
MCT + 2 % (w/w) Al-DiSt 3750 µg/mL GnRH [6-D-Phe], 
MCT + 3 % (w/w) Al-DiSt + 1 % (w/w) hydrogenated lecithin + 5 % (w/w) PEG-35 castor oil 
1875 µg/ml GnRH [6-D-Phe] 
MCT + 3 % (w/w) Al-DiSt + 0.05 % (w/w) sorbitan monooleat + 0.05 % (w/w) polysorbate 
80 1875 µg/ml GnRH [6-D-Phe]  
Castor oil: MCT 50:50 % (w/w) 3750 µg/ml GnRH [6-D-Phe] 
The effect was evaluated and considered successful if first, the estrous cycle was blocked and 
there were no follicles larger than 5mm and second, Corpus luteum (CL) showed a reduced 
size in comparison to previous measurements. A CL regression was expected on days 15-17 
of the estrous cycle, corresponding to 4-6 days post application. If a follicle growth, an 
ovulation or cyst development appeared, the cycle blockage was regarded as unsuccessful.  
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The control group received the oil medium without GnRH [6-D-Phe]. Ultrasonography 
showed a follicle growth and no effect of the placebo (0.2 ± 0.4 days) (Figure 4.12). MCT + 
2 % (w/w) Al-DiSt 3750 µg/mL GnRH [6-D-Phe] resulted in 7 and 11 days of cycle blocking 
in two animals. Three animals displayed a permanent cycle blockage. Thus the average effect 
was 42.6 ± 30.7 days. Four animals injected with 1875 µg/mL GnRH [6-D-Phe] in the vehicle 
of MCT + 3 % (w/w) Al-DiSt + 1 % (w/w) hydrogenated lecithin + 5 % (w/w) PEG-35 castor 
oil showed follicle growth between day 10 and day 11 resulting in an effect of 4 to 5 days. 
One animal in the group displayed no cycle blocking effect. The average effect was 3.6 ± 2.1 
days. Two animals treated with 1875 µg/mL GnRH [6-D-Phe] in the vehicle MCT + 3 % 
(w/w) Al-DiSt + 0.05 % (w/w) sorbitan monooleate + 0.05 % (w/w) polysorbate 80 showed 
10 to 13 days of cycle blockage and three of the animals had permanent cycle blockage. This 
resulted in an average effect of 43.6 ± 29.3 days. The animals which received 3750 µg/ml 
GnRH [6-D-Phe] in castor oil: MCT 50:50 % (w/w) showed the most irregularities. Cycle 
blockage for 4 to 8 days was seen in three animals and two animals showed no effect. The 
average blockage lasted 3.4 ± 3.4 days (Supplementary Data Table 4.6). 
Statistical analysis showed that the mean cycle blocking effect of the group MCT + 3 % 
(w/w) Al-DiSt + 1 % (w/w) hydrogenated lecithin + 5 % (w/w) PEG-35 castor oil was 
significantly longer than the one of the control group (p<0.05) (Supplementary Data Table 
4.8). There were no significant differences between animals treated with castor oil: MCT 
50:50 % (w/w) 3750 µg/ml GnRH [6-D-Phe] and placebo (p>0.05) (Supplementary Data 
Table 4.10). 
In summary, the in vivo study confirmed that a treatment with GnRH [6-D-Phe] oil depot 
suspension could successfully prolong the luteal phase of the estrus cycle and inhibit a follicle 
development and growth. The most pronounced cycle blocking effect, with regards to effect 
synchronicity, length and observed adverse reactions, were detected in the group MCT + 3 % 
(w/w) Al-DiSt + 1 % (w/w) hydrogenated lecithin + 5 % (w/w) PEG-35 castor oil. In contrast 
the vehicles without self-emulsifying character, MCT + 3 % (w/w) Al-DiSt + 0.05 % (w/w) 
sorbitan monooleate + 0.05 % (w/w) polysorbate 80 and MCT + 2 % (w/w) Al-DiSt displayed 
irregular cycle blockage effect. Increased peptide concentration of 3750 µg/mL in castor oil: 
MCT 50:50 % (w/w) did not lead to a significant prolongation of the blocking effect (3.4 ± 
3.4 days). The in vivo study results showed further that a mixed surfactant based SEDD of 
GnRH [6-D-Phe] with hydrogenated lecithin and PEG-35 castor oil achieved a more 
consistent cycle blocking effect compared to the pure gelled oil and pure oil vehicle 
formulations. 
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Figure 4.12| In vivo effect of the oil depot GnRH [6-D-Phe] formulations 
 
4.3 CONCLUSION 
The experiments demonstrated that the incorporation of additives to a pure MCT oil vehicle 
for the sustained delivery of GnRH [6-D-Phe] was favourable due to the following 
characteristics: First, the Al-DiSt gelled MCT oil displayed a clear shear-thinning behaviour 
in comparison to the pure oil, making the multiple dose withdrawal from a vial easier. 
Second, the incorporated hydrogenated lecithin as well as PEG-35 castor oil resulted in the 
formation of a self-emulsifying drug delivery system of GnRH [6-D-Phe], thus obtaining a 
more consistent and controlled release with reduced initial in vitro burst. The sustained 
release might be partially due to the gelled oil matrix. Although the 0.05% sorbitan 
monooleate/ polysorbate 80 mixture could achieve a longer in vivo blocking effect in 
comparison to 5% PEG-35 castor oil and 1% hydrogenated lecithin mixture, it was only of a 
moderate synchronicity. Therefore, in order to prolong the obtained consistent in vivo effect 
of MCT + 3 % (w/w) Al-DiSt + 1 % (w/w) hydrogenated lecithin + 5 % (w/w) PEG-35 castor 
oil, it might be beneficial to reduce the GnRH [6-D-Phe] solubility through salt or polymer 
complexation.  
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4.4 MATERIALS AND METHODS 
Gonadorelin [6-D-Phe] acetate peptide (pE1–H2–W3–S4–Y5–(D)F6–L7–R8–P9–G10–NH2) or (pGlu-His-
Trp-Ser-Tyr-D-Phe-Leu-Arg-Pro-Gly-NH2) was provided by BFC Biopept-Feinchemie as lyophilized powder 
and acetate salt (purity 99.76 %, water content 6.73 % and acetate peptide ratio (MW/MW) 1.8). Gelling agents: 
Aluminiumdistearte (Alugel30
®
HEP), Baerlocher, D-Unterschleissheim, Aluminium monostearate 
(Aluminiumstearate NF
®
), Ferro, D-Frankfurt; Wetting agents: hydrogenated phosphatidylcholine (lecithin) 
(Phospholipon
®
90H) Lipod D-Ludwigshafen, ethoxylated sorbitan monooleate;Polysorbate 80 (Tween
®
80) 
Sigma Aldrich, D- Taufkirchen, sorbitan monooleate (Span
®
80) Merck Schuchardt, D-Hohenbrunn and 
Resuspendibility enhancer: Polyoxyl (PEG) 35 castor oil (Kolliphor
®
ELP) BTC Europe, D-Burgbergheim; Oil 
vehicle: miglyol
®
812 (MCT) Caesar & Loretz, D-Hilden, castor oil (Gustav Heess, D-Leonberg). 
GnRH [6-D-Phe] micronization The cryogenic micronization of GnRH [6-D-Phe] bulk lyophilisate was 
performed using a Retsch Cryo Mill (Retsch Technology, Haan, Germany). The grinding process was performed 
for the duration of 8 min at 25 Hz. The cycle included a precooling phase of 10 min at 5 Hz. 
GnRH [6-D-Phe] oil depot suspension preparation: The gelling agent Aluminiumdistearte (Al-DiSt) was 
weighed and suspended in the MCT oil vehicle to a final weight of 9.5 g (corresponding to 10 mL). The prepared 
mixture was heated at 174° C for 2 hours under N2. After cooling down to 25° C the wetting agent, hydrogenated 
lecithin and the resuspendibility enhancer PEG-35 castor oil were incorporated into the gelled oil matrix and 
stirred at 160° C for 1 hour under N2. Sorbitan monooleate and polysorbate 80 were incorporated into the gelled 
oil matrix and stirred at 25° C for 1 hour under N2. The castor oil: MCT 50:50 % (w/w) matrix was heated and 
agitated under inert atmosphere (N2) at 60° C and then cooled down to room temperature at 25° C. The cryo-
ground GnRH [6-D-Phe] lyophilizate was suspended in the prepared oil matrices at ambient temperature of 
25° C using an Ultra-Turrax T-10 basic (IKA Labortechnik, Germany) for 5 minutes at 2000 rpm. The 
1875 µg/mL GnRH [6-D-Phe] oil depot suspensions F1-F11 were aliquoted in 20R glass vials. 
Rheology: Viscosity profile Viscosity measurement and flow curves evaluation of the F1-F11 formulations 
were performed with MCR 100 (Anton Paar Germany, Ostfildern-Scharnhausen) cone plate system CP – 1 
(50 mm diameter, a cone angle of 1°, and a gap of 0.042 mm). The viscosity η was defined depending on the 
shear rate ẏ and measuring sections a) 0 – 500 s
-1 
(30 points, 6 s per point; 180 s measurement time), b) 500 s
-1 
(1 
point, 6 s per point, 6 s measurement time), c) 500 – 0 s
-1 
(30 points, 6 s per point, 180 s measurement time). 
Amplitude sweep Amplitude sweep measurements were performed with cone plate system CP – 1 (50 mm 
diameter, a cone angle of 1°, and a gap of 0.2 mm). The storage and loss moduli G‘/G‘‘ were defined depending 
on strain γ or shear stress τ and the measuring sections a)                      ; discarded (12 points, 5 
s per point, 60 s measurement time), b)                    ; (30 points, 15 s per point, 450 s 
measurement time), tan δ was determined in the viscoelastic region (τ= 0.1-10 Pa). Frequency sweep Frequency 
sweep measurements of the stability samples were performed with cone plate system CP – 1 (50 mm diameter, a 
cone angle of 1°, and a gap of 0.2 mm). The storage and loss moduli G‘/G‘‘ were defined depending on strain γ 
or shear stress τ and the measuring sections a)                        ; discarded (12 points, 5 s per 
point, 60 s measurement time), b)                      ; (30 points, 15 s per point, 450 s measurement 
time), ŋ* was determined in the viscoelastic region (f=0.1-10 Hz).  
GnRH [6-D-Phe] particle size distribution and characterization The particle size distribution of F1-F11 was 
analysed employing a Laser Diffraction Particle Size Analyzer LA-950 (Retsch Technology, Haan). The samples 
were prepared in triplicate (n=3). 0.2 mL of the oil suspension was withdrawn from the vial and measured in a 
solution of 1 % sorbitan monooleate in isooctane (m/v) in a standard measuring cell with 10 mL volume. 
Injection force determination The injectability/syringeability of F1-F11 were performed with the TA.XT.plus 
Texture Analyser (Stable Micro Systems, Godlming, UK). The formulations were injected into air using a 
NORM-JECT 1 mL Tuberkulin + Luer syringe (Henke-Sass-Wolf GmbH, Germany) with either a FINE-JECT 
18 Gx2‘‘, 1.2x50 mm needle (Henke-Sass-Wolf GmbH, Germany) or a FINE-JECT 16 Gx1½‘‘, 1.6x40 mm 
needle (Henke-Sass-Wolf GmbH, Germany). The software Exponent was set to compression test mode with the 
parameters: 10 mm/sec pre-test speed, and 3.9 mm/sec test speed, and 10.00 mm/sec post-test speed, trigger 
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force: 0.001 N. The applied force from the texture analyser was recorded in [N] against the distance of the 
syringe plunger (max. 64 mm). 
Camera images The photographic images were taken with the Nikon D5300 reflex camera (Nikon, Japan), 
Nikon DX, AF-S Micro NIKKOR 85mm 1:3.5G EG (Nikon, Japan), and Nikon Speedlight SB910 with white 
filter (Nikon, Japan). A manual focusing function was used. Each formulation was shaken 2 minutes at 12 Hz 
with a Mixer Mill MM200 (Retsch Technologies, Germany) and filled into glass vials. To analyse the 
sedimentation rate of the 11 formulations, images were taken at the following time points: 0 h, 0.5 h, 2 h, 3 h, 
4 h, 5 h, and 24 hours. 
Oil-Water Interface Tension and Drop Shape Analyser The wettability and spreading of F1-F11 were 
analysed with sessile drop measurements on a Drop Shape Analyser (Krüss, Germany), using NORM-JECT 
1 mL Tuberkulin + Luer syringes (Henke-Sass-Wolf, Germany) and a NE94 steel needle with 1.8 mm diameter 
(Krüss, Germany). The surrounding phase in the cuvette was PBS (pH 7.4), resembling the muscle tissue fluid of 
the swine. 
Light microscopy 5 µL of F1-F11 formulation were injected in 10 µL PBS (pH 7.4) and filled into a 0.5 mL 
Eppendorf cap. The cap was gently wheeled around up to 5 times from left to right. The light micrographs were 
taken with VHX – 500 FD (Keyence, Osaka, Japan) using a 500x magnification. 
SEDD (Microemulsion) characterization 1mL of the formulations was injected into 6 mL of PBS (pH 7.4) and 
shaken in an incubated shaker 3031 (GFL, Burgwedel, Germany) at 39° C and 60 rpm over 24 h. TEM was 
applied to analyse the microemulsion structures. 5 µl of the filtered but undiluted sample was pipetted on a 
Quantifoil ®Multi A holey carbon coated grid blotted and allowed to air dry at room temperature. A RT-TEM at 
a JEOL 200 kV JEM-FS2200 instrument and a RT EM-21010/EM-21311HTR specimen holder were used.  
In vitro release study In the in vitro release study 1.5 mL formulation were filled in VISKING® dialysis tubing, 
MWCO 12 – 14 kD, RC, 28 mm (SERVA, Germany). The release medium was 30 mL PBS (pH 7.4). The in-
vitro evaluation was performed in duplicate and in an incubated shaker 3031 (GFL, Germany) at 39° C and 
60 rpm. 1 mL sample was used for the RP-HPLC analysis at the following intervals 1 h, 3 h, 5 h, 7 h, 22 h, 25 h, 
28 h, 46 h, 52 h, 76 h, 100 h, 172 h, 196 h, 220 h, and 336 h (14 days). The GnRH [6-D-Phe] content in the oil 
vehicle and in the donor cell was extracted using organic solvents, dichloromethane (DCM), where GnRH [6-D-
Phe] is not soluble in combination with PBS (pH 7.4). 2 mL sample was weighted into a falcon tube, 4 mL DCM 
and 6 mL PBS (pH 7.4) were added. The tube was vortexed at room temperature (25° C) and put into an 
incubated shaker 3031 (GFL, Germany) at 39° C and 60 rpm for 24 h. The quantity of the peptide in the upper 
aqueous phase was analysed by RP-HPLC at 220 nm. 
Determination of the GnRH [6-D-Phe] (RP-HPLC) The GnRH [6-D-Phe] content was analysed by RP-HPLC 
using a LUNA C8 (4.6 mm x 250 mm; size = 5 µm; Phenomenex, USA) column, with a C8 pre-column (4 mm x 
3 mm; size = 5 µm) at an HPLC Agilent 1100/1200 series (Agilent Technologies, USA) (mobile phase A (water 
+ 1 mL/L Trifluoroacetic acid (TFA) (v/v)) and mobile phase B (800 g Acetonitrile + 200 g water + 1.2 mL 
TFA), 1.1 mL/min flow, column temperature 40° C, and autosampler temperature 2 – 8° C. The Retention Time 
(RT) of GnRH [6-D-Phe] was 8.5 ± 1.5 minutes with UV detection at 220 nm.  
In vivo 2
nd
 preclinical study The second in vivo testing as well as the analysis of the resulting data was 
performed between 09.04.2014 and 25.06.2014 from the University in Leipzig from Prof. Dr. Johannes Kauffold 
with the support of Dr. Haukur Sigmarrson, Dr. Mathias Hoops, Rosa Stark and Catherine Poser. The number of 
the tested animals was 25 (german landrace and pietrain breeds) with an average weight of 148 KG and 241- 243 
days old. The gilts were administered with Altrenogest, eCG and GnRH in order to synchronize the estrus cycle 
of the gilts according to an established schedule (Supplementary Data Table 4.5). The sonographic examination 
was performed with a Fazone CB (Fujifilm) with curved array type C9-3 with an ultrasound frequency of 3-9 
MHz. The examination was performed at 6MHz frequency and 10 cm depth and a gain of 84 dB. The 
sonography examination represented a new method developed by Prof. Dr Johannes Kauffold
20,21
. The follicle, 
corpora hemorrhagica and corpora lutea were analyzed. Follicles with a diameter of 10 mm or larger, which did 
not ovulate were considered to be ovarian cysts. Single cysts were differentiated from polycystic ovarian 
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syndrome. The ovulation included the collapse of the preovulatory follicle and the appearance of the corpora 
hemorrhagica. 
Statistical Analysis The effect of treatment and a comparison between the formulations was performed using a 
t-test: two sample assuming unequal variances with the software QI Macros 2017 (Denver, USA). 
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4.6 SUPPLEMENTARY DATA 
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Figure 4.13| Rheometer-Amplitude Sweep of F1-F11 1875 µg/ml GnRH [6-D-Phe] oil depot formulations 
(a), (c), (e) at 25° C (b), (d), (f) at 39° C 
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Figure 4.14| Rheometer-Frequency Sweep of F1-F11 1875 µg/ml GnRH [6-D-Phe] oil depot formulations 
(a), (c), (e) at 25° C (b), (d), (f) at 39° C 
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Step II. Preclinical Study 
Oil Depot Suspension of Gonadorelin[6-D-Phe] 
1 1. day Sonographic  examination of the 25 gilts to determine sexual maturity 
2 11.-28. day Daily administration of 5 ml Regumate
®
 4 mg/ml (= 20 mg Altrenogest) per oral over 18 
days to inhibit the folicle development 
3 30. day  
(40 h after last 
Regumate 
administration) 
4,2 ml Intergonan
®
 240 I.E./ml intramuscular(i.m.) (= 1000 IE equine chorionic-
gonadotropin (eCG)) to stimulate the follicle development 
4 33. day 
(78 h after  eCG 
administration) 
1,0 ml Gonavet Veyx
®
 i.m. (= 50 µg Gonadorelin[6-D-Phe]) to induce ovulation 
5 35. - 45. day Daily clinical and sonographic examination of the 25 gilts 
6 46. day Clinical and  sonografic examination of the 25 gilts; separating the 25 gilts in 5 groups with 
different substances for application for intramuscular application 
5 Gilts 
Group 1 
1875 µg/mL 
MCT + 3 % (w/w) Al-DiSt 
+ 0.05 % (w/w) sorbitan 
monooleate + 0.05 
%  (w/w) polysorbate 80 
5 Gilts 
Group 2 
1875 µg/mL 
MCT + 3 % (w/w) 
Al-DiSt + 1 % (w/w) 
hydrogenated 
lecithin + 5 % (w/w) 
PEG-35 castor oil 
5 Gilts 
Group 
3 
MCT 
5 Gilts 
Group 4 
3750µg/ml 
MCT + 2 % 
(w/w) Al-DiSt 
5 Gilts 
Group 5 
3750µg/ml Castor 
oil: MCT 50:50 % 
(w/w) 
7 47. - 72. day Daily clinical and sonographic examination of the 25 gilts 
 
Table 4.5| In vivo Study Timetable 
 
Group Results 
Placebo 
MCT 
n=5 
normal cycle 6 d.p.i. and ovulation 
normal cycle 7 d.p.i. and ovulation 
normal cycle 7 d.p.i. and ovulation 
normal cycle 7 d.p.i. and ovulation 
normal cycle 8 d.p.i. and ovulation 
GnRH [6-D-Phe] 3750 µg/ml 
MCT + 2 % (w/w) Al-DiSt  
n=5 
7 days cycle blocking effect 
11 days cycle blocking effect 
permanent cycle blocking effect 
permanent cycle blocking effect 
permanent cycle blocking effect 
GnRH [6-D-Phe] 1875 µg/ml 
MCT + 3 % (w/w) Al-DiSt + 1 % (w/w) hydrogenated 
lecithin +  
5 % (w/w) PEG-castor oil  
n=5 
no cycle blocking effect 
4 days cycle blocking effect 
4 days cycle blocking effect 
5 days cycle blocking effect 
5 days cycle blocking effect 
GnRH [6-D-Phe] 1875 µg/ml 
MCT + 3 % (w/w) Al-DiSt + 0.05 % (w/w) sorbitan 
monooleate + 0.05 % (w/w) polysorbate 80 
n=5 
10 days cycle blocking effect 
13 days cycle blocking effect 
permanent cycle blocking effect 
permanent cycle blocking effect 
permanent cycle blocking effect 
GnRH [6-D-Phe] 3750 µg/ml 
Castor oil: MCT 50:50 % (w/w) 
n=5 
no cycle blocking effect 
no cycle blocking effect 
4 days cycle blocking effect 
5 days cycle blocking effect 
8 days cycle blocking effect 
 
Table 4.6| In vivo Study Results 
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t-Test: Two-Sample Assuming 
Unequal Variances 
a=0.05    
Equal Sample Sizes      
  Placebo Treatment 1 
GnRH [6-D-Phe] 
3750 µg/ml 
MCT + 2 % 
(w/w) Al-DiSt 
diff 95% Confidence Interval 
Mean 0.2 42.6 -42.400 -80.529 -4.271 
Variance 0.2 942.8    
Observations 5 5    
Hypothesized Mean Difference 0     
df 4     
t Stat -3.087     
P(T<=t) one-tail - Difference < 
Hypothesized Difference 
0.018 0.982 Difference > Hypothesized Difference 
T Critical one-tail 2.132     
P(T<=t) two-tail 0.037  Reject Null Hypothesis because p < 0.05 (Means 
are Different) 
T Critical Two-tail 2.776         
 
Table 4.7| Statistical analysis t-test placebo-GnRH [6-D-Phe] 3750 µg/ml MCT + 2 % (w/w) Al-DiSt 
 
t-Test: Two-Sample Assuming 
Unequal Variances 
a=0.05    
Equal Sample Sizes      
  Placebo Treatment 2 
GnRH [6-D-Phe] 
1875 µg/ml 
MCT + 3 % 
(w/w) Al-DiSt + 
1 % (w/w) 
hydrogenated 
lecithin +  
5 % (w/w) PEG-
35 castor oil  
 
diff 95% Confidence Interval 
Mean 0.2 3.6 -3.400 -6.034 -0.766 
Variance 0.2 4.3    
Observations 5 5    
Hypothesized Mean Difference 0     
df 4     
t Stat -3.584     
P(T<=t) one-tail - Difference < 
Hypothesized Difference 
0.012 0.988 Difference > Hypothesized Difference 
T Critical one-tail 2.132     
P(T<=t) two-tail 0.023  Reject Null Hypothesis because p < 0.05 (Means 
are Different) 
T Critical Two-tail 2.776         
 
Table 4.8| Statistical analysis t-test placebo-GnRH [6-D-Phe] 1875 µg/ml MCT + 3 % (w/w) Al-DiSt + 1 % (w/w) 
hydrogenated lecithin + 5 % (w/w) PEG-35 castor oil  
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t-Test: Two-Sample Assuming 
Unequal Variances 
a=0.05    
Equal Sample Sizes      
  Placebo Treatment 3 
GnRH [6-D-Phe] 
1875 µg/ml 
MCT + 3 % 
(w/w) Al-DiSt + 
0.05 % (w/w) 
sorbitan 
monooleate + 
0.05 % (w/w) 
polysorbate 80 
diff 95% Confidence Interval 
Mean 0.2 43.6 -43.400 -79.813 -6.987 
Variance 0.2 859.8    
Observations 5 5    
Hypothesized Mean Difference 0     
df 4     
t Stat -3.309     
P(T<=t) one-tail - Difference < 
Hypothesized Difference 
0.015 0.985 Difference > Hypothesized Difference 
T Critical one-tail 2.132     
P(T<=t) two-tail 0.030  Reject Null Hypothesis because p < 0.05 (Means 
are Different) 
T Critical Two-tail 2.776         
 
Table 4.9| Statistical analysis t-test placebo-GnRH [6-D-Phe] 1875 µg/ml MCT + 3 % (w/w) Al-DiSt + 0.05 % (w/w) 
sorbitan monooleate + 0.05 % (w/w) polysorbate 80 
 
t-Test: Two-Sample Assuming 
Unequal Variances 
a=0.05    
Equal Sample Sizes      
  Placebo Treatment 4 
GnRH [6-D-Phe] 
3750 µg/ml 
Castor oil: MCT 
50:50 % (w/w) 
diff 95% Confidence Interval 
Mean 0.2 3.4 -3.200 -7.501 1.101 
Variance 0.2 11.8    
Observations 5 5    
Hypothesized Mean Difference 0     
df 4     
t Stat -2.066     
P(T<=t) one-tail - Difference < 
Hypothesized Difference 
0.054 0.946 Difference > Hypothesized Difference 
T Critical one-tail 2.132     
P(T<=t) two-tail 0.108  Cannot reject Null Hypothesis because p > 0.05 
(Means are the same) 
T Critical Two-tail 2.776         
 
Table 4.10| Statistical analysis t-test placebo-GnRH [6-D-Phe] 3750 µg/ml Castor oil: MCT 50:50 % (w/w) 
  
CHAPTER 4 
91 
4.7 FIGURES AND TABLES 
Figure 4.1| Rheology of mixtures of MCT with a gelling agent and/or wetting agent and/or 
resuspendibility enhancer ...................................................................................................................... 66 
Figure 4.2| 2
nd
 generation GnRH [6-D-Phe] oil depot suspension ........................................................ 67 
Figure 4.3| Rheology of F1-F11 1875 µg/ml GnRH [6-D-Phe] oil depot formulations ........................ 68 
Figure 4.4| Camera images of F1-F11 1875 µg/ml GnRH [6-D-Phe] oil depot formulations over 24 h
 ............................................................................................................................................................... 70 
Figure 4.5| F max and DGF of F1-F11 1875 µg/ml GnRH [6-D-Phe] oil depot formulations ............. 71 
Figure 4.6| Mean (the mean particle diameter over volume) and median particle size of F1-F11 
1875 µg/ml GnRH [6-D-Phe] oil depot formulations ........................................................................... 72 
Figure 4.7| Drop shape analysis in PBS (pH 7.4) of F1-F11 1875 µg/ml GnRH [6-D-Phe] oil depot 
formulations........................................................................................................................................... 73 
Figure 4.8| Light microscopy of F1-F11 1875 µg/ml GnRH [6-D-Phe] oil depot formulations 
emulsified in PBS pH 7.4 ...................................................................................................................... 74 
Figure 4.9| Light microscopy and Transmission electron microscopy (TEM) of the oil phase and the 
microemulsified oil phase ..................................................................................................................... 75 
Figure 4.10| In vitro release profiles of F1-F11 1875 µg/ml GnRH [6-D-Phe] oil depot formulations in 
visking dialysis tubing, MWCO 12 – 14 kD ......................................................................................... 77 
Figure 4.11| In vitro release profiles of GnRH [6-D-Phe] oil depot formulations.in visking dialysis 
tubing, MWCO 12 – 14 kD ................................................................................................................... 78 
Figure 4.12| In vivo effect of the oil depot GnRH [6-D-Phe] formulations........................................... 80 
Figure 4.13| Rheometer-Amplitude Sweep of F1-F11 1875 µg/ml GnRH [6-D-Phe] oil depot 
formulations........................................................................................................................................... 86 
Figure 4.14| Rheometer-Frequency Sweep of F1-F11 1875 µg/ml GnRH [6-D-Phe] oil depot 
formulations........................................................................................................................................... 87 
 
Table 4.1| Composition of F1-F11 1875 µg/ml GnRH [6-D-Phe] oil depot formulation ..................... 67 
Table 4.2| Rheometer-Amplitude Sweep of F1-F11 1875 µg/ml GnRH [6-D-Phe] oil depot 
formulations at 25° C and 39° C ........................................................................................................... 69 
Table 4.3| Frequency-Amplitude Sweep of F1-F11 1875 µg/ml GnRH [6-D-Phe] oil depot 
formulations at 25° C and 39° C ........................................................................................................... 69 
Table 4.4| Particle size distribution and Dv50 and Dv90 fractions ........................................................... 72 
Table 4.5| In vivo Study Timetable ........................................................................................................ 88 
Table 4.6| In vivo Study Results ............................................................................................................ 88 
Table 4.7| Statistical analysis t-test placebo-GnRH [6-D-Phe] 3750 µg/ml MCT + 2 % (w/w) Al-DiSt
 ............................................................................................................................................................... 89 
Table 4.8| Statistical analysis t-test placebo-GnRH [6-D-Phe] 1875 µg/ml MCT + 3 % (w/w) Al-DiSt 
+ 1 % (w/w) hydrogenated lecithin + 5 % (w/w) PEG-35 castor oil ..................................................... 89 
Table 4.9| Statistical analysis t-test placebo-GnRH [6-D-Phe] 1875 µg/ml MCT + 3 % (w/w) Al-DiSt 
+ 0.05 % (w/w) sorbitan monooleate + 0.05 % (w/w) polysorbate 80 .................................................. 90 
Table 4.10| Statistical analysis t-test placebo-GnRH [6-D-Phe] 3750 µg/ml Castor oil: MCT 50:50 % 
(w/w) ..................................................................................................................................................... 90 
 
 
 
RELEASE ADDITIVES 
92 
 
 
 
 
 
 
 
 
CHAPTER FIVE 
RELEASE POLYMERS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5 
95 
5 GnRH [6-D-Phe] acetate Oil Depot Suspension: The Effect of 
Polymers on the Release Characteristics 
Yordanka Yordanova
1
, Laura Liberto
1
, Kathrin Hoffmann
1
, Wolfgang Zaremba
2
 Wolfgang 
Friess
1
  
1. Department of Pharmacy, Pharmaceutical Technology & Biopharmaceutics, Ludwig-Maximilians- 
Universitaet, Butenandtstrasse 5, 81377 Muenchen, Germany 
2. Veyx Pharma GmbH, Scientific Department, Soehreweg 6, 34639 Schwarzenborn, Germany 
The incorporation of gelling agent, wetting agent and resuspendibility enhancer 
considerably improves the applicability and homogeneity of oily suspensions of 
GnRH [6-D-Phe]. The self-emulsifying character of vehicles based on medium chain 
triglycerides (MCT) with aluminiumdistearate (Al-DiSt), hydrogenated lecithin and 
macrogol-hydrogenated castor oil led to sustained and controlled release of GnRH [6-D-
Phe]. It provided an estrus cycle blockage in swine for 4 to 5 days with adequate 
synchronicity. To further sustain the effect, HPC, HPMC and HP-β-CD polymers were 
added to the formulation. The resulting suspensions were evaluated in vitro with respect 
to rheology, particles size and release. The incorporation of HPMC and HPC resulted in 
a higher viscosity in castor oil-MCT in comparison to the Al-DiSt gelled MCT with 
hydrogenated lecithin and PEG-35 castor oil. The median particle size Dv50 for the 
formulations with HPMC and HPC remained nearly unchanged in comparison to the 
formulation with pure GnRH [6-D-Phe]. 2 % of low and high molecular HPMC, HPC 
and HP-β-CD were insufficient to sustain the further release of GnRH [6-D-Phe] and to 
achieve a higher percentage of total released GnRH [6-D-Phe].  
 
5.1 INTRODUCTION 
Many different vehicles including microparticles, liposomes and nanoparticles have been 
investigated for the parenteral delivery of proteins and peptides. The biodegradable 
microparticles are in most cases based on poly (D,L-lactide-co-glycolide) (PLGA) because of 
its long safety history. The success of PLGA is evidenced by the numerous marketed 
formulations such as Lupron Depot
®
, Decapeptyl
®
, Sandostatin LAR
®
 Depot and 
Somatuline
®
 LA
1
.  
Over the last years self-emulsifying drug delivery systems have emerged as a vital strategy to 
formulate poor water-soluble compounds for oral bioavailability enhancement
2
. Only recently 
have they gained on importance as delivery strategy for proteins and peptides, where the 
hydrophilic macromolecules get entrapped in the oil phase of the emulsion, protecting them 
from enzymatic degradation
3
. Our current formulation approach uses the advantages of such a 
formulation for the controlled and sustained release of GnRH [6-D-Phe]. The self-emulsifying 
system is composed of aluminiumdistearate (Al-DiSt) gelled MCT and two surfactants, 
hydrogenated lecithin and PEG-35 castor oil
4
. The incorporation of Al-DiSt inhibited a burst 
release. However, a major challenge of the gelled matrix remains its ability to encapsulate the 
GnRH [6-D-Phe] peptide upon contact with the aqueous medium, inhibiting the peptide 
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release
2
. This problem might be solved by adding polymeric precipitation inhibitors, which 
have been shown to improve the bioavailability and absorption variability of poorly water 
soluble compounds, e.g. hydroxypropylmethyl cellulose (HPMC) in dispersion formulations
5–
8
 and a supersaturable self-emulsifying drug delivery system of paclitaxel
9
.  
In the current study GnRH [6-D-Phe] acetate was combined with hydrophilic polymers, 
freeze-dried and incorporated into Al-DiSt gelled MCT with hydrogenated lecithin and PEG-
35 castor oil and into a castor oil-MCT mix. The effect of HPMC, hydroxypropyl cellulose 
(HPC), hydroxypropyl-beta-cyclodextrin (HP-β-CD) and their interaction with GnRH [6-D-
Phe] and Al-DiST gelled oil matrix was analyzed. The results were used to identify a 
polymer_GnRH [6-D-Phe] combination with prolonged and complete release characteristics. 
Furthermore, HPMC of different viscosity grades was investigated as to determine whether 
longer chain length and hence higher viscosity might be beneficial for the complete and 
sustained release of GnRH [6-D-Phe].  
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5.2 RESULTS AND DISCUSSION 
5.2.1 GnRH [6-D-Phe]_Polymer Oil Depot Suspension 
Mixtures of 0.2 % (w/w) GnRH [6-D-Phe] and 2 % (w/w) HPMC, HPC and HP-β-CD were 
freeze-dried and incorporated at 1875 µg/ml GnRH [6-D-Phe] in the oil vehicles. Oil vehicle 
1 (OV1) consists of MCT + 3 % (w/w) Al-DiSt + 1 % (w/w) hydrogenated lecithin + 5 % 
(w/w) polyoxyl (PEG)-35 castor oil. Oil vehicle 2 (OV2) is composed of castor oil: MCT 
50:50  % (w/w) (Figure 5.1). In total 12 formulations were composed (Table 5.1). 
 
 
Figure 5.1| GnRH [6-D-Phe]_Polymer oil depot suspension  
 
Formulations  Polymer % (w/w) GnRH [6-D-Phe] % (w/w) 
GnRH [6-D-Phe]_HPMC K4M_OV1 2 0.2 
GnRH [6-D-Phe]_HPMC K4M_OV2 2 0.2 
GnRH [6-D-Phe]_HPMC K100M_OV1 2 0.2 
GnRH [6-D-Phe]_HPMC K100M_OV2 2 0.2 
GnRH [6-D-Phe]_HPMC K200_OV1 2 0.2 
GnRH [6-D-Phe]_HPMC K200M_OV2 2 0.2 
GnRH [6-D-Phe]_HPC_OV1 2 0.2 
GnRH [6-D-Phe]_HPC_OV2 2 0.2 
GnRH [6-D-Phe]_HP-β-Cyclodextrin_OV1 2 0.2 
GnRH [6-D-Phe]_HP-β-Cyclodextrin_OV2 2 0.2 
GnRH [6-D-Phe]_OV1  0.2 
GnRH [6-D-Phe]_OV2  0.2 
 
Table 5.1| Composition of GnRH [6-D-Phe]_Polymer oil depot formulations 
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5.2.2 Rheology 
Aqueous solutions of GnRH [6-D-Phe]_HPMC and HPC showed thixotropic behaviour with 
increasing viscosity in the order HPMC K4M~HPC< HPMC K100M< HPMC K200M 
(Supplementary Data Figure 5.8). GnRH [6-D-Phe]_HPMC K4M and HPC showed nearly 
identical shear-thinning behaviour at 25° C and 39° C. The incorporation of GnRH [6-D-
Phe]_HPMC and GnRH [6-D-Phe]_HPC into the oil vehicles led to a weakened polymer 
network and viscosity decrease
10
. 
Whereas the inclusion of HPC and HPMC at 2 % (w/w) resulted in a higher viscosity in 
Castor oil-MCT in comparison to pure GnRH [6-D-Phe], it did not influence the viscosity of 
the Al-DiSt gelled MCT with hydrogenated lecithin and PEG-35 castor oil (Figure 5.2). 
Fluctuations in viscosity values are related to individual large particles or particle 
agglomerates exceeding the size of the measuring gap of 0.042 mm resulting in a stick-slip 
phenomenon. This emerged primarily with castor oil – MCT based formulations and can be 
explained by the absence of stabilizing agents, resulting in the formation of difficult to 
separate particle agglomerates.  
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Figure 5.2| Rheology of GnRH [6-D-Phe]_Polymer oil depot formulations  
(a), (c) at 25° C (b), (d) at 39° C 
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5.2.3 Particle Size Distribution and Characterization 
The median particle size Dv50 of the dispersed formulations with HPMC and HPC was 
comparable (Figure 5.3). GnRH [6-D-Phe]_HP-β-CD displayed particles in the lowest Dv50 
range of 4.7-5.7 µm (Table 5.2). The larger particles of HPMC and HPC resulted most 
probably from agglomeration. However, their size did not exceed the critical value of 
0.325 mm required for an unproblematic application through 16 G needle
11,12
. 
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Figure 5.3| Mean (the mean particle diameter over volume) and median particle size of GnRH [6-D-Phe]_Polymer oil 
depot formulations 
 
Formulation Dv50 [µm] ± SD Dv90 [µm] ± SD 
GnRH [6-D-Phe]_HPMC K4M_OV1 14.1 ± 0.3 29.1 ± 1.6 
GnRH [6-D-Phe]_HPMC K4M_OV2 13.3 ± 1.8 25.5 ± 7.4 
GnRH [6-D-Phe]_HPMC K100M_OV1 12.5 ± 0.3 20.3 ± 3.9 
GnRH [6-D-Phe]_HPMC K100M_OV2 12.9 ± 0.2 22.2 ± 0.9 
GnRH [6-D-Phe]_HPMC K200_OV1 14.1 ± 0.3 34.3 ± 1.5 
GnRH [6-D-Phe]_HPMC K200M_OV2 11.8 ± 0.3 19.9 ± 1.3 
GnRH [6-D-Phe]_HPC_OV1 9.6 ± 0.1 16.3 ± 0.1 
GnRH [6-D-Phe]_HPC_OV2 14.0 ± 0.5 30.4 ± 1.7 
GnRH [6-D-Phe]_HP-β-Cyclodextrin_OV1 5.7 ± 0.2 10.2 ± 0.9 
GnRH [6-D-Phe]_HP-β-Cyclodextrin_OV2 4.7 ± 0.5 9.4 ± 1.4 
GnRH [6-D-Phe]_OV1 18.4 ± 1.0 27.1 ± 2.3 
GnRH [6-D-Phe]_OV2 19.3 ± 1.8 34.5 ± 9.1 
 
Table 5.2| Particle size distribution and Dv50 and Dv90 fractions  
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The cryoground GnRH [6-D-Phe]_polymer lyophilisate was platelet-like in case of HPMC 
and in the higher µm range in comparison to HPC and HP-β-CD (Figure 5.4). 
GnRH [6-D-Phe]_HPMC K4M GnRH [6-D-Phe]_HPMC K100M  
    
GnRH [6-D-Phe]_HPMC K200M  GnRH [6-D-Phe]_HPC  
    
GnRH [6-D-Phe]_ HP-β-Cyclodextrin    
  
  
 
Figure 5.4| Scanning electron microscopy (SEM) of the cryoground GnRH [6-D-Phe]_polymer 
 
5.2.4 Self-Emulsifying Character  
GnRH [6-D-Phe]_HPMC and GnRH [6-D-Phe]_HPC in MCT + 3 % (w/w) Al-DiSt + 1 % 
(w/w) hydrogenated lecithin + 5 % (w/w) PEG-35 castor oil formed nanostructures upon 
injection in PBS (pH 7.4) (Figure 5.5). In contrast, GnRH [6-D-Phe]_HPC in castor oil: MCT 
50:50 % (w/w) formed individual large HPC structures in the µm range. HPMC and HPC 
might interact with hydrogenated lecithin and PEG-35 castor oil at the aqueous/oil interface 
after injection, leading to the formation of micelles of surfactant or polymer as well as mixed 
micelles
13
. HPMC and HPC absorb at the oil/water interface creating a diffuse corona around 
emulsion droplets with a steric repulsive effect
14,15
. 
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Figure 5.5| Transmission electron microscope (TEM) images after injection in 6 mL PBS (pH 7.4) at 39° C in an 
incubated shaker after 24h 
 
MCT + 3 % (w/w) Al-DiSt + 1 % (w/w) hydrogenated lecithin + 5 % (w/w) PEG-35 castor oil 
act as a self-emulsifying drug delivery system
16,17,18
. Upon injection into PBS (pH 7.4), all 
formulations formed small droplets under 200 nm. In contrast, the majority of castor oil: MCT 
50:50 % (w/w) formulations generated an unstable emulsion with droplet size larger than 
600nm (Table 5.3). 
Formulation Z-average d ± SD [nm] PDI ± SD 
GnRH [6-D-Phe]_HPMC K4M_OV1 233.1 ± 24.7 0.519 ± 0.1 
GnRH [6-D-Phe]_HPMC K4M_OV2 7090.3 ± 809.2 0.355 ± 0.2 
GnRH [6-D-Phe]_HPMC K100M_OV1 85.8 ± 5.4 0.567 ± 0.1 
GnRH [6-D-Phe]_HPMC K100M_OV2 673.9 ± 134.7 0.638 ± 0.1 
GnRH [6-D-Phe]_HPMC K200M_OV1 172.0 ± 26.9 0.329 ± 0.1 
GnRH [6-D-Phe]_HPMC K200M_OV2 660.8 ± 83.3 0.518 ± 0.1 
GnRH [6-D-Phe]_HPC_OV1 94.3 ± 12.2 0.317 ± 0.1 
GnRH [6-D-Phe]_HPC_OV2 650.2 ± 109.9 0.483 ± 0.1 
GnRH [6-D-Phe]_ HP-β-Cyclodextrin_OV1 78.6 ± 2.3 0.391 ± 0.1 
GnRH [6-D-Phe]_ HP-β-Cyclodextrin_OV2 637.7 ± 93.1 0.493 ± 0.1 
GnRH [6-D-Phe]_OV1 97.4 ± 0.7 0.446 ± 0.1 
GnRH [6-D-Phe]_OV2 677.5 ± 30.9 0.609 ± 0.1 
 
Table 5.3| Droplet size determination after injection of GnRH [6-D-Phe]_polymer oil depot formulations in 6 mL PBS 
(pH 7.4) at 39° C in an incubated shaker after 24h  
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The MCT + 3 % (w/w) Al-DiSt + 1 % (w/w) hydrogenated lecithin + 5 % (w/w) PEG-35 
castor oil tends to spread upon injection into a hydrogel to a greater extent in comparison to 
castor oil: MCT 50:50 % (w/w). This was not affected by the addition of polymer (Figure 
5.6). 
GnRH [6-D-Phe]_HPMC 
K4M_OV1 
GnRH [6-D-Phe]_HPMC 
K4M_OV2 
GnRH [6-D-Phe]_HPMC 
K100M_OV1 
GnRH [6-D-Phe]_HPMC 
K100M_OV2 
    
GnRH [6-D-Phe]_HPMC 
K200M_OV1 
GnRH [6-D-Phe]_HPMC 
K200M_OV2 
GnRH [6-D-Phe]_HPC_OV1 GnRH [6-D-Phe]_HPC_OV2 
    
GnRH [6-D-Phe]_HP-β-
Cyclodextrin_OV1 
GnRH[6-D-Phe]_HP-β-
Cyclodextrin_OV2 
GnRH [6-D-Phe]_OV1 GnRH [6-D-Phe]_OV2 
    
 
Figure 5.6| Drop shape analysis in 0.5 % Benecel K100M in PBS (pH 7.4) of GnRH [6-D-Phe]_Polymer oil depot 
formulations 
 
5.2.5 In vitro Release Studies 
Both the purely oil based vehicle castor oil: MCT 50:50 % (w/w) and the formulation based 
on MCT, hydrogenated lecithin and PEG-35 castor oil exhibited a substantial initial burst. 
Approximately 80 % GnRH [6-D-Phe] was released in the first 3 hours. In contrast adding 
3 % Al-DiSt to the latter formulation resulted in suppression of the burst release of GnRH [6-
D-Phe] (Figure 5.7). Al-DiSt gelled oil vehicle might increase the water repellence and hence 
slow down the diffusion of the aqueous phase into the oil depot
4
. Contrary to our initial 
assumption of achieving a more complete and sustained release of GnRH [6-D-Phe] through 
HPMC, HPC and HP-β-CD incorporation, after 3 – 4 days the release came to rest similar to 
the reference (Supplementary Data Figure 5.9). 
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Figure 5.7| In vitro release profiles of GnRH [6-D-Phe] Polymer oil depot formulations in visking dialysis tubing, 
MWCO 12 – 14 kD  
 
5.3 CONCLUSION 
The effect of the incorporated 2 % HPMC, HPC and HP-β-CD into GnRH [6-D-Phe] on the 
suspension viscosity was more pronounced with castor oil: MCT 50:50 % (w/w). When 
suspended in gelled self-emulsifying vehicle of MCT + 3 % (w/w) Al-DiSt + 1 % (w/w) 
hydrogenated lecithin+ 5 % (w/w) PEG-35 castor oil, a shear thinning behaviour resulted, 
which was independent of polymer class or chain length. Upon injection in PBS pH 7.4, 3 % 
Al-DiSt gelled MCT with hydrogenated lecithin and PEG-35 castor oil formed multiple 
nanostructures in the 200-1000 nm range, whereas castor oil – MCT displayed individual 
structures in the higher µm range. In vitro burst release was suppressed with the self-
emulsifying vehicle in comparison to the pure oil. 2 % of low and high molecular HPMC as 
well as HPC and HP-β-CD were insufficient to achieve a higher percentage of the total 
released GnRH [6-D-Phe]. Therefore to further extend the release interval and achieve a more 
complete release of GnRH [6-D-Phe], the addition of complex forming metal salts may be 
advantageous.  
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5.4 MATERIALS AND METHODS 
Gonadorelin [6-D-Phe] acetate peptide (pE1–H2–W3–S4–Y5–(D)F6–L7–R8–P9–G10–NH2) or (pGlu-His-
Trp-Ser-Tyr-D-Phe-Leu-Arg-Pro-Gly-NH2) was provided by BFC Biopept-Feinchemie as lyophilized powder 
and acetate salt (purity 99.76  %, water content 6.73 % and acetate peptide ratio (MW/MW) 1.8). Gelling 
agents: Aluminiumdistearte (Alugel 30 ®HEP), Baerlocher, D-Unterschleissheim; Wetting agents: 
hydrogenated phosphatidylcholine(lecithin) (Phospholipon
®
90H) Lipod D-Ludwigshafen; Resuspendibility 
enhancer: Polyoxyl (PEG)-35 castor oil (Kolliphor
®
ELP) BTC Europe, D-Burgbergheim; Polymers: 
Hydroxypropylmethylcellulose (HPMC) K4M, hydroxypropylmethylcellulose (HPMC) K100M, 
hydroxypropylmethylcellulose (HPMC) K200M, hydroxypropylcellulose (HPC), 2-hydroxypropyl-β-
cyclodextrin HP7 (Ashland, D-Düsseldorf); Oil vehicle: miglyol
®
812 (MCT) Caesar & Loretz, D-Hilden, castor 
oil (Gustav Heess, D-Leonberg). 
GnRH [6-D-Phe]_polymer complexes preparation Solution of 0.2 % (w/w) GnRH [6-D-Phe] with 2 % (w/w) 
polymer were prepared. GnRH [6-D-Phe] -polymer mixtures were freeze dried using a Christ Epsilon 2-6 D 
freeze-dryer (Martin Christ Gefriertrocknungsanlagen GmbH, D-Osterode) (ambient pressure; freezing 3 h, 
−50° C, 150 mTorr; primary drying: 60 h,−20° C; secondary drying: 18 h, 20° C) with process and plant control 
LPC plus SCADA software. 
GnRH [6-D-Phe] polymer lyophilisate micronization The cryogenic micronization of GnRH [6-D-Phe] 
polymer lyophilisate was performed using a Retsch Cryo Mill (Retsch Technology, Haan, Germany). The 
grinding process was performed for the duration of 2 minutes at 25Hz with a precooling phase of 5 min in liquid 
nitrogen. 
GnRH [6-D-Phe] polymer oil depot preparation The GnRH [6-D-Phe] polymer formulations preparation was 
performed in a two-step process. The gelling agent Al-DiSt was weighed and suspended in the oil vehicle MCT 
to a final weight of 95 g (corresponding to 100 mL). The prepared mixture was heated at 174° C for 2 hours 
under inert atmosphere (N2). After cooling down to 25° C hydrogenated lecithin and PEG-35 castor oil were 
incorporated into the gelled oil matrix and stirred at 160° C for 1 hour under N2. The castor oil: MCT 50:50 % 
(w/w) matrix was heated and agitated under inert N2 at 60° C and then cooled down to room temperature at 
25° C. 200 mg cryoground GnRH [6-D-Phe]_polymer lyophilisate was suspended in the prepared oil matrices at 
temperature of 25° C using an Ultra-Turrax T-10 basic (IKA Labortechnik, Germany) for 5 minutes at 2000 rpm. 
The GnRH [6-D-Phe] Polymer oil depot suspensions were aliquoted in 20R glass vials. References GnRH [6-D-
Phe] were prepared using bulk GnRH [6-D-Phe] lyophilisate.  
Rheology: Viscosity profile Viscosity measurement and flow curves evaluation was performed with MCR 100 
(Anton Paar Germany, Ostfildern-Scharnhausen) cone plate system CP – 1 (50 mm diameter, a cone angle of 1°, 
and a gap of 0.042 mm). The viscosity η was defined depending on the shear rate ẏ and measuring sections a) 0 – 
500 s
-1 
(30 points, 6 s per point; 180 s measurement time), b) 500 s
-1 
(1 point, 6 s per point, 6 s measurement 
time), c) 500 – 0 s
-1 
(30 points, 6 s per point, 180 s measurement time).  
GnRH [6-D-Phe] extraction from the polymer and oil matrix The GnRH [6-D-Phe] was extracted from the 
prepared GnRH [6-D-Phe] polymer oil depot suspensions using dichloromethane (DCM) in combination with 
PBS (pH 7.4). 2 mL oil depot suspension was weighted into a falcon tube, 4 mL DCM and 6 mL PBS-buffer 
(pH 7.4) were added. The tube was shaken or vortexed at room temperature (25° C) and put into a horizontal 
shaker 3017 (GFL, Germany) at 25° C and 100 rpm for 48 h. The RP-HPLC analysis was performed at 220 nm.  
GnRH [6-D-Phe] polymer particle size distribution and characterization The particle size distribution of 
GnRH [6-D-Phe] polymer oil depot suspensions was analysed employing a Laser Diffraction Particle Size 
Analyzer LA-950 (Retsch Technology, Haan). The samples were prepared in triplicate (n=3). 0.2 mL of the oil 
suspension withdrawn from the vial and measured in a solution of 1 % span 80 in isooctane (m/v) in a standard 
measuring cell with 10 mL volume. 
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Scanning Electron Microscopy. The SEM images of the cryoground GnRH [6-D-Phe]_polymer lyophilisate 
were taken with FEI Helios G3 UC instrument with EDX detector (Hillboro, Oregon, USA) with Microscope 
Control Version 10.1.1 software. SEM micrographs were collected at a magnification of 2500 and accelerating 
voltage of 5.0KV 
Oil-Water Interface Tension and Drop Shape Analyser The wettability and spreading were analysed with 
pendant drop measurements on a Drop Shape Analyser (Krüss, Germany), using NORM-JECT 1 mL Tuberkulin 
+ Luer syringes (Henke-Sass-Wolf, Germany) and a NE94 steel needle with 1.8 mm diameter (Krüss, Hamburg, 
Germany). The surrounding phase in a semi-micro PMMA cuvettes (Brand GmBH, Wertheim, Germany) was 
0.5 % (m/m) Benecel K100M in PBS-buffer (pH 7.4), resembling the muscle tissue of the swine. 
SEDD (Microemulsion) characterization The microemulsion droplet size was determined by dynamic light 
scattering using Zetasizer Nano-ZS (Malvern Instruments Ltd., Herrenberg, Germany). 1 mL of the formulations 
was injected into 6 mL in PBS-buffer (pH 7.4) and shaken in an incubated shaker 3031 (GFL, Burgwedel, 
Germany) at 39° C and 60 rpm over 24 h. The diluted and filtered samples were measured in disposable 
Plastibrand semi-micro PMMA cuvettes (Brand GmBH, Wertheim, Germany) after 20 seconds equilibration 
time at 25° C and with PBS as dispersant. Positioning, attenuation selection and measuring duration as well as 
number of sub runs for the three performed measurements per sample were optimised automatically for each run 
by the Zetasizer Software 6.32. Z-average and polydispersity index (PdI) were calculated applying the general 
purpose (normal resolution) analysis model. TEM was applied to analyse the microemulsion structures. 5 µl of 
the filtered sample but undiluted sample was pipetted on a Quantifoil ®Multi A holey carbon coated grid blotted 
and allowed to air dry at room temperature. A RT-TEM at a JEOL 200 kV JEM-FS2200 instrument and a RT 
EM-21010/EM-21311HTR specimen holder were used.  
In vitro release study In the in vitro release study 1.5 mL formulation were filled in VISKING® dialysis tubing, 
MWCO 12 – 14kD, RC, 28 mm (SERVA, Germany). The release medium was 30 mL PBS-buffer (pH 7.4). The 
in vitro evaluation was performed in duplicates and in an incubated shaker 3031 (GFL, Germany) at 39° C and 
60 rpm. 1 mL sample was used for the RP-HPLC analysis at the following intervals 1 h, 3 h, 5 h, 7 h, 22 h, 25 h, 
28 h, 46 h, 52 h, 76 h, 100 h, 172 h, 196 h, 220 h, and 336 h (14 days). The GnRH [6-D-Phe] content in the oil 
vehicle and in the donor cell was extracted using 2 mL DCM and 2 mL PBS (pH 7.4). After 24 hours of an 
equilibration of the drug between the two phases the drug quantity in the supernatant was determined with RP-
HPLC. 
Determination of the GnRH [6-D-Phe] (RP-HPLC) The GnRH [6-D-Phe] content was analysed by RP-HPLC 
using a LUNA C8 (4.6 mm x 250 mm; size = 5 µm; Phenomenex, USA) column, with a C8 pre-column (4 mm x 
3 mm; size = 5 µm) at an HPLC Agilent 1100/1200 series (Agilent Technologies, USA) (mobile phase A (water 
+ 1 mL/L Trifluoroacetic acid (TFA) (v/v)) and mobile phase B (800 g Acetonitrile + 200 g water + 1.2 mL 
TFA), 1.1 mL/min flow, column temperature 40° C, and autosampler temperature 2 – 8° C. The Retention Time 
(RT) of GnRH [6-D-Phe] was 8.5 ± 1.5 minutes with UV detection at 220 nm.  
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Figure 5.8| Rheology of GnRH [6-D-Phe]_Polymer aqueous solution  
(a) at 25° C (b) at 39° C 
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Figure 5.9| In vitro release profiles of GnRH [6-D-Phe] Polymer oil depot formulations in visking dialysis tubing, 
MWCO 12 – 14 kD  
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The incorporation of cellulosic polymers into GnRH [6-D-Phe] could not increase the 
amount of released peptide in a sustained manner. Therefore Zn 
2+
: GnRH [6-D-Phe] 
complexation was tested. Attenuated Total Reflection Fourier Transform Infrared 
spectroscopy (ATR–FTIR) revealed the existence of higher order assembly of Zn 
2+
: 
GnRH [6-D-Phe]. Nuclear Magnetic Resonance spectroscopy (NMR) indicated a weak 
interaction between Zn 
2+
 and GnRH [6-D-Phe]. Atomic Force Microscopy (AFM) 
showed the existence of GnRH [6-D-Phe] oligomers and fibrils. In contrast to already 
existing short peptide fibrils, GnRH [6-D-Phe] nanostructures and fibrils form in a Tris-
buffered pH environment in a controlled manner through a temperature reduction and 
a pH shift. Molecular Dynamic (MD) simulation of the 10:1 Zn 
2+
: GnRH [6-D-Phe] 
explored the interaction and dimerization processes. The Zn 
2+
: GnRH [6-D-Phe] 
assembly was tested as a platform for the sustained delivery of GnRH [6-D-Phe] and 
incorporated into castor oil-medium chain triglycerides (MCT) mixture and 3% 
aluminiumdistearate (Al-DiSt) gelled MCT with hydrogenated lecithin and macrogol-
hydrogenated castor oil. The in vitro release from the lyophilized Zn 
2+
: GnRH [6-D-Phe] 
was slow and continuous over 14 days and not influenced by the oil matrix.  
6.1 INTRODUCTION 
A non-covalent complexation of peptides with metal ions controlling their release is a 
method, which resembles their storage in vesicles at physiological conditions. Insulin, for 
instance, is a prominent example for a peptide stored in the pancreas in the form of insoluble 
zinc complex
1
. The extended availability of insulin from an insoluble zinc complex has been 
long known and utilized. The development of insulin sustained release formulations for 
injection originated from studies of the insulin solubility in acetate and phosphate buffer
2
. The 
studies found the efficiency of insulin precipitation to be a function of pH and zinc salt 
concentration. Recently, a similar approach was adopted with other peptide compounds in 
order to achieve their controlled and sustained release. A non-covalently bound adduct of 
glucagon-like peptide 1 (GLP-1) agonist with zinc acetate could prolong its terminal half-life 
t1/2 after subcutaneous application from 2 h to 8.5 h. It further reduced the initial burst release 
of GLP-1 from the formulation vehicle, indicating its potential for long term release
3
. A 
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precipitation of recombinant Hirudin (rHir) by zinc salt at neutral pH was as well shown to 
result in Zn 
2+
-rHir suspension with a prolonged biological activity in rats
4
. The prepared 
suspension was then further optimized with regards to pH and zinc salt
5
. Similarly, 
corticotrophin (ACTH) was precipitated with zinc salt
6
. The addition of zinc induced the 
dimerization of human growth hormone (hGH). The Zn 
2+-
hGH dimer was more stable than 
the monomeric hGH form
7,8
. The formed structures of Zn 
2+
-hGH were later found to be 
fibrils of amyloidogenic nature, able to release monomers upon dilution
9
. Various studies 
have investigated short amyloidogenic peptides and their assemblies that mimic the 
amyloidosis process
10,11,12,13,14
. The amyloid structures have also been considered as a 
possible source for sustained release of small peptides, e.g. the GnRH analogue Leuprorelin 
(LHRH)
15
. In this connection, LHRH was complexed and precipitated with Zn 
2+
, using 
sodium hydroxide (NaOH) solution for the pH adjustment. The lyophilizate was then 
incorporated into in situ forming implants
16
. The same technique for complexation and 
precipitation was applied in another study with GnRH, tyroliberin (TRH), dalarelin and 
ACTH for the formation of Zn 
2+
-peptide aqueous suspension
17
. Comparable to hGH, LHRH 
exhibited a similar tendency to form β-sheet rich aggregates with amyloid-like character
15
. In 
both cases, peptides with the ability to form amyloids were investigated. The amyloid 
structures are highly organized stable aggregates, which in most cases are associated with 
neurodegenerative diseases
18
. However, in the studies with hGH and LHRH, the concept of 
amyloids was applied to prepare complexes capable of slowly releasing the active peptide.  
Based on the ―amyloid concept‖ from these studies, we investigated two approaches to 
complex GnRH [6-D-Phe] with Zn 
2+
. The first method was performed in a Tris buffer 
temperature controlled environment and applied the reciprocal relationship between 
temperature and pH of the Tris buffer in order to simultaneously precipitate and freeze-dry the 
Zn
2+: 
GnRH [6-D-Phe] complex. The second in situ method used similar concept with 
exception of the Tris buffer salt, which was added to the oil vehicle. Thus precipitation takes 
place after application. Both Zn 
2+
: GnRH [6-D-Phe] complexes were characterized and 
evaluated (Figure 6.1). 
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Figure 6.1| Overview of the in vitro GnRH [6-D-Phe] nanostructures and fibrils formation and evaluation 
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6.2 RESULTS AND DISCUSSION 
6.2.1 New approach to complex GnRH [6-D-Phe] by Zn 2+ and controlled pH shift 
In the current study we applied two techniques to complex GnRH [6-D-Phe] and compared 
them to each other in order to select the most suitable one. The percentage of free GnRH [6-
D-Phe] was analyzed by Reversed-Phase Chromatography (RP-HPLC).  
The first technique was the method of choice used in earlier studies of precipitating LHRH, 
rHir, ACTH, TRH etc. and involved increasing the pH of the peptide solution containing 
Zn 
2+ 
from 7.2 to 8.2 by the addition of NaOH
5,16,19,17
. The GnRH [6-D-Phe] was complexed 
at 2.5 mg/mL from 5 mg/mL bulk concentration. Below pH 7.8 the percentage of precipitated 
GnRH [6-D-Phe] remained low at all Zn 
2+
: GnRH [6-D-Phe] molar ratios and no correlation 
between molar ratio and pH could be acertained. Above pH 7.8, we observed an increase and 
a maximum of precipitated GnRH [6-D-Phe] of 95.9 ± 0.1 % at a 10:1 Zn 
2+
: GnRH [6-D-
Phe] molar ratio (Figure 6.2 a; Supplementary Data Table 6.6). The high percentage of 
precipitated peptide might be due to the interaction of the histidine (His) side chain with Zn 
2+
 
through its imidazole group. One major drawback of the technique is the unsatisfactory 
accuracy using the pH-adjustment with NaOH solution due to lack of buffer capacity at the 
pH value of interest. Thus upon addition of NaOH extremely unstable and high local pH 
values may result. This can lead on the one hand to the coinciding precipitation of Zn (OH)2 
from a mixture of complexed, free peptide and unbound Zn 
2+
 and on the other to 
epimerization at the serine (Ser) of GnRH [6-D-Phe], preceding a Ser hydroxyl group 
triggered peptide bond hydrolysis
20
. 
The second technique was based on a recent study of Valery et al., which showed that a 
change of pH value and thus deprotonation of the His residue in the GnRH agonist, TRH, 
could trigger a self-assembly of the peptide into nanotubes
21
. This pH dependent switch can 
be applied in the bottom-up development of pH-responsive nanomaterials as well as for the in 
vitro induced conformational change and fibrillation of GnRH [6-D-Phe]. In our study, this 
was achieved through a temperature controlled pH-shift between 7.2 and 8.2 with a Tris-
buffered system, as an alternative to NaOH
22
. 
The percentage of precipitated peptide reached 99.2 ± 0.2 % at a 10:1 Zn 
2+
: GnRH [6-D-Phe] 
ratio in 0.05 M Tris buffer pH 7.8 after temperature reduction from 25° C to 5° C, over 24 h. 
In contrast, the precipitation efficiency in a 0.05 M Tris buffer pH 7.2 reached only 36.2 ± 
0.1 % (Figure 6.2 b). This could be explained by the measured-temperature-induced pH 
increase of the Tris-buffered system with 0.03 pH units per 1° C
23
. Cooling the Zn 
2+
: 
GnRH [6-D-Phe] in Tris buffer (pH 7.8) from 25° C to 5° C promoted a pH increase from 
pH 7.3 to pH 7.9. At this pH the His-side chain is in a deprotonated state and can form 
hydrogen bonds or enhance the peptide interaction with Zn 
2+ 
and the formation of an 
assembly. In contrast the solution of Zn 
2+
: GnRH [6-D-Phe] in Tris buffer with pH 7.2 
reached pH 7.3 at 5° C (Supplementary Data Table 6.7). 
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Figure 6.2| Precipitated GnRH [6-D-Phe] from Zn 2+: GnRH [6-D-Phe] solution  
(a) with 0.6 N NaOH at pH > 7.8 and pH<7.8 (b) in 0.05 M Tris buffer at 5° C (starting pH at 25° C); the left panel illustrates 
an increased, but uncontrolled, precipitation at molar ratio Zn 2+:GnRH [6-D-Phe] 10:1 at pH > 7.8 with 0.6 N NaOH; the 
right panel illustrates a new method of a temperature controlled Tris buffer precipitation of Zn 2+:GnRH [6-D-Phe] 10:1 at 
5° C 
 
6.2.2 Existence of higher-order assembly of GnRH [6-D-Phe]  
In order to study the conformational changes and secondary structures, resulting upon adding 
different molar concentrations of Zn 
2+ 
to GnRH [6-D-Phe], we used Attenuated Total 
Reflection Fourier Transform Infrared spectroscopy (ATR–FTIR). The bands at 1416 cm
-1
 
and 1434-1454 cm
-1
 indicated an increase in the C-H bending and -C=O stretching vibration, 
respectively
24–26
(Figure 6.3 a). Absorbance spectra analysis in the amide II range (1500-
1600 cm
-1
) yielded two major peaks at ~1520 cm
-1 
and 1560 cm
-1
. The peak at 1560 cm
-1
 can 
be assigned to the N-H bend in plane and stretch. The peak at 1520 cm
-1 
has been associated 
in earlier studies with vibrations of heterocyclic compounds, e.g. furan ring, phenyl ring, 
imidazole ring and can be attributed to the stretching vibration of the –C=N bond in the 
imidazole heterocycle of the His side chain
27–29
(Figure 6.3 a). The amide I region (1600-
1700 cm
-1
) presented one major band at 1650 cm
-1
 as an indicator of an alpha-helical 
structure. The characteristic beta-sheet regions of 1610-1630 cm
-1 
and 1680-1700 cm
-1
 were 
visibly overlapped from the major alpha-helical peak. A deconvolution of the absorbance 
spectra could unveil a beta-sheet peak in the 1604-1617 cm
-1 
range (Supplementary Data 
Figure 6.13). With increasing Zn 
2+ 
molar concentrations, most stunning appears to be the 
change in the percentage of beta-sheet and carbonyl stretching area. The observed changes are 
good indicators of the initiation of oligomer formation at 4:1 and the maximum stretching of 
the carbonyl group at 10:1 Zn 
2+
: GnRH [6-D-Phe] molar ratios (Figure 6.3 a, Table 6.1). 
With higher Zn 
2+
 concentrations the beta-sheet peak disappeared and an increase of the 
carbonyl stretching due to the formation of ZnO/ Zn (OH)2 resulted. Its strong peak at 1560 
cm
-1 
coincides with the peptide amide II region. Analysis of the second-derivative amide I 
region showed bands at~1611 cm
-1
 and at ~1690 cm
-1
, typical for oligomers in solution
30–
35
(Figure 6.3 b). This supports the hypothesis that the oligomeric structure of GnRH [6-D-
Phe] forms with increasing molar concentration of Zn 
2+
. 
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Figure 6.3| FT-IR Spectra of the Zn 2+: GnRH [6-D-Phe] assemblies in comparison to GnRH [6-D-Phe] 
(a) normalized, absorbance spectra (b) normalized second derivative of the absorbance spectra 
 
 Main peaks cm
-1
 (% Area) 
-C-H bending 
and C=O 
stretching 
-C=N (Imidazole) Amide II Beta-sheet Amide I 
GnRH [6-D-Phe] 1416 (2%) 
1434 (2%) 
1454 (6%) 
1514 (3%) 1568 (27%) 1612 (6%) 1652 (54%) 
Zn 
2+
:GnRH [6-D-Phe] 
2_1 
1414 (4%) 
1435 (5%) 
1456 (7%) 
1514 (2%) 1563 (17%) 1608 (10%) 1653 (54%) 
Zn 
2+
:GnRH [6-D-Phe] 
4_1 
1417 (8%) 
1435 (1%) 
1452 (8%) 
1515 (3%) 1560 (20%) 1617 (20%) 1657 (40%) 
Zn 
2+
:GnRH [6-D-Phe] 
10_1 
1416 (13%) 
1435 (1%) 
1450 (7%) 
1517 (4%) 1561 (32%) 1604 (9%) 1653 (35%) 
Zn 
2+
: GnRH [6-D-Phe]  
20_1 
1415 (20%) 
1447 (5%) 
- 1560 (40%) - 1653 (15%) 
 
Table 6.1| Main peaks and integrated peak area in the deconvoluted normalized absorbance spectra of Zn 2+: 
GnRH [6-D-Phe] assemblies in comparison to GnRH [6-D-Phe] 
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6.2.3 Binding of Zn 2+ to GnRH [6-D-Phe]  
The LHRH interactions with Zn 
2+
, Ni 
2+
 and Cu
2+ 
were studied in the 1980s
19,17
. The results 
of the 
1
H-NMR spectroscopy favoured a view that the coordination between Zn 
2+
 and LHRH 
takes place at the carbonyl oxygen of the His-Trp peptide bond
19
. In addition, the imidazole of 
the His residue coordinates to the Zn 
2+
 ligand. This coordination to Zn 
2+
 happens in a fast 
proton exchange. The changes of the chemical shift in the aromatic part of the 
1
H-NMR in 
correlation to the added molar concentration of Zn 
2+ 
can be traced back to two distinct 
occurrences. The first one involves the already mentioned His and Trp residue interaction 
with Zn 
2+ 
(Supplementary Data Figure 6.12). The second one can be due to a stronger 
peptide-peptide interaction
36,37
. Using the observed change in the chemical shift (   , we 
fitted the data to a hyperbolic function with the following equation:  
   
        
  
        
 
Equation 6.1| Chemical shift Δδ in correlation to Zn 2+ 
 
This allowed us to determine the dissociation constants (Kd) of the Zn 
2+
: GnRH [6-D-Phe] 
assembly, assuming a 1:1 stoichiometry. The calculated value of the dissociation constant Kd 
(38.4 ± 4.8 mM
1
) indicated a weak interaction between Zn 
2+
 and GnRH [6-D-Phe]. The Zn 
2+
 
ligand concentration for the interaction with GnRH [6-D-Phe] was in the range of 4-160 mM 
(Figure 6.4).  
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Figure 6.4| NMR shift in solution-state NMR spectra vs. Zn 2+ concentration for the determination of the dissociation 
constant Kd of the Zn 
2+:GnRH [6-D-Phe] 1:1 stoichiometry 
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6.2.4 Zn 2+: GnRH [6-D-Phe] assembly: nanostructures and fibrils  
In order to visualize the formation process of the assembly, we took atomic force microscopy 
(AFM) images in solution and in dry state at the highest precipitation efficiency, Zn 
2+
: 
GnRH [6-D-Phe] 10:1. The observed fast proton exchange and interaction in the 
1
H-NMR 
spectra required the use of a D2O: DMSO-d6 (80:20) solvent in order to capture the images. 
In solution, nanostructures with a diameter of up to 5nm in the presence of Zn 
2+
 were 
recorded (Figure 6.5 a, b; Supplementary Data Figure 6.14). The assembly process appeared 
to be dynamic and going through different stages: immediately after preparation large circular 
aggregates formed (Figure 6.5 a), which resulted after 48h in 5 nm nanostructures (Figure 
6.5 b). The smaller size oligomers might be due to solvation of peptide chains from the 
preliminary formed large aggregate back into solution. In dry state, Zn 
2+
: GnRH [6-D-Phe] 
small fibrils with a diameter of up to 10 nm were observed (Figure 6.5 c, d).  
a (z-scale 0-50 nm) b (z-scale 0-5 nm) 
  
c (z-scale 0-5nm) d (z-scale 0-10nm) 
  
 
Figure 6.5| AFM image of the Zn 2+: GnRH [6-D-Phe] 10:1 complex 
(a), (b) oligomers after preparation with tapping mode in Tris buffer solution (c), (d) fibrils with tapping mode in air (z-scale 
indicates the average size of the formed oligomers and fibrils) 
 
The effect of increasing Zn 
2+
 ion concentration on GnRH [6-D-Phe] fibrillization was further 
studied with Thioflavin T (ThT) assay. ThT is a benzothiazole dye used to visualize and 
quantify misfolded protein fibrils or amyloid both in vitro and in vivo
38
. The assay could show 
the formation of secondary structures with increasing Zn 
2+
 concentration. Above a 10:1 
Zn 
2+
: GnRH [6-D-Phe] ratio, the obtained fluorescence values decreased. Pure GnRH [6-D-
Phe] and aggregated Aβ42 were included and served as negative and positive control, 
respectively (Table 6.2). 
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 ThT Fluorescence [a.u.] ± SD 
0h 1h 3h 5h 24h 
GnRH [6-D-Phe] 1.1 ± 5.6E-03 1.2 ± 2.8E-03 1.2 ± 1.8E-03 1.1 ± 4.6E-03 1.1 ± 2.1E-03 
2:1 5.7 ± 8.7E-03 5.6 ± 2.5E-02 5.3 ± 1.6E-02 6.4 ± 5.9E-02 5.8 ± 1.6E-02 
4:1 7.9 ± 1.3E-02 6.3 ± 2.0E-02 7.3 ± 9.2E-03 5.6 ± 3.4E-02 5.8 ± 1.7E-02 
10:1 2.5 ± 6.3E-03 2.8 ± 4.1E-03 3.3 ± 3.9E-02 4.9 ± 4.1E-02 2.4 ± 8.6E-03 
20:1 1.2 ± 3.1E-03 1.0 ± 5.2E-03 1.2 ± 7.7E-03 1.1 ± 9.4E-03 1.0 ± 7.4E-03 
Aβ 42 5.1 ± 1.8E-02 3.9 ± 1.1E-02 5.9 ± 1.2E-01 4.7 ± 1.9E-01 4.7 ± 1.9E-01 
 
Table 6.2| ThT fluorescence recorded over 24h of the Zn 2+: GnRH [6-D-Phe] assemblies in comparison to GnRH [6-
D-Phe] and Aβ 42 
 
6.2.5 Molecular dynamics simulation of Zn 2+: GnRH [6-D-Phe] 10:1 assembly 
Using molecular dynamics (MD) simulations, we further explored the interaction between 
Zn 
2+
 and GnRH [6-D-Phe] in the 10:1 ratio. Analysis of the trajectory with the linear 
interaction energy method showed three dimerization events driven by VdW and electrostatic 
interactions in the Zn 
2+
: GnRH [6-D-Phe] 10:1 (Supplementary Data Figure 6.15). These 
interactions could further confirm the observed weak coordination of Zn 
2+
 to GnRH [6-D-
Phe] in the 
1
H-NMR spectra
39,40
. In the first dimerization event, the Arg8 residue of peptide 1 
was engulfed by the second peptide. The dimer's interface consists of Leu7, Arg8 and Pro9 of 
peptide 1 and pGlu1, Ser4, Pro9, Gly-NH210 of peptide 2 (Figure 6.6 a). The second and third 
dimerization events present a flatter interface, which is composed of residues pGlu1, His2 
Tyr5 D-Phe6 Pro9 of peptide 1 and Trp3 Ser4 Tyr5 of peptide 2 (Figure 6.6 b). During the 
first dimerization event there was a pronounced conformational change of peptide 1, reflected 
from the RMSD values (Figure 6.6 c, d). A cluster analysis showed that the dimer formed in 
the first dimerization event (at around 10000 frames) is the most prominent species in the 
course of the simulation. MD simulations showed that the dimer formation is furthermore 
driven by hydrogen bond formation between the peptide residues (Supplementary Data Figure 
6.16). 
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a b 
  
c d 
  
 
Figure 6.6| MD simulation 
(a), (b) Dimer structures of GnRH [6-D-Phe]-1 in blue, GnRH [6-D-Phe]-2 in yellow, Zn 2+ in black, interfacial residues 
pictured as VdW spheres (c), (d) RMSD value peptide 1 and RMSD value peptide 2 
 
6.2.6 Zn 2+: GnRH [6-D-Phe] complex and oil depot suspension preparation  
In order to generate a GnRH-depot system two new approaches were evaluated. In the first 
setup, complexation of GnRH [6-D-Phe] in the presence of Zn 
2+
 was directly performed in 
the freezing phase of a lyophilization process. The temperature-dependent pH switch of the 
Tris buffer system led to the formation of Zn 
2+
: GnRH [6-D-Phe] complex 10:1, which was 
simultaneously stabilized in a 3D freeze-dried matrix (Figure 6.7). The complex was then 
incorporated in medium chain triglycerides (MCT) + 3 % (w/w) aluminium distearate (Al-
DiSt) + 1 % (w/w) hydrogenated lecithin + 5 % (w/w) PEG-35 castor oil (OV1) or in castor 
oil: MCT 50:50 % (w/w) (OV2) oil vehicle. For the second in situ method, the Tris buffer salt 
was added to the oil vehicle separately from GnRH [6-D-Phe], enabling a possible 
precipitation as dissolution of both suspended water soluble compounds takes place after in 
vivo application (Figure 6.7). Both Zn 
2+
: GnRH [6-D-Phe] complexes in the oil vehicles were 
characterized and evaluated. 
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Figure 6.7| Zn 2+: GnRH [6-D-Phe] complex and oil depot preparation 
 
6.2.7 Rheology 
The freeze-dried Zn 
2+
: GnRH [6-D-Phe] 10:1 complex in MCT + 3 % (w/w) Al-DiSt + 1 % 
(w/w) hydrogenated lecithin + 5 % (w/w) PEG-35 castor oil displayed a thixotropic profile at 
25° C (Figure 6.8). Fluctuations in viscosity values are related to individual large particles or 
particles agglomerates exceeding the size of the measuring gap of 0.042 mm resulting in a 
stick-slip phenomenon. This emerged primarily with castor oil-MCT based formulations and 
can be explained by the absence of stabilizing agents, resulting in the formation of difficult to 
separate particle agglomerates. 
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Figure 6.8| Rheology of Zn 2+: GnRH [6-D-Phe] oil depot formulations for Zn 2+: GnRH [6-D-Phe] 10:1 complex and 
in situ complex in OV1 and OV2  
(a), (c) at 25° C (b), (d) at 39° C 
 
6.2.8 Particle Size Distribution and Characterization  
The median particle size Dv50 for the dispersed freeze-dried Zn 
2+
: GnRH [6-D-Phe] 10:1 
complex was comparable in both oil vehicles (Table 6.3). The particle size distribution was 
symmetric (Figure 6.9). Their size did not exceed the critical value of 0.325 mm required for 
an unproblematic application through 16 G needle
41,42
. 
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Figure 6.9| Mean (the mean particle diameter over volume) and median particle size of GnRH [6-D-Phe]_Polymer oil 
depot formulations 
 
Formulation Dv50 [µm] ± SD Dv90 [µm] ± SD 
Zn 
2+_
GnRH [6-D-Phe] 10:1_in situ complex_OV1 21.6 ± 0.3 79.9 ± 3.6 
Zn 
2+_
GnRH [6-D-Phe] 10:1_in situ complex_OV2 12.9 ± 0.2 35.8 ± 5.4 
Zn 
2+_
GnRH [6-D-Phe] 10:1_complex_OV1 14.1 ± 0.3 107.9 ± 3.4 
Zn 
2+_
GnRH [6-D-Phe] 10:1_complex_OV2 13.3 ± 1.8 114.0 ± 23.2 
 
Table 6.3| Particle size distribution and Dv50 and Dv90 fractions  
 
Upon injection into PBS (pH 7.4), the 3% Al-DiSt gelled MCT with hydrogenated lecithin 
and hydrogenated macrogol-castor oil formed small droplets under 100 nm. In contrast, the 
formulations based on the pure mixture of castor oil and MCT generated an unstable emulsion 
with droplet size above 300 nm (Table 6.4). This trend was observed regardless of the 
incorporated Zn 
2+
: GnRH [6-D-Phe] complex and can be related to MCT + 3 % (w/w) Al-
DiSt + 1 % (w/w) hydrogenated lecithin + 5 % (w/w) PEG-35 castor oil acting as a self-
emulsifying drug delivery system
43,44,45
. 
Formulation Z-Average d ± SD [nm] PDI ± SD 
Zn 
2+_
GnRH [6-D-Phe] 10:1_complex_OV2 734.2 ± 122.5 0.620 ± 0.1 
Zn 
2+_
GnRH [6-D-Phe] 10:1_complex_OV1 56.4 ± 8.8 0.394 ± 0.1 
Zn 
2+_
GnRH [6-D-Phe] 10:1_in situ complex_OV2 370.9 ± 35.6 0.418 ± 0.1 
Zn 
2+_
GnRH [6-D-Phe] 10:1_in situ complex_OV1 66.4 ± 0.5 0.504 ± 0.1 
 
Table 6.4| Droplet size determination after injection of Zn 2+: GnRH [6-D-Phe] oil depot formulations in 6 mL PBS 
(pH 7.4) at 39° C in an incubated shaker after 24h 
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6.2.9 In vitro Release Studies  
The in vitro release of the GnRH [6-D-Phe] peptide formed by in situ complexation with 
Zn 
2+ 
 in the oil vehicle OV1: MCT + 3 % (w/w) Al-DiSt+ 1 % (w/w) hydrogenated lecithin + 
5 % (w/w) PEG-35 castor oil or OV2 : castor oil: MCT 50:50 % (w/w) reached a maximum of 
40 % after 2-3 days (Figure 6.10). In contrast, the preformed complex formulations in OV1 
and OV2 showed slow and continuous in vitro release profiles over 14 days with a minor 
burst effect. The release from the reference formulation based on pure GnRH [6-D-Phe] in 
castor oil: MCT 50:50 % (w/w) was fast and almost complete within 24 h. In contrast the 
release was more sustained over 4 days from Al-DiSt gelled MCT with hydrogenated lecithin 
and PEG-35 castor oil. 
In order to determine the release kinetics from the Zn 
2+
:GnRH [6-D-Phe] formulations, the 
data was fitted to first-order, Higuchi, zero-order and Korsemeyer-Peppas models
46
. The 
formulations clearly did not follow zero order release kinetics (Figure 6.11). The model that 
best fitted the release data was evaluated by correlation coefficient (R
2
) (Table 6.5). The 
release profile of the preformed complex formulation in OV1 could be best explained by the 
Higuchi model, as the plot showed linearity with R
2 
value of 0.9416. The Korsmeyer-Peppas 
plots of all formulations showed fair linearity (R
2 
values between 0.95-0.97) with a 
considerably high slope value (n). This indicated a coupling of diffusion and erosion 
mechanisms or so called anomalous diffusion
47
. 
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Figure 6.10| In vitro release profiles of Zn 2+: GnRH [6-D-Phe] oil depot formulations in visking dialysis tubing, 
MWCO 12 – 14 kD  
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Formulation 
First-order
1 
R
2
 
Higuchi
2 
R
2
 
Zero-order
3 
R
2
 
Korsmeyer-Peppas
4 
R
2
 
n 
10:1_complex_OV1 0.8574 0.9416 0.7589 0.9784 24.342 
10:1_complex_OV2 0.8214 0.8848 0.7087 0.9296 18.314 
10:1_in situ 
complex_OV1 
0.5505 0.7552 0.5092 0.9533 16.491 
10:1_in situ 
complex_OV2 
0.6654 0.7891 0.5836 0.8960 13.566 
GnRH [6-D-
Phe]_OV1 
0.5405 0.7460 0.4949 0.9471 27.433 
GnRH [6-D-
Phe]_OV2 
0.0721 0.2894 0.1229 0.5010 19.913 
 
Table 6.5| In vitro release kinetic values of GnRH [6-D-Phe] from selected Zn 2+: GnRH [6-D-Phe] oil depot 
formulations 
1First-order equation, log Q=Log Q0 –kt/2.303;
 2Higuchi equation, Q=kt ½; 3Zero-order equation, Q=Q + kt; 4Korsmeyer-
Peppas equation, Qt/Qµ=kt
n 
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Figure 6.11| Linear fit of in vitro release kinetic values of GnRH [6-D-Phe] from selected Zn 2+: GnRH [6-D-Phe] and 
GnRH [6-D-Phe] oil depot formulations 
(a) 1First-order equation, log Q=Log Q0 –kt/2.303; (b) 
2Higuchi equation, Q=kt ½; (c) 3Zero-order equation, Q=Q + kt; (d) 
4Korsmeyer-Peppas equation, Qt/Qµ=kt
n 
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Compared to the reference formulations without Zn 
2+
, the release profiles of the complex and 
in situ complex formulations were not influenced by the oil matrix. Thus the interaction of 
Zn 
2+ 
with GnRH [6-D-Phe] in a preformed lyophilized complex could accomplish a superior 
controlled release of GnRH [6-D-Phe] with minor burst effect. It represents a simple and 
scalable formulation approach. 
 
6.3 CONCLUSION 
As illustrated above a short synthetic decapeptide, GnRH [6-D-Phe] can form nanostructures 
and fibrils in vitro through the addition of Zn 
2+
 ions. The aggregation tendency seems to 
depend on Zn 
2+
 concentration, reaching a maximum efficiency of almost 100% at a 10:1 
Zn 
2+
: GnRH [6-D-Phe] ratio. The oligomerization and mature fibrils formation of GnRH [6-
D-Phe] are Zn 
2+
 induced. GnRH [6-D-Phe] fibrils form in a Tris-buffered pH 7.8-8.2 
environment in a controlled manner through temperature reduction and a pH shift. The in 
vitro release of the GnRH [6-D-Phe] peptide from the freeze-dried assembly was sustained 
and continuous over 14 days and can be viewed as a promising platform for the controlled 
delivery of peptides. 
Recent articles have highlighted the numerous fields of application of similar self-assembled 
peptide –based nanostructures
48–50
. The further investigation of the GnRH [6-D-Phe]: Zn 
2+
 
self-assembling/oligomerization process is necessary in order to evaluate to what extent it can 
find application in other research fields. 
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6.4 MATERIALS AND METHODS 
Gonadorelin [6-D-Phe] acetate peptide (pE1–H2–W3–S4–Y5–(D)F6–L7–R8–P9–G10–NH2) or (pGlu-His-
Trp-Ser-Tyr-D-Phe-Leu-Arg-Pro-Gly-NH2) was provided by BFC Biopept-Feinchemie as lyophilized powder 
and acetate salt (purity 99.76 %, water content 6.73% and acetate peptide ratio (MW/MW) 1.8). Amyloid β-
Protein (1-42) (H-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-
Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala-OH) was 
provided by Bachem Holding AG as lyophilizied powder; Gelling agents: Aluminiumdistearte (Alugel 30 
®HEP), Baerlocher, D-Unterschleissheim); Wetting agents: hydrogenated phosphatidylcholine(lecithin) 
(Phospholipon
®
90H) Lipod D-Ludwigshafen; Resuspendibility enhancer: Polyoxyl (PEG)-35 castor oil 
(Kolliphor
®
ELP) BTC Europe, D-Burgbergheim; Complexing agent: Zinc acetate dehydrate (Zn (CH3COO
-
)2 
(Merck KGaA, D-Darmstadt); Oil vehicle: miglyol 812 (MCT) (Caesar & Loretz, D-Hilden), castor oil (Gustav 
Heess, D-Leonberg). 
Formation of the Zn 
2+
: GnRH [6-D-Phe] assembly with 0.6 N NaOH. Equal amounts of 4 mM GnRH [6-D-
Phe] and 16 mM, 40 mM, 60 mM, 80 mM, 120 mM, 160 mM, 200 mM and 240 mM Zn(CH3COO
-
)2 aqueous 
solutions were combined. The pH adjustment was performed using a 0.6 N NaOH under stirring carefully with a 
dropwise addition along the side wall. The formed precipitate was centrifuged at 12000 x g for 10 min, washed 
with highly purified water. GnRH [6-D-Phe] in the supernatant as well as in the precipitate was analyzed through 
a Reversed Phase Chromatography (RP-HPLC) (Supplementary Data Table 6.6). 
Formation of the Zn 
2+
: GnRH [6-D-Phe] assembly in Tris buffer. Equal amounts of 4 mM GnRH [6-D-Phe] 
and 40 mM, 60 mM, 200 mM Zn(CH3COO
-
)2 solution in 0.05 M Tris buffer (pH=7.2, 7.4, 7.6, 7.8, 8.2) were 
combined. Precipitation was performed at reduced temperature, 5° C. The formed precipitate was centrifuged at 
12000 x g for 10 min, washed with highly purified water. GnRH [6-D-Phe] in the supernatant as well as in the 
precipitate was analyzed through a RP-HPLC (Supplementary Data Table 6.7). 
ATR-FTIR Equal amounts of 4 mM GnRH [6-D-Phe] and 8 mM, 16 mM, 40 mM, 80 mM Zn(CH3COO
-
)2 
solution in a 0.05 M Tris buffer (pH 7.8) were combined. Aliquots of 30µl of each prepared solution were loaded 
and the spectra were recorded with a Tensor 27 FTIR spectrometer (Bruker Optics, Ettlingen, Germany) using a 
Bio-ATR unit at 20° C. Corresponding blank spectra were subtracted. Spectra were recorded at 4 cm
-1 
resolution 
and the second derivative spectrum was generated (OPUS, Bruker Optics, Ettlingen, Germany).The spectra data 
analysis and Fourier Self-Deconvolution (FSD) was performed with Origin 2018 software. FSD was performed 
using bandwidth of 10 cm
−1
 and noise suppression factor of 0.3. The structure content of the deconvoluted peaks 
was determined using Gaussian band shapes by an iterative curve fitting.  
NMR Spectroscopy Solution 
1
H-NMR zinc titration of the peptide in D2O: DMSO-d6 (80:20) solvent was 
performed in a 0.05 M Tris buffer (pH 7.8) at 25° C on a Bruker Avance III HD 800 MHz and at a reduced 
temperature 5° C on a Varian NMR System 400 MHz. The binding efficiency of Zn 
2+
 to peptide was determined 
through the NMR analysis of the Zn 
2+
: GnRH [6-D-Phe] assemblies. The spectra were evaluated using the 
MestReNova Software 10.0.2-15465 (Supplementary Data Figure 6.12). 
Atomic force microscopy (tapping in Air) The 10:1 Zn 
2+
: GnRH [6-D-Phe] (20 ng/µL; 20 µL volume) was 
deposed onto poly-L-lysine coated mica for 2 min, followed by gentle rinsing with water and dried in a N2-gas 
stream. Coating the mica with (+) charged poly-L-lysine repulsed the (+) charged arginine peptide residues of 
chains not involved in the dimerization process, allowing better imaging. AFM imaging was performed on a 
Multimode AFM, equipped with a Nanoscope III controller and a type E scanner. Images were recorded on dried 
samples, under ambient conditions, and using Silicon cantilevers (Olympus; AC160TS; resonance frequency 
≈300 kHz). Typical scans were recorded at 1–3 Hz line frequency, with optimized feedback parameters and at 
512 × 512 pixels. For image processing and analysis, Scanning Probe Image Processor (v6.4; Image Metrology) 
was employed. Image processing involved background correction using global fitting with a third-order 
polynomial and line-by-line correction through the histogram alignment routine. 
Atomic force microscopy (tapping in Tris buffer solution) The AFM images were performed using the AFM 
NanoWizard® 4 from JPK Instruments with SPM software and an integrated Axiovert 200 inverted microscope 
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from Zeiss. As cantilever the qp-BioAC CB3 (Nanosenors; resonance frequency ≈ 30 kHz) was used. A mica-
chip was glued on a microscope slide and 20 µl of the 10:1 Zn 
2+
: GnRH [6-D-Phe] was added. After 5 min 
incubation time, the mica-substrate was washed with Tris buffer. The imaging was performed in 1 ml Tris buffer 
and with the tapping mode (QI™ Advanced Imaging). The following values have been set: Z-length 50 - 70 nm; 
duration 2 ms and pixel size 256x256. All images were processed and optimized with Data Processing Software 
from JPK. The processing involved removing incorrect lines, replacing outlier pixel values with the median 
value of neighbouring pixels and line-by-line correction with a first-order polynomial fit. A histogram is 
calculated for each line and only the data between the lower and upper limits is used for fitting the polynomial. 
Thioflavin-T Binding Assay. The fluorescence intensity was measured in multi-well plates in an Agilent Cary 
Eclipse Fluorescence Spectrophotometer (exc.at 440 nm (slit width 5nm), em. at 482 nm (slit width 10 nm), and 
averaging over 60 s). 100 µl of each Zn 
2+
: GnRH [6-D-Phe] sample, prepared in 0.05 M Tris buffer pH 7.8 
containing 20 % DMSO, was vortexed gently and mixed with 200 µL 50 µM ThT solution prepared in the same 
buffer and stored at 5° C. Aβ42 lyophilizate was dissolved in 0.05 M Tris pH 7.8 containing 20 % DMSO and 
stored at 5° C over 24 h for the purpose of forming minimal peptide aggregation. 100 µl of 150µM Aβ42 and 
100 µl of 4mM GnRH [6-D-Phe] were used as controls and treated the same way as the Zn
2+
: GnRH [6-D-Phe] 
samples. The fluorescence intensity of all samples was measured over 24 hours.  
MD simulations Molecular dynamic simulations were performed using the Amber 16 suite
51
. Non-standard 
residue files were generated using antechamber and the peptide structure was generated with t-leap. Two 
identical GnRH [6-D-Phe] molecules and 20 zinc ions were placed at random coordinates in a TIP3P water box 
using 10 Å of padding. Energy minimization was performed with pmemd. MPI with the steepest descent method 
for 5000 cycles and with the conjugate gradient method at constant volume for the remaining 45000 cycles. The 
system was then heated from 0 to 300 K and equilibrated for 200 ps with pmemd.cuda. A Langevin thermostat 
with a collision frequency set to 5 ps
-1 
was used. Pressure was kept constant using isotropic position scaling and 
a Monte Carlo barostat. The SHAKE algorithm was turned on. After equilibration, a 500 ns production run was 
performed with the same thermostat and barostat settings as during equilibration. VdW and electrostatic 
interaction energies were calculated using the LIE method as implemented in cpptraj and plotted with 
matplotlib
39,40,52
. 
Zn 
2+
: GnRH [6-D-Phe] complex preparation Zn 
2+
:GnRH [6-D-Phe] 10:1 preformed complex was prepared 
from equal amounts of 4 mM GnRH [6-D-Phe] and 40 mM Zn(CH3COO
-
)2 in 0.05 M Tris buffer pH 7.8. The pH 
of the resulting mixture at 25° C was 7.2. The temperature was then reduced to 5° C and resulted in a pH 
increase to pH 7.8. The mixture was kept at 5° C for 24 h and then freeze dried. The in situ Zn 
2+
: GnRH [6-D-
Phe] 10:1 complex was prepared from equal amounts of 4 mM GnRH [6-D-Phe] and 40 mM Zn (CH3COO
-
)2 in 
water. The pH of the resulting mixture at 25° C was 6.5. Similarly to the preformed complex the temperature 
was reduced to 5° C. The pH stayed constant. The mixture was kept at the same conditions as the preformed 
complex and freeze dried. Both complexes were freeze dried using a Christ Epsilon 2-6 D freeze-dryer (Martin 
Christ Gefriertrocknungsanlagen GmbH, D-Osterode) (ambient pressure; freezing 3 h, −50° C; 150 mTorr; 
primary drying: 60 h,−20° C; secondary drying: 18 h, 20° C) with process and plant control LPC plus SCADA 
software. 
Zn 
2+
: GnRH [6-D-Phe] lyophilisate micronization The cryogenic micronization of Zn 
2+
: GnRH [6-D-Phe] 
lyophilisate and the separately added Tris buffer were performed using a Retsch Cryo Mill (Retsch Technology, 
Haan, Germany). The grinding process was performed for the duration of 1 minute at 25 Hz with a precooling 
phase of 10 min in liquid nitrogen. 
Zn 
2+
: GnRH [6-D-Phe] oil depot preparation The Zn 
2+
: GnRH [6-D-Phe] oil depot formulations preparation 
was performed under a laminar flow cabinet in a two-step process. The gelling agent Aluminiumdistearte (Al-
DiSt) was weighed and suspended in the oil vehicle miglyol 812 (MCT) to a final weight of 95 g (corresponding 
to 100 mL). The prepared mixture was heated at 174° C for 2 hours under N2. After cooling down to 25° C 
hydrogenated lecithin and PEG-35 castor oil were incorporated into the gelled oil matrix and stirred at 160° C 
for 1 hour under N2. The castor oil: MCT 50:50 % (w/w) matrix was heated and agitated under inert atmosphere 
(N2) at 60° C and then cooled down to room temperature at 25° C. The cryo-ground Zn 
2+
: GnRH [6-D-Phe] 
lyophilizate was suspended in the prepared oil matrices at ambient temperature of 25° C using an Ultra-Turrax 
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T-10 basic (IKA Labortechnik, Germany) for 5 minutes at 2000 rpm. 139.8 mg of Tris buffer salt consisting of 
2.01 g Trizma HCl and 1.485 g Trizma Base was added to the in-situ complex formulation. The 5000 µg/ml 
Zn 
2+
: GnRH [6-D-Phe] oil depot suspensions were aliquoted in 20R glass vials. Both reference suspensions 
were prepared using bulk GnRH [6-D-Phe] lyophilisate at the same concentration. 
Rheology: Viscosity profile Viscosity measurement and flow curves evaluation were performed with MCR 100 
(Anton Paar Germany, Ostfildern-Scharnhausen) cone plate system CP – 1 (50 mm diameter, a cone angle of 1 °, 
and a gap of 0.042 mm). The viscosity η was defined depending on the shear rate ẏ and measuring sections a) 0 – 
500 s
-1 
(30 points, 6 s per point; 180 s measurement time), b) 500 s
-1 
(1 point, 6 s per point, 6 s measurement 
time), c) 500 – 0 s
-1 
(30 points, 6 s per point, 180 s measurement time).  
Zn 
2+
: GnRH [6-D-Phe] particle size distribution and characterization The particle size distribution of 
Zn 
2+
: GnRH [6-D-Phe] oil depot suspensions was analysed employing a Laser Diffraction Particle Size 
Analyzer LA-950 (Retsch Technology, Haan). The samples were prepared in triplicate (n=3). 0.2 mL of the oil 
suspension withdrawn from the vial and measured in a solution of 1 % span 80 in isooctane (m/v) in a standard 
measuring cell with 10 mL volume. 
SEDD (Microemulsion) characterization The microemulsion droplet size was determined by dynamic light 
scattering using Zetasizer Nano-ZS (Malvern Instruments Ltd., Herrenberg, Germany). 1mL of the formulations 
was injected into 6mL of PBS (pH=7.4) and shaken in an incubated shaker 3031 (GFL, Burgwedel, Germany) at 
39° C and 60 rpm over 24h. The diluted and filtered samples were measured in disposable Plastibrand semi-
micro PMMA cuvettes (Brand GmBH, Wertheim, Germany) after 20 seconds equilibration time at 25° C and 
with buffer as dispersant. Positioning, attenuation selection and measuring duration as well as number of sub 
runs for the three performed measurements per sample were optimised automatically for each run by the 
Zetasizer Software 6.32. Z-average and polydispersity index (PdI) were calculated applying the general purpose 
(normal resolution) analysis mode 
GnRH [6-D-Phe] extraction from the complex and oil matrix In order to establish a suitable extraction 
method for the determination of the GnRH [6-D-Phe] content in the oil depot suspension the following 
extraction experiments were performed: the GnRH [6-D-Phe] was extracted from the prepared Zn 
2+
: GnRH [6-
D-Phe] oil depot suspensions using dichloromethane (DCM), where GnRH [6-D-Phe] is not soluble in 
combination with HEPES (pH 7.4). HEPES was selected as medium instead of PBS buffer, since phosphate can 
precipitate the zinc salt from the complex. 2 mL oil depot suspension was weighted into a falcon tube, 4 mL 
DCM and 6 mL HEPES (pH 7.4) were added. The tube was shaken or vortexed at room temperature (25° C) and 
put into an incubated shaker 3031 (GFL, Germany) at 39° C and 60 rpm for 48 h. The RP-HPLC analysis was 
performed at 220 nm. A second extraction method was applied: 2 ml of each formulation were pipetted into 6 ml 
HEPES (pH 7.4). The falcon tubes were placed in an incubated shaker 3031 (GFL, Germany) at 39° C and 
60 rpm for 48 h. The tubes were then centrifuged for 60 minutes at 4000 rpm and 5° C. 1 ml of the lower 
aqueous phase was used for RP-HPLC at 220 nm. The extraction with HEPES (pH 7.4) delivered results of 
nearly 100% and indicated high extraction efficiency.  
In vitro release study The in vitro release study was conducted using VISKING® dialysis tubing, MWCO 12 – 
14 kD, RC, 28 mm (SERVA, Germany). The tubes were filled with 1.5 mL formulation. The release medium 
was 20 mL HEPES (pH 7.4). HEPES was selected as release medium instead of PBS buffer, since phosphate can 
precipitate the zinc salt from the complex. The in vitro evaluation was performed in duplicates and in an 
incubated shaker 3031 (GFL, Germany) at 39° C and 60 rpm. 1 mL sample was used for the RP-HPLC analysis 
at the following time points: 1 h, 3 h, 5 h, 7 h, 22 h, 25 h, 28 h, 46 h, 52 h, 76 h, 100 h, 172 h, 196 h, 220 h, and 
336 h (14 days). The GnRH [6-D-Phe] content in the oil vehicle and in the donor cell was extracted using 2mL 
HEPES buffer (pH 7.4). After 48 hours of an equilibration of the peptide between the two phases the emulsion 
was centrifuged for 60 minutes at 4000 rpm and 5° C. The quantity of the peptide in the lower aqueous phase 
was analysed by RP-HPLC at 220 nm. 
Determination of the GnRH [6-D-Phe] (RP-HPLC) The GnRH [6-D-Phe] content in the formed 
precipitate/fibrils was analysed by RP-HPLC after dissolution in 0.1 % acetic acid, using a LUNA C8 (4.6 mm x 
250 mm; size = 5 µm; Phenomenex, USA) column, with a C8 pre-column (4 mm x 3 mm; size = 5 µm) at an 
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HPLC Agilent 1100/1200 series (Agilent Technologies, USA) (mobile phase A (water + 1 mL/L Trifluoroacetic 
acid (TFA) (v/v)) and mobile phase B (800 g Acetonitrile + 200 g water + 1.2 mL TFA), 1.1 mL/min flow, 
column temperature 40° C, and autosampler temperature 2 – 8° C. The Retention Time (RT) of GnRH [6-D-Phe] 
was 8.5 ± 1.5 minutes with UV detection at 220 nm.  
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6.6 SUPPLEMENTARY DATA 
a 
 
b 
 
 
Figure 6.12| Solution-state NMR Spectra of Zn 2+: GnRH [6-D-Phe] assemblies  
molar ratio 1:1 , 2:1, 4:1, 8:1,10:1, 20:1, 40:1, GnRH [6-D-Phe] in Tris buffer (pH 7.8) (a) at 25° C (b) at 5° C 
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1 2 3 4 
Ratio 
Zn 
2+
: GnRH 
pH 
at 25° C 
pH 
adjusted 
with 
0.6 N NaOH 
GnRH [6-D-Phe] 
[ % ] ± SD 
pH 
adjusted 
with 
0.6 N NaOH 
GnRH [6-D-Phe] 
[ % ] ± SD 
4:1 6.4 7.0 1.2 ± 0.2 8.2 9.8 ± 0.2 
10:1 6.4 7.0 1.2 ± 0.2 8.3 95.9 ± 0.1 
15:1 6.5 7.8 41.5 ± 0.1 8.3 28.4 ± 0.1 
20:1 6.5 7.1 6.8 ± 0.1 8.1 33.9 ± 0.3 
30:1 6.6 7.2 15.2 ± 0.2 8.1 44.2 ± 0.1 
40:1 6.6 7.3 26.3 ± 0.1 8.2 54.7 ± 0.3 
50:1 6.6 7.2 24.9 ± 0.2 8.0 54.9 ± 0.2 
60:1 6.6 6.8 13.3 ± 0.1 8.1 61.2 ± 0.3 
 
Table 6.6| Precipitation of the Zn 2+: GnRH [6-D-Phe] assembly with 0.6 N NaOH 
Column 1 indicates the Zn2+: GnRH molar ratios. Column 2 represents the pH of the corresponding aqueous Zn2+: GnRH at 
25° C. Column 3 represents the adjusted pH at ~ 7.0 with 0.6N NaOH and corresponding % precipitated peptide. Column 4 
represents the adjusted pH at ~ 8.0 with 0.6N NaOH and corresponding % precipitated peptide. The titration with NaOH did 
not offer enough precision to adjust the pH value of the solutions in the range of pH=7.2- 8.2 at 0.2 pH units step 
 
 
1 2 3 4 5 2 3 4 5 2 3 4 5 
pH 
Tris 
Buffer 
Ratio 
Zn2+: 
GnRH 
pH 
25° C 
pH 
5° C 
GnRH [6-
D-Phe] 
at 5° C 
[ % ] ± SD 
Ratio 
Zn2+: 
GnRH 
pH 
25° C 
pH 
5° C 
GnRH [6-D-
Phe] 
at 5° C 
[ % ] ± SD 
Ratio 
Zn2+: 
GnRH 
pH 
25° C 
pH 
5° C 
GnRH [6-D-
Phe] 
at 5° C 
[ % ] ± SD 
7.2 10:1 6.7 7.3 36.2 ±0.1 15:1 6.7 7.3 no 
precipitation 
50:1 6.3 6.9 no 
precipitation 
7.4 6.9 7.5 53.6 ±0.1 6.8 7.4 40.5 ±0.1 6.4 7.0 no 
precipitation 
7.6 7.1 7.7 59.9 ±0.1 7.0 7.6 48.8 ±0.1 6.6 7.2 no 
precipitation 
7.8 7.3 7.9 99.9 ±0.2 7.1 7.7 50.5 ±0.1 6.8 7.4 12.2 ±0.1 
8.2 7.5 8.1 45.7 ±0.1 7.2 7.8 13.9 ±0.1 6.7 7.3 16.2 ±0.1 
 
Table 6.7| Precipitation of the Zn 2+: GnRH [6-D-Phe] assembly in Tris buffer (pH 7.8) at 5° C 
Column 1 represents the pH of the used Tris-buffer. Column 2 indicates the Zn2+: GnRH molar ratio. Column 3 represents 
the pH of Zn 2+: GnRH [6-D-Phe] assembly in the corresponding Tris-buffer at 25° C. Column 4 represents the pH of Zn 2+: 
GnRH [6-D-Phe] assembly in the corresponding Tris-buffer at 5° C. Column 5 represents the corresponding % precipitated 
peptide after reduction of 25° C to 5° C over 24 h. 
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Figure 6.13| Deconvoluted FT-IR absorbance spectra 
 (a) GnRH [6-D-Phe] and (b) 2:1; (c) 4:1; (d) 10:1 ; (e) 20:1 Zn 2+: GnRH [6-D-Phe] assemblies  
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Figure 6.14| AFM image of the Zn 2+: GnRH [6-D-Phe] 
(a)-(e) tapping mode Tris buffer solution with dilution 1:1000 after 48h 
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Figure 6.15| Average linear interaction energy 
(a) VdW and electrostatic of R1-R10 amino acid residue of the first peptide chain and R11-R20 amino acid residue of the 
second peptide chain (b)electrostatic of all amino acid residue with Zn 2+  
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Figure 6.16| Peptide dimerization 
(a) Cluster analysis of the formed dimer (b) Total number of hydrogen bonds formed between peptide residues during a 500 
ns MD simulation. 
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SUMMARY 
The goal of this thesis was to obtain an environmentally safe and economically-priced 
formulation for swine estrous cycle synchronization. Based on the veterinary requirements, a 
GnRH [6-D-Phe] acetate multi – dose oil depot formulation was pursued.  
Due to the short GnRH [6-D-Phe] plasma half – life of up to 2 hours, a suitable depot vehicle 
was necessary to achieve sustained release with at least two week physiological effect. For 
this purpose, low viscosity 50:50 % (w/w) castor oil/ MCT and high viscosity 90:10 % (w/w) 
castor oil/MCT were investigated at first. The required two week physiological effect 
demanded to establish a suitable in vitro model. The established model could differentiate 
between formulations with regards to vehicle viscosity and peptide concentration effect. The 
first in vivo study showed the most pronounced cycle blocking effect with castor oil: MCT 
50:50 % (w/w) 1875 µg/ml GnRH [6-D-Phe], which lasted an average of 3.8 ± 1.3 days. 
1875 µg/mL GnRH [6-D-Phe] in low viscosity castor oil: MCT 50:50 % (w/w) achieved a 
longer and more consistent cycle blocking effect compared to 1875 µg/mL GnRH [6-D-Phe] 
in high viscosity castor oil: MCT 90:10 %. 
Formulating GnRH [6-D-Phe] in a less prone to oxidation oily mixture of castor oil/MCT 
proved to be beneficial. Storage of the castor oil: MCT 50:50 % (w/w) 1875 µg/ml GnRH [6-
D-Phe] oil depot suspension at 2-8° C, 25° C and 40° C over 12 months did not affect its 
chemical or physical integrity. 
At an effective concentration of 1875 µg/mL GnRH [6-D-Phe], the incorporation of 
aluminium distearate as gelling agent, hydrogenated lecithin as well as PEG-35 castor oil to 
pure MCT oil resulted in a favourable shear-thinning behaviour. This may potentially reduce 
the spreading of the formulation at the injection site and facilitate easier withdrawal from a 
multi – dose container. The combination of hydrogenated lecithin and PEG-35 castor oil 
resulted in the formation of a self-emulsifying drug delivery system of GnRH [6-D-Phe]. As a 
result, the release was more consistent and controlled with reduced initial in vitro burst. The 
second in vivo study could confirm that the best cycle blocking effect of 4 to 5 days with 
regards to synchronicity, length and adverse reactions, was achieved with 1875 µg/mL 
GnRH [6-D-Phe] in MCT + 3 % aluminium distearate + 1 % hydrogenated lecithin + 5 % 
PEG-35 castor oil. 
In order to achieve a sustained and more complete release from the self-emulsifying oil 
vehicle, GnRH [6-D-Phe] acetate was combined with 2 % HPMC, HPC and HP-β-CD 
polymers, freeze-dried and incorporated into the Al-DiSt gelled MCT with hydrogenated 
lecithin and PEG-35 castor oil and into a castor oil-MCT mix. The addition of polymers of 
different grades to GnRH [6-D-Phe] increased the viscosity when incorporated in the pure 
mixture of castor oil: MCT 50:50 % (w/w) in comparison to self-emulsifying vehicle. 
Multiple nanostructures in the 200-1000 nm range formed upon injection of the self-
emulsifying vehicle into PBS, whereas castor oil – MCT displayed single structures of self-
assembled polymer in the higher µm range. The tested 2 % of low and high molecular HPMC, 
HPC and HP-β-CD were insufficient to achieve a more sustained and complete release of 
GnRH [6-D-Phe].  
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Interestingly, Zn 
2+
 ions and GnRH [6-D-Phe] formed nanostructures and fibrils in vitro. The 
association efficiency was maximal at a 10:1 Zn 
2+
: GnRH [6-D-Phe] ratio. The GnRH [6-D-
Phe] fibrils could be formed in a Tris-buffer in a controlled manner through temperature 
reduction resulting in a pH shift of the buffer. This approach allowed simultaneously 
precipitating and freeze-drying the Zn
2+
: GnRH [6-D-Phe] complex. A second in situ method 
used similar concept with exception of the Tris buffer salt, which was added to the oil vehicle. 
Thus association takes place after application. The release profiles of the complex and in situ 
complex formulations were not influenced by the oil matrix. The in vitro release of GnRH [6-
D-Phe] from the freeze-dried assembly was sustained and continuous over 14 days and can be 
viewed as a promising platform for the controlled delivery of peptides. 
In summary, the work in the thesis highlighted exemplary steps towards the development of a 
stable GnRH [6-D-Phe] oil depot suspension. It further underlies the importance of combining 
the oily vehicle development approach with the modification of the GnRH [6-D-Phe] peptide 
in order to successfully deliver the peptide in a sustained and controlled manner.  
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When the dissertation is not the single thing that you can remember from the last couple of 
years, than you know you have done it the right way….. 
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